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1
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE
Peripheral arterial occlusive disease (PAD) is a common condition that occurs due to 
a decrease in blood flow and oxygenation of tissue.1 PAD mainly affects the lower 
extremities, with clinical manifestations ranging from no symptoms to intermittent 
claudication (IC) and possibly even tissue loss, which may eventually require amputation 
of the affected limb.2 
IC is the mildest clinical manifestation of PAD caused by progressive narrowing of the 
arteries of the peripheral circulation. IC manifests as a cramping pain in muscles of the 
calf, thigh, and/or buttock due to ischemia caused by insufficient blood flow and tissue 
oxygenation. Classically, IC manifests after a period of exercise and then subsides 
rapidly while resting. If PAD progresses to critical limb ischemia, tissue ischemia is even 
present during rest and a final stage involving tissue loss can occur. 
Etiology
PAD is caused by the continuous process of atherosclerosis. Atherosclerosis can be 
defined as the progressive narrowing and hardening of arteries due to the accumulation 
of lipids, inflammatory cells, and smooth muscle cells within the intima of the vascular 
wall, forming an atherosclerotic plaque.3 The most predominant risk factors for 
atherosclerosis are smoking, hypertension, diabetes mellitus, hypercholesterolemia, 
and an increasing age. Although the process of atherosclerosis can occur in every 
artery, it can become symptomatic if it affects coronary, cerebral, abdominal and 
peripheral arteries of upper or lower extremities. Acute manifestations, like a heart 
attack or acute critical limb ischemia, are thought to occur when an atherosclerotic 
plaque ruptures, and the thrombogenic content of the plaque comes into contact with 
coagulation factors, causing the formation of a thrombus, which can occlude the artery. 
If the atherosclerotic plaque does not rupture, but is slowly progressive in thickness, 
chronic manifestations such as angina pectoris or PAD can occur due to a decrease in 
blood flow and oxygenation of tissue.
Epidemiology
Total disease prevalence of PAD, based on objective testing, has been evaluated in 
several epidemiologic studies and ranges from 3% to 10% in adults, increasing to 15% 
to 20% in persons over 70 years of age.4 Prevalence of IC is more difficult to determine, 
since the symptoms do not always predict the presence or absence of PAD. A patient 
with severe PAD may not show any symptoms of IC, because the patient is not physically 
active or the range of exercise is limited by some other condition. In contrast, some 
patients with symptoms suggesting IC may not have PAD; for instance spinal stenosis 
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can produce symptoms similar to IC in the absence of vascular disease. Likewise, 
patients with very mild PAD may develop symptoms of IC only when they become very 
physically active. However, disease prevalence of IC is estimated 3% in patients aged 
40 and 6% in patients aged 60 years, contributing15-40% to the PAD population.2 
Although for IC patients the prognosis is favorable, with regard to PAD progression 
(and eventually amputation), they score considerably worse for many measures of 
quality of life and functional capacity measures than individuals without PAD.2,5,6 
Furthermore, for IC, a 5-year mortality rate of 19% is described, 70% of which is due 
to cardiovascular causes. Non-fatal cardiovascular events (e.g. myocardial infarction 
or stroke) of patients with IC are found in 29% at 5-year follow-up.7 
MANAGEMENT OF INTERMITTENT CLAUDICATION
Treatment of IC (and PAD in general) should address two important targets: reduction 
of cardio- and cerebrovascular events (and associated morbidity and mortality) and 
improvement of health-related quality of life and functional capacity. To manage these 
targets, all patients with IC should receive cardiovascular risk management. 
Cardiovascular risk management consists of antiplatelet therapy, statin therapy, 
treatment of hypertension, tight glycemic control, and lifestyle interventions aimed at 
smoking cessation, weight reduction and increase of physical activity. Limited data 
exists on lifestyle interventions in PAD. However, in coronary heart disease, lifestyle 
modification programmes were associated with reductions in all-cause mortality, 
cardiac mortality, cardiac readmissions and non-fatal re-infarctions. Furthermore, 
lifestyle interventions positively affected risk factors and related lifestyle behaviors 
at post-treatment and persisted at long-term follow up.8 Besides cardiovascular risk 
management, the primary and most effective treatment for IC is exercise therapy.9 The 
combination of both is considered the most important factor in improving associated 
health traits.10,11
Exercise therapy
In 1898, the successful results of exercise therapy for IC were first described by Wilhelm 
Erb, a German neurologist.12 He described the amount of exercise necessary to provoke 
symptoms, localised the anatomical defect and described the societal implications of 
PAD. The first randomised controlled trial was performed by Larsen and Lassen in 
1966.13 In this study, seven patients treated with exercise therapy were compared with 
a control group of seven patients who were given ‘medical treatment’ in the form of 
lactose tablets. The exercise group showed a significant increase in maximum walking 
time, whereas the patients in the control group did not improve. 
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Nowadays, exercise therapy for patients with IC is extensively studied.14 In a Cochrane 
systematic review of randomized clinical trials, exercise therapy is associated with an 
overall improvement in walking ability of approximately 50% to 200% compared with 
no exercise therapy. Given its clear benefits, the importance of exercise therapy is 
highlighted in contemporary international guidelines.2,15
Exercise training provides significant symptomatic benefit for patients with IC; however, 
the exact mechanisms of this improvement remain unclear.16 The mechanisms of 
response to exercise training have been reviewed previously and include improvement 
in walking efficiency, induction of vascular angiogenesis, inflammatory activation, 
increased exercise pain tolerance, reversed endothelial and mitochondrial dysfunction, 
and metabolic adaptations within skeletal muscle. 2,17-20
Supervised exercise therapy
In contrast to exercise therapy, supervised exercise therapy (SET) entails adequate 
coaching by a physical therapist or another exercise specialist (e.g. an exercise 
physiologist, an exercise therapist, a human movement scientist or a specialized 
cardiovascular nurse). It aims to increase maximum walking distance, physical activity 
and health-related quality of life. 
In a Cochrane systematic review, SET showed a significant improvement in maximal 
treadmill walking distance compared with non-supervised exercise therapy regimens, 
with an increase in walking distance of approximately 180 meters more in the 
supervised group.21 Although no clear evidence exists, most frequently described 
programs employ treadmill walking of sufficient intensity to cause claudication 
symptoms. Exercise is continued till near maximum pain, followed by rest, and then a 
next cycle of exercise is started over the course of a 30–60 minute session. During the 
exercise session, treadmill exercise is performed at a speed and grade that will induce 
claudication symptoms. The patient should stop walking when claudication pain is 
considered moderate. Exercise sessions are typically conducted three times a week for 
at least 3 months.2,22
Alternative exercise therapy
Besides walking, there are alternative modes of SET, such as cycling, upper-extremity 
cycle ergometer exercise, and strength training, and these are also associated with a 
significantly improved walking capacity.23-25 A recent systematic review comparing any 
mode of exercise, whether supervised or unsupervised, was published.26 It suggested 
that alternative modes of aerobic exercise, other than walking, appear equally beneficial 
as walking exercise, while the effects of progressive resistance training and upper body 
exercise seem only promising. The effect size of each exercise mode was calculated 
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and compared to the effect size of walking exercise. However, due to heterogeneity, no 
meta-analysis was performed on specific randomised controlled trials (RCTs) comparing 
the standard of supervised walking exercise to alternative exercise regimes.
Home-based exercise therapy
Although SET proved effective in the treatment of PAD by increasing maximal and 
pain-free walking time or distance, the existing exercise programs are not designed 
to change day-to-day walking behavior.27 Moreover, limitations continue to hinder 
implementation of supervised exercise programs in daily practice. Some describe a 
lack of a supervised setting to which patients can be referred or a lack of knowledge 
among referring healthcare professionals. In other studies participants were not willing 
to persist with an exercise program to maintain the benefit.2,20,28 Home-based walking 
programs that use a group-mediated cognitive behavioral intervention, incorporating 
both group support and self-regulatory skills, were chosen to be a solution for these 
patients. A home-based walking exercise program significantly improved walking 
endurance, physical activity, and patient-perceived walking endurance in patients with 
IC.28 These findings have implications for the large number of patients with PAD who 
are unable or unwilling to participate in supervised exercise programs.
Physical activity monitoring
Daily physical activity (PA) levels of IC patients are lower than those of healthy 
controls.29,30 However, PA is scantly used as an outcome parameter in trials concerning 
IC treatment.27,31 Although SET has proven effective in improving walking distances, it 
is questionable whether an increased walking capacity is of benefit during the patient’s 
daily life activities. In other words, if an IC patient is able to walk further, this finding 
does not necessarily imply that PA levels and/or exercise behavior are positively 
influenced. Perhaps a potential goal of future PAD treatment should be to at increase 
the daily PA level. 
In patients with IC, PA is rarely measured objectively in terms of energy expenditure.30,32,33 
Regularly described methods for PA measurements are PA questionnaires, pedometers, 
or activity monitors. However, only the latter method is found capable of adequately 
assessing energy expenditure.34,35 The newest generation of activity monitors is based 
on tri-axial accelerometer techniques, measuring accelerations in three dimensions that 
can be converted to intensities and METs (metabolic equivalents). In this way, PA is 
determined more precisely, as was demonstrated by high correlations between indirect 
calorimetry and generated MET output at different walking speeds.34,36,37




There are many surgical and endovascular interventions that can be used for the 
symptomatic treatment of IC, such as endarterectomy bypass surgery or percutaneous 
transluminal angioplasty (PTA), with or without stent placement. The general consensus 
is that patients with critical limb ischemia should undergo invasive vascular interventions 
to restore blood flow and to prevent amputation. 2 However, the role of vascular 
interventions in IC is still debated. The preferred choice for primary treatment is often 
conservative management of SET and vascular risk management, since this is a safe 
and effective method and limb prognosis is favorable. This in contrast to the associated 
comorbidity and mortality of vascular interventions, estimated to be <0.5% for PTA and 
up to 5-10% for bypass surgery.9
Nowadays, the effectiveness of management of IC is measured in most cases in terms 
of walking performances (using a treadmill protocol) or disease-specific quality of life 
questionnaires. In the last decade, several studies have compared SET, PTA and a 
combination of treatments for IC. In general, most studies included both patients with 
femoropopliteal and aortoiliac artery disease and found no difference between SET and 
PTA regarding walking distances or disease specific quality of life, even after 7 years 
of follow-up.38-43 Invasive interventions and reinterventions occurred more often in the 
PTA group.41 In a systematic review, SET was compared to PTA for all specific disease 
locations.43 Unfortunately, the investigators could not perform a meta-analysis due to 
shortcomings in the design of individual studies, the heterogeneity of interventions and 
the heterogeneity of assessment and reporting of outcome measures. 
Results of individual RCTs lead to debate on how to manage patients with IC related 
to specific disease locations. For IC due to femoropopliteal disease, PTA and SET are 
found to be equally effective in improving walking distance and quality of life at a 
follow up of 12 months.42 For aortoiliac disease, SET resulted in a superior treadmill 
walking distance after 6 months compared to PTA, but PTA resulted in a non-significant 
greater improvement of disease-specific quality of life.40 However, when combining 
both treatments, significantly better results in walking distance and disease specific 
quality of life are found for mixed aortoiliac and femoropopliteal disease, indicating a 
possible adjuvant benefit of combining both treatments.44-46 
Choosing the optimal intervention for patients with IC can also be influenced decisively 
by the costs of interventions. In several cost-effectiveness studies, SET was considered 
the most cost-effective treatment for IC.47,48 However, in an economic analysis following 
a randomized controlled trial, a combination of SET and PTA appeared to be more 
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cost-effective than PTA alone, since costs per quality adjusted life year (QALY) were 
significantly higher in the PTA group (€ 11.777 for PTA vs. €10.650 for PTA + SET vs. 
6.147 for SET).48 
However, though proven to be effective, SET program are in many cases not fully 
reimbursed by healthcare insurance companies. As a consequence, SET is largely 
underutilized. Besides the reimbursement issues of SET, other arguments such as patient 
resistance and professional self-interest could play an additional role.49 Patients may 
receive an evidently insufficient and less cost-effective “go home and walk” advice, or a 
vascular intervention as an alternative first-line treatment strategy. A stepped care model 
strives to initially refer all IC patients to a SET program and reserve revascularization 
for those who do not respond to SET. Implementation of a stepped care model may 
lead to a significant annual saving of up to 33 million euros of healthcare resources.50 
AIM AND OUTLINE OF THE THESIS
The aim of this thesis was to describe methods for improving management of IC in 
the Netherlands. This thesis elucidates possible indications for SET and presents a 
promising future outcome measure to evaluate SET. Furthermore, this thesis describes 
a novel care intervention to implement SET in the Netherlands. This thesis is important 
for both caregivers and healthcare policy makers, because it describes from a practical 
point of view when and how SET should be physically performed, implemented and 
evaluated using new outcome measures and quality indicators. From an organisational 
point of view, this thesis describes how a stepped-care conservative management of IC 
can be implemented in a chronic-care model for the Dutch population. 
For patients with IC, SET is considered the cornerstone of conservative management, 
although cardiovascular management and lifestyle coaching are both considered 
equally important. In Chapter 2 the current knowledge and future perspectives on 
SET are described. Furthermore, we present the current evidence on cardiovascular 
risk management for IC patients. However, in clinical practice SET appears to be 
underutilized for different reasons. We therefore investigated the current opinion of 
Dutch vascular surgeons on SET as treatment option for PAD. We specifically investigated 
to what extent and on which criteria Dutch vascular surgeons decide to offer or deny 
SET to patients with IC. Results of this nationwide inquiry are described in Chapter 3.
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After elucidating the indications for SET in current clinical practice, this thesis focuses 
on the performance and clinical evaluation of SET programs. In Chapter 4, a systematic 
review describes the effects of different supervised exercise modes on maximal 
and pain-free walking distance. In Chapter 5, physical activity monitoring is used 
to describe a new outcome measure for evaluating SET, the real-life physical activity 
level. The daily physical activity level of patients with IC is determined and results are 
compared both with healthy adults and with current PA standards. The effect of SET 
on the daily physical activity level and ambulatory activities are described in Chapter 
6. In particular, we wanted to find out the effect of a SET program on the number 
of patients achieving the ACSM/AHA public health minimum recommendations for 
physical activity. 
Still, several shortcomings prevent SET from being available for the Dutch population 
of IC patients. Chapter 7 describes the organisational aspects of the shortcomings in 
the Dutch healthcare system. To improve the availability of SET, we provide the design 
of a national integrated care network (ClaudicatioNet). Based on the chronic care 
model as a conceptual framework, 51 regional care networks of general practitioners, 
vascular surgeons, central caregivers and physical therapists are initiated to enhance 
the quality, access, continuity, efficiency and costs of the Dutch healthcare system.
An important factor in evaluating conservative management of IC is how to measure 
its quality. At present, there is no evidence of how the quality of physical therapy 
management should be monitored. Therefore, in Chapter 8 quality indicators for SET 
are developed using an expert Delphi procedure.
In Chapter 9, the main findings of this thesis are discussed. Methodological aspects 
of the different studies, implications for clinical practice, and implications for future 
research are described. Finally in Chapter 10, this thesis is summarised both in English 
and in Dutch. 
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ABSTRACT
Intermittent claudication (IC) has a high prevalence in the older population and is 
closely associated with cardiovascular and cerebrovascular disease. High mortality 
rates are reported due to ongoing atherosclerotic disease. Because of these serious 
health risks, treatment of IC should address reduction of cardiovascular events (and 
related morbidity/mortality) and improvement of the poor health-related quality of 
life (QoL) and functional capacity. In several randomized clinical trials and systematic 
reviews, supervised exercise therapy (SET) is compared with non-supervised exercise, 
usual care, placebo, walking advice or vascular interventions. The current evidence 
supports SET as the primary treatment for IC. SET improves maximum walking distance 
and health-related QoL with a marginal risk of co-morbidity or mortality. This is also 
illustrated in contemporary international guidelines. Community-based SET appears to 
be at least as efficacious as programs provided in a clinical setting. In the Netherlands, 
a national integrated care network (ClaudicatioNet) providing specialized care for 
patients with IC is currently being implemented. Besides providing a standardized 
form of SET, the specialized physical therapists stimulate medication compliance 
and perform lifestyle coaching. Future research should focus on the influence of co-
morbidities on prognosis and effect of SET outcome and the potential beneficial effects 
of SET combined with a vascular intervention.




The atherosclerotic process of progressive narrowing and hardening of arteries can 
occur in every artery in the human body, however it mainly affects the coronary, 
cerebral and peripheral arteries of the lower extremities.1, 2 Lower extremity peripheral 
arterial occlusive disease (PAOD) has an estimated prevalence between 1.6% to 4.5% 
in the general population and rises to 19.1% in the Dutch population, aged 55 years 
and older.3-6 The primary sites of involvement of PAOD are the femoral and popliteal 
arteries in 80-90%, the tibial and peroneal arteries in 40-50% and in 30% the aorta 
and iliac arteries.7 The manifestation of PAOD ranges from no symptoms to tissue loss 
that eventually requires amputation of the affected limb. The majority of patients with 
PAOD, have asymptomatic or atypical disease.2
Intermittent claudication (IC), the mildest symptomatic manifestation of PAOD, has a 
prevalency in the general population of approximately 3% in patients aged 40, to 6% 
in patients aged 60 years and increasing in older age.2 In women, the incidence rates 
of IC are approximately 50% lower than in men.8, 9 In IC, progressive atherosclerotic 
narrowing results in decreased oxygen availability in the periphery of the buttocks 
and/or lower extremities. During exercise, the lack of oxygen causes an anaerobic 
state in which lactic acid and other metabolites are formed. This causes cramping or 
aching pain in the buttock, hip, thigh, calf or in rare occasions the foot, forcing the 
patient to pause. In rest, the oxygen debt can be redeemed and symptoms are relieved. 
However, when PAOD progresses, the pain becomes constant and the increasing 
oxygen debt can no longer be redeemed. This condition, called critical limb ischemia, 
can eventually progress to the final stage of tissue loss. Although amputation is the 
greatest fear for patients with IC, the prognosis of the affected limb is favorable. After a 
5-year follow-up period, 28.8% of all patients with IC still have claudication symptoms 
and only 1.6%-4.1% need a limb amputation.8, 9 
PAOD and IC are strong predictors for coinciding atherosclerotic disease and related 
mortality. The prevalence of cerebrovascular disease in patients with IC is about 25-50%.10 
The 10-year mortality rate due to cardiovascular disease is 62% for men with PAOD 
compared to 17% in the population of men without PAOD. For women with PAOD the 10-
year mortality rate is 33% compared to 12% without PAOD.11 In a subgroup of patients 
with severe and symptomatic PAOD a 15-fold increase in mortality rate was found.11 
For IC, a 5-year mortality rate of 19.2 % is described, of which 70% is due to 
cardiovascular causes. Non-fatal cardiovascular events (e.g. myocardial infarction, 
stroke) in patients with IC are found in 29% at 5 year of follow-up.9 Compared to 
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patients with IC, subjects with asymptomatic PAOD appear to have the same increased 
risk of cardiovascular events and death.9 Nonetheless, for those afflicted, IC has a 
negative impact on walking ability and health-related quality of life (QoL).12, 13 
Because of these serious health risks, treatment of IC (and PAOD in general) should 
address two important targets; reduction of cardiovascular events (and related 
morbidity and mortality) and improvement of the poor health-related QoL and functional 
capacity. To manage these targets, all patients with IC should receive a multicomponent 
therapy consisting of cardiovascular risk modification including lifestyle coaching and 
supervised exercise therapy (SET). A (minimal) invasive vascular intervention should 
be performed only when indicated. Since there is no outcome measurement available 
that truly compares the benefit of different treatment strategies (i.e. SET vs. vascular 
interventions vs. a combination of both), clear criteria to identify patients that will benefit 
the most from a certain intervention are not available. Existing outcome measurements 
like walking distances, exercise tests, health related QoL questionnaires and arterial 
patency each have their flaws and are not ideally suitable to compare the contribution 
of the different treatments to the ultimate goal of treatment; regaining physical activity. 
In this article we aim to provide an up to date overview of the current literature 
regarding SET as an integrated part of the treatment for patients with IC. In addition 
we will address some future perspectives and trends in the management of IC that are 
linked to this multicomponent strategy. 
CURRENT STATUS
General management of IC
The development of IC is accelerated by the same cardiovascular risk factors as known 
for other expressions of atherosclerotic disease (i.e., coronary heart disease and 
cerebrovascular disease). Treatment of IC should therefore consist of a multicomponent 
therapy of cardiovascular risk modification (1), including lifestyle coaching (2) and 
symptomatic treatment (3). The first two components aim to prevent cardiovascular events 
(myocardial infarction, stroke) and related morbidity and mortality. Recommendations 
from numerous consensus documents, including the American College of Cardiology/ 
American Heart Association (ACC/AHA) and Trans-Atlantic Inter-Society Consensus 
on Management of Peripheral Arterial Disease (TASC II) guidelines on PAOD, 
identify patients with PAOD as a high-risk population who require intensive risk 
factor modification.1, 2 The modifiable risk factors for atherosclerosis are smoking, 
hypertension, diabetes mellitus, hyperlipidemia and obesity.14 
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International guidelines support the aggressive treatment of high blood pressure in 
patients with PAOD.15, 16 In this high-risk group the current recommendation is a goal 
of 140/90 mmHg, or even 130/80 mmHg if the patient also has diabetes or renal 
insufficiency. In PAOD, thiazides and ACE inhibitors should be considered as initial 
blood-pressure lowering drugs to reduce the risk of cardiovascular events. Beta-
adrenergic blocking drugs have been discouraged in PAOD because of the possibility 
of worsening claudication symptoms. In a Cochrane review there was no supporting 
evidence that beta-blockers adversely affect walking distance in people with intermittent 
claudication.17 However, due to the lack of large published trials beta blockers should 
be used with caution, but are not contraindicated in PAOD. 
Diabetes increases the risk of PAOD approximately three- to four-fold, and the risk of 
claudication two-fold. Diabetes is also associated with peripheral neuropathy, which 
could lead to an increased risk of foot ulcers and foot infections. In recent years, there 
has been much discussion about the optimal treatment strategy (aggressive or standard 
glucose lowering therapy) of type 2 diabetes mellitus. In a meta-analysis, an intensive 
glucose-lowering regime (glycated haemoglobin level below 6.0%) was compared to 
standard therapy (targeted a level of 7.0-7.9%) in type 2 diabetes mellitus. Overall, 
intensive therapy significantly reduced coronary events without a significant effect on 
events of stroke or all-cause mortality.18 However, aggressive control of blood glucose 
levels can not be recommended after publication of the long term results of intensive 
therapy. The results described a significantly reduced nonfatal myocardial infarction 
risk but an increased 5-year all-cause mortality rate (hazard ratio 1.21; 95% C.I. 1.02-
1.44) related with aggressive glucose lowering.19
In case of hyperlipidemia, dietary modification should be the initial intervention to 
control abnormal lipid levels. The Heart Protection Study demonstrated the benefits of 
cholesterol-lowering statin therapy in 6.748 patients with PAD and 13.788 other high-
risk participants, regardless of their presenting cholesterol levels.20 Allocation to 40 
mg simvastatin daily reduced the rate of the first major vascular events by about one-
quarter, and that of peripheral vascular events by about one-sixth, with large absolute 
benefits seen in participants with PAD because of their high vascular risk. Consequently, 
according this study statin therapy should be considered for all patients with PAOD. In 
contrast, the older ACC/AHA guidelines recommend achieving an LDL cholesterol level 
<2.59 mmol/L (<100 mg/dL) in all patients with PAOD. In patients with PAOD and 
a history of other vascular disease (i.e., coronary heart disease and cerebrovascular 
disease) it is reasonable to lower LDL cholesterol levels to 1.81 mmol/L (70 mg/dL).1 
Statins should be the primary lipid-lowering agents to lower LDL cholesterol levels. 
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Blood homocysteine levels are positively associated with cardiovascular disease, but 
it is uncertain whether the association is causal. Studies, investigating the effects of 
folic acid supplementation on major vascular events in patients with peripheral arterial 
disease, are lacking. However, in a RCT, including 12.064 survivors of myocardial 
infarction, long-term reductions in blood homocysteine levels with folic acid and 
vitamin B12 supplementation did not lead to a reduction of cardiovascular events and 
seems therefore not indicated. 21
Antiplatelet therapy reduces major vascular events (vascular death, nonfatal MI and 
nonfatal stroke) in patients with PAOD by 23%.22 Therefore, all symptomatic patients 
with or without a history of other cardiovascular disease should be prescribed long 
term antiplatelet therapy. Unfortunately, adherence to cardiovascular medication is 
fairly low.23 Self-reported consistent use (reported on ≥2 consecutive follow-up surveys 
and then through death, withdrawal, or study end) of cardiovascular medication 
was analysed using the Duke Databank for Cardiovascular Disease in patients with 
coronary artery disease, with or without heart failure.24 In 2002, consistent use was 
reported: for aspirin, 71%; beta-blockers, 46%; lipid-lowering therapy, 44%; aspirin 
and beta-blockers, 36%; and all three, 21%. Because of these findings the assessment 
of medication compliance should be incorporated in the standard care for patients with 
PAOD. 
Medication compliance as part of a SET program leans towards lifestyle coaching. 
Lifestyle coaching is the second component of the multicomponent therapy for IC and 
forms an essential part of cardiovascular risk modification. In general, the existence 
and potential value of lifestyle coaching programmes are well known. However, in 
most cases lifestyle coaching forms no part of standard care for patients with PAOD. 
Essential topics of lifestyle coaching are smoking cessation, dietary advice, weight 
control and stimulation of physical activity. Smoking is considered the single most 
important modifiable risk factor for the development of PAOD. Smokers have a risk of 
PAOD that is 4 times that of non-smokers and experience onset of symptoms almost 
one decade earlier.24-26 However, patients who are able to quit smoking are less likely 
to develop critical limb ischemia and have improved survival.27 
Patients who are moderately overweight (body mass index 25–30) or who are obese 
(body mass index >30) should receive counselling for weight reduction by means of 
dietary advice and stimulation of physical activity. Dietary advice should address 
the need for a negative caloric balance with carbohydrate restriction and reduction 
of calorie intake. The level of physical activity should be assessed and compared to 
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the global recommendations on physical activity for health, composed by the World 
Health Organization.28 All adults should do at least 150 minutes or moderate-intensity 
aerobic physical activity (usually a 5 or 6 on a scale of 0–10 of personal capacity) or 
75 minutes of vigorous-intensity aerobic physical activity (usually a 7 or 8 on a scale 
of 0–10 of personal capacity) throughout the week. 
The third and last component addresses the poor health-related QoL in patients with 
IC.  Patients with IC have a considerably poorer health status, functional capacity 
and health-related QoL compared to individuals without PAOD.12, 13 Treatments used 
to improve these impairments are pharmacologic treatment, (supervised) exercise 
therapy and invasive forms of treatment (e.g. percutaneous and surgical vascular 
interventions). The latter are occasionally used as first-line treatment. 
Pharmacologic treatment for relief of claudication symptoms typically involves other 
drugs than those used for risk reduction. Cilostazol is currently the most effective drug 
for IC.29 Approved by the FDA in 1999, the primary action of cilostazol is to inhibit 
phosphodiesterase type 3, which results in vasodilatation and inhibition of platelet 
aggregation, arterial thrombosis and vascular smooth muscle proliferation. A three to 
six-month course of cilostazol is a possible first line pharmacotherapy for the relief of 
claudication symptoms, as evidence shows both an improved walking distance as well 
as QoL.30 Naftidrofuryl can also be considered. In a meta-analysis naftidrofuryl showed 
an clinically meaningful improvement in pain-free and maximum walking distance in 
patients with IC.31 It is a 5-hydroxytryptamine type 2 antagonist and may improve 
muscle metabolism, and reduce erythrocyte and platelet aggregation. Approval of 
cilostazol or naftidrofuryl for IC is however limited to certain countries. 
 
Exercise Therapy
Exercise therapy is the first suggested therapy for patients with IC. In 1898 Wilhelm 
Erb, a German neurologist, described the successful results of exercise therapy for a 
patient with IC.32 The first randomised clinical trial (RCT) was performed by Larsen en 
Lassen in 1966.33 In this study, 7 patients treated with exercise therapy were compared 
with a control group of 7 patients who were given ‘medical treatment’ in the form of 
lactose tablets. For the group treated with exercise, a significant increase in maximum 
walking time was seen, whereas the patients in the control group did not improve. 
Nowadays, exercise therapy for patients with IC is extensively studied. In a Cochrane 
review by Watson et al. exercise therapy was compared with usual care or placebo on 
data of functional capacity outcome measurements.34 A total of twenty-two trials met the 
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inclusion criteria involving a total of 1200 participants with IC. In conclusion, compared 
to placebo and usual care, exercise therapy significantly improved maximal walking 
time with a mean difference of 5.12 minutes (95% confidence interval 4.51 – 5.72) 
and an improved maximum walking distance of 113.2 metres (range 95.0 to 131.4). 
Exercise therapy also showed a positive effect on the reduction of cardiovascular risk 
factors including hypercholesterolemia, hypertension, and diabetes mellitus.35
The most common exercise therapy prescription consists of a single oral advice, usually 
without supervision or follow-up. The adherence of patients given an oral exercise 
advice appears to be low. Comorbidity, lack of (specific) advice, fear, and lack of 
discipline and supervision are barriers to actually perform regular walking exercise.36 
For these reasons the importance of supervision was recognised. 
Supervised exercise therapy
Supervised exercise therapy (SET) entails adequate coaching by a physical therapist (PT) 
or other exercise specialist (e.g. exercise physiologist, exercise therapist, specialised 
cardiovascular nurse) and aims to increase maximal walking distance, physical activity 
and health-related QoL. The most effective programs employ treadmill walking that is 
of sufficient intensity to bring on claudication symptoms. Exercise is continued till near 
maximum pain, followed by rest, over the course of a 30–60 minute session. Exercise 
sessions are typically conducted three times a week for 3 months.2 A Cochrane review 
by Bendermacher et al. compared SET with non-supervised exercise programmes for 
patients with IC.37 SET showed statistically significant and clinically relevant differences 
in improvement of maximal walking distance compared with non-supervised exercise 
therapy regimens, with an overall effect size of 0.58 (95% confidence interval 0.31 to 
0.85) at three months. This translates into an improvement of approximately 150 meters 
of maximum walking distance in favour of the supervised group. However, additional 
studies on QoL appear to be needed to definitely demonstrate clinical effectiveness.
In a number of RCT’s SET is compared to endovascular revascularisation or surgical 
reconstruction. Spronk et al. compared functional capacity and health-related QoL 
in patients with IC during a 12 month follow-up after endovascular revascularisation 
or hospital-based SET.38 The results demonstrate that after 12 months patients with IC 
benefited equally from either endovascular revascularisation or hospital-based SET. 
Improvement is however more instantly following revascularisation. In another RCT, 
Creasy et al. found a progressive and significant improvement in walking distance 
for patients treated with exercise therapy. For the group treated with endovascular 
revascularisation a non-significant increase in walking distance was found after 3 
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months followed by a steady detoriation until 12 months follow-up.39 Only one study 
compared SET to surgical reconstruction.40 In both groups walking distance improved 
but no significant difference was found. 
To evaluate the complementary effects of angioplasty with SET, Mazari et al. randomised 
claudicants with angioplasty-suitable femoropopliteal lesions, to SET, angioplasty or 
angioplasty + SET. All the groups demonstrated significant clinical and quality of life 
improvements, but the angioplasty + SET group produced a much greater improvement 
in clinical outcome measures than angioplasty or SEP alone, without a significant QoL 
improvement.41 Also, in the MIMIC trial patients with femoropopliteal and aortoiliac 
arterial disease, were randomised to receive either PTA or no PTA against a background 
of supervised exercise and best medical therapy. The maximum walking distance was 
38% greater in the PTA group for the femoropopliteal trial (95%; CI 1-90)(p=0.04) and 
78% greater in the PTA group for the aortoiliac trial (95%; CI 0-216) (p=0.05). No 
benefits were found for health-related QoL.42
Few studies consider the long-term (>12 months) effects of SET. Gardner et al. tried 
to determine whether improvements in physical function after 6 months of SET could 
be sustained over a subsequent 12-months in older patients with IC.43 They concluded 
that improvements in maximum walking distance and physical activity level, after 6 
months of exercise training, are prolonged for an additional 12 months using a less 
intense exercise maintenance program. Ratliff et al. reported a 3-year follow-up of 212 
patients with IC who initially were treated with SET, with an exercise programme of two 
sessions a week for 10 weeks.44 Their results show that the maximum walking distance 
seen at 12 weeks is still present at three years. Based on this limited experience, it 
appears that SET has long-term benefits for patients with IC. 
In the majority of all reviewed studies on SET, an outpatient hospital setting was offered. 
This approach seems appropriate in trials, but has several limitations in daily clinical 
practise. First, the capacity of an exercise therapy program in an outpatient clinic is 
limited and not sufficient to provide SET for all patients with IC. Second, attending 
a hospital 3 times a week comes with considerable transportation costs and is time-
consuming for the individual patient. For this reason, implementation of a community-
based SET program was instigated.45 The first results of a cohort study of patients treated 
with community-based SET resulted in a highly statistically significant improvement 
in maximum walking distance (on a treadmill) after 3 and 6 months.46 The authors 
concluded that comparison of these results with historical studies on hospital-based SET 
should be done with caution due to the variability in the prescribed exercise regimens 
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and used treadmill walking tests. However, SET in a community-based setting seemed 
to be at least as efficacious as the programs provided in a clinical setting, but with a 
higher capacity.
In the ExitPAD trial, a multicenter RCT, Nicolaï et al. compared exercise therapy in the 
form of a ‘go home and walk’ advice (WA) with community-based SET for patients with 
IC.47 SET appeared to be significantly more effective than WA in improving maximum 
walking distance and health-related QoL. The data from the ExitPAD trial were also 
used to assess the cost-effectiveness of SET versus WA.48 For community-based SET, the 
incremental cost-effectiveness ratio for cost per QALY was €28.693. At a willingness-to-
pay threshold of €40.000 per QALY, SET seemed a cost-effective therapeutic option for 
patients with IC. Based on this evidence, (community-based) SET programs should be 
made available for all patients with IC, as stated in several national and international 
guidelines.1, 2, 49, 50 
FUTURE PERSPECTIVES
Although SET is considered the best evidence based therapy for all patients with IC, 
general practitioners, vascular surgeons or vascular specialists do not always have 
the disposal of (community-based) physical or exercise therapists (PTs) with specific 
knowledge of IC or exercise training. Also, not all PTs have sufficient experience 
with this specific patient category. Patients suffer from a variety of comorbidities and 
modifiable lifestyle factors, potentially generating suboptimal results. Unfortunately, too 
many examples of PTs treating patients with IC with massages and other alternative, 
non-evidence based treatments exist. For this reason Nicolaï et al extensively trained 
all participating community-based PTs before they were allowed to participate in the 
ExitPAD trial.47
To standardise treatment and assure quality of PTs in the Netherlands, the Royal Dutch 
Society for Physical Therapy developed 20 evidence based guidelines. This includes 
the guideline ‘Intermittent claudication’ published in 2003.51 Assessing guideline 
adherence was performed for the guideline ‘Lower back pain’. Bekkering et al. showed 
an adherence to the low back pain guideline for Dutch PTs in only 30% of the patients.52 
When PTs had undergone an active implementation strategy, adherence increased by 
12%. For the guideline ‘Intermittent claudication’ no studies on guideline adherence 
have been performed. It seems however likely that guideline adherence in general is 
suboptimal. Therefore the assignment of quality indicators is in our view necessary. For 
example, in Parkinson’s disease, guideline recommendations were transformed into 
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quality indicators and incorporated into a questionnaire.53 This questionnaire was sent 
to 41 expert PTs and 286 general PTs. The score of the expert panel (35.1, SD 4.2) was 
significantly higher compared to those of the general PTs (22.2, SD 7.7). The results 
emphasise that quality improving interventions are needed as guideline adherence is 
suboptimal. 
In the ideal situation, all patients with IC should receive an evidence based standardised 
form of SET by an exercise specialist. Due to lack of capacity, hospital-based exercise 
therapy should be reserved for cases with severe (cardiac) comorbidity. For this reason 
the ClaudicatioNet concept was launched in the Netherlands, in January 2011. 
ClaudicatioNet is a concept of an integrated care network between PTs, vascular 
surgeons, and general practitioners. ClaudicatioNet aims to implement nationwide 
coverage of regional networks for supervised exercise therapy (SET) and lifestyle 
interventions by PTs. Participating PTs are required to comply with a progressive 
set of quality standards over a period of 3-4 years. These efforts should result in a 
transparent, high quality care network as evaluated by objective quality indicators. 
For example, data on maximal walking ability, quality of life, comorbidities, lifestyle 
parameters, and cardiovascular risk factors will be recorded in a national database. 
PTs also need to obtain a set number of continuous medical education (CME) points on 
topics linked to PAOD. 
In our opinion, regular medication compliance should be performed four times a year 
as part of this standard SET program. If deviations of prescribed medication are noted 
by the exercise specialist the patient’s general practitioner and/or medical specialist 
should be notified. We hypothesized that due to the frequent (2-3 times a week) contacts 
of patients with their PTs, as part of a SET program, it is more likely that patients will 
truly report non-adherence. However, this is not yet substantiated.
Current and future research on SET focuses on the influence of specific comorbidities 
on prognosis and effect of SET outcome, besides the additional value of SET combined 
with a percutaneous vascular intervention (PVI).
Currently, in the Netherlands, two multicenter RCT’s are including patients to evaluate 
the effectiveness and cost-effectiveness of SET. The ERASE-trial compares SET with a 
PVI complementary to SET.54 The optimal treatment strategy for IC due to an iliac artery 
obstruction will be determined in the SUPER-trial.55 The SUPER-trial compares SET and 
deferred PVI in case of SET failure to an immediate PVI. Results have to be awaited 
and interpreted in view of the limited experience in SET among the participating PTs.  
In the United States, another large multicenter RCT is being conducted. In approximately 
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25 centers 252 patients will be followed over a period of 18 months.56 The treatment 
arms are: 1. optimal medical care (OMC); 2. OMC and primary stent placement; 3. 
OMC and SET; and 4.combined stenting with SET and OMC. In this so called CLEVER 
trial, the researchers aim to find the optimal treatment strategy for IC for the endpoints 
maximal walking duration and health-related QoL. In these trials no usage of the future 
possibilities aimed for in ClaudicatioNet will be measured (i.e. lifestyle coaching, 
smoking cessation strategies, concurrent use of concomitant comorbidity guidelines 
like COPD etc.). However, currently it is the best SET we have and results are eagerly 
waited for.
Although there is little evidence yet, SET could also be effective for patients with critical 
limb ischemia as an adjuvant to a revascularisation procedure. Kruidenier et al. 
performed a RCT to investigate the effects of SET after a PVI for patients with all stages of 
PAOD, mainly IC.57 They found that SET following PVI was more effective in increasing 
maximum walking distance than PVI alone. Badger et al. evaluated the efficacy of 
an exercise program after arterial bypass surgery for short distance intermittent 
claudication or critical ischemia.58 SET resulted for this group in an increased maximum 
walking distance of 175% compared to 4% for the group with usual care. These studies 
indicate that SET is a useful adjunct after a PVI or lower limb bypass surgery. Further 
research should confirm the clinical effectiveness of SET after a vascular intervention for 
the subgroup of patients with critical limb ischemia.
CONCLUSION
Multicomponent treatment of IC should address two important targets; reduction of 
cardiovascular events (and related morbidity and mortality) and improvement of the 
poor health-related QoL and functional capacity. Based on current evidence, SET 
appears to be the primary and most effective intervention for patients with IC. With 
the implementation of ClaudicatioNet in The Netherlands, a nationwide integrated 
care network of specialised PTs, enables the delivery of a multicomponent therapy to 
all patients with IC. Current and future research focuses on the influence of specific 
comorbidities on prognosis and effect of SET outcome and the potential beneficial 
effects of SET combined with (minimally) invasive vascular interventions.
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ABSTRACT
Objectives 
Although international guidelines state that supervised exercise therapy (SET) should be 
offered to all patients with intermittent claudication (IC), SET appears to be underutilised 
in clinical practice. The aim of this study was to document current opinions of Dutch 
vascular surgeons on SET as treatment option for peripheral arterial occlusive disease 
(PAOD).
Materials and methods
Vascular surgeons and fellows in vascular surgery were asked to complete a 24-question 
survey either at the 2011 Annual Meeting of the Dutch Society for Vascular Surgery 
or online.
Results
Ninety-one participants, including 83 vascular surgeons (51% of all Dutch vascular 
surgeons), completed the survey. The respondents would refer 75.4% of newly 
diagnosed patients with IC for SET. SET was considered less useful in patients with 
IC and major (cardiopulmonary) comorbidity or a significant iliac artery stenosis. In 
critical limb ischemia, the combination of SET and angioplasty was considered useful in 
71.9%. Respondents regarded patient satisfaction (63.3%) and improvement in pain-
free or maximal walking ability (26.6%) as clinically most relevant goals of SET. Most 
(84.4%) agreed that SET should also include lifestyle management.
Conclusion
Although the vast majority of Dutch vascular surgeons consider SET as an important 
treatment option for PAOD, SET should receive more emphasis in clinical practice since 
arguments not to refer for SET are outdated. Furthermore, vascular surgeons agree that 
lifestyle management should be integrated in SET.
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INTRODUCTION
In the management of intermittent claudication (IC), supervised exercise therapy 
(SET) leads to superior results (walking distances, quality of life) compared to a single 
walking advice.1,2 When compared to angioplasty, patients with IC benefited equally 
from either angioplasty or hospital-based SET after a 12-month follow-up.3,4 SET is 
safe and does not cause morbidity or mortality. For this reason, initial management 
of IC should consist of cardiovascular risk management and SET, as clearly stated in 
contemporary international guidelines.5,6
Community-based SET seems as efficacious as hospital-based SET, is cost-effective 
and should therefore be available for all patients with IC.7,8 Nonetheless, in clinical 
practice, SET seems underutilised because of limited availability of physical or exercise 
therapists with specific knowledge on peripheral arterial occlusive disease (PAOD) 
and/or a SET treatment protocol. For this reason Nicolaï et al. extensively trained 
all participating community-based physical therapists before they were allowed to 
participate in the multicenter randomised controlled ExitPAD trial.2 Another explanation 
for the underutilisation of SET could be the differing views on the indications for SET, 
such as concomitant significant cardiopulmonary comorbidity, patient’s age, aortic or 
iliac artery obstruction as cause of IC, or SET in combination with revascularisation for 
critical limb ischemia (CLI). Furthermore, in severe or invalidating cases of IC vascular 
surgeons often perform a vascular intervention. However, a solid definition of ‘severely 
disabling’ or ‘invalidating’ IC is lacking. 
The aim of this study is to document current opinions of vascular surgeons and fellows 
in vascular surgery on SET as treatment option for PAOD. We specifically wanted to 
find out to what extent and on which criteria Dutch vascular surgeons decide to offer 
or deny SET to patients with PAOD.
MATERIALS AND METHODS
In spring 2011, Dutch vascular surgeons and fellows in vascular surgery were asked 
to complete a 25-question survey regarding SET as treatment option for PAOD. 
Participants could complete the survey on the Annual Meeting of the Dutch Society for 
Vascular Surgery or on a secure online website. Most questions (21/25) were defined 
as statements that participants could agree or disagree with. One question was a 
multiple answer question, three were open-ended questions (regarding the number of 
SET referrals per hospital, percentage of all patients with IC referred and criteria for 
successful conservative therapy). 
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Data extraction
Data extraction was performed by two independent investigators (GL, HvD). All surveys 
were analysed for missing answers and the number of responses per question were 
noted. If answers were unclear, the same investigators determined if the answer could 
be classified to a specific category. If this was not possible or in case of disagreement 
between the two investigators the answer was excluded from analysis. For the open-
ended question ‘when is conservative therapy considered successful’, answers were 
classified by each of the two investigators. In case of disagreement, concurrence was 
sought by means of discussion. For the remaining open-ended questions the numbers 
and percentages were extracted. When a range of numbers or percentages was given, 
the mean was calculated and used as definitive answer. 
Statistical Analysis
Data were analysed for both descriptive and analytical statistics. Because of a 
skewed distribution of continuous variables (referral data), evaluated by a one-
sample Kolmogorov-Smirnov test, we performed a Mann-Whitney U Test to determine 
statistical difference between two groups. Medians and interquartile ranges (IQR) were 
calculated to describe the spread of data. A p-value < 0.05 was considered to indicate 
statistical significance. All analyses were performed using IBM SPSS Statistics Version 
19 (SPSS Inc., Chicago).
RESULTS
Participants
In total 91 participants, including 83 vascular surgeons, completed the survey. This 
comprises 51% of all Dutch vascular surgeons and seems therefore representative 
as nationwide survey. All respondents are further classified by gender, age group, 
professional career and hospital setting (Table 1). 
Referral information
The number of new patients with IC, treated annually, was estimated to be 476 per 
hospital (median 400, IQR 260-640). No significant (p=0.626) difference was found 
between academic and non-academic hospitals. Overall, 88 respondents estimated to 
refer on average 75.4% (median 80%, IQR 66.3 – 95.0) of their patients with IC for 
SET.
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TABLE 1 Baseline characteristics
Number of Responses (%)










Fellow in vascular surgery 8 (8.8)
Vascular surgeon 83 (91.2)
Professor in vascular surgery 3 (3.3)
Hospital setting
Academic hospital 15 (16.5)
Non-academic hospital 76 (83.5)
SET indications
Table 2 lists the attitude towards indications for SET. Most respondents had a positive 
attitude towards SET in general. However, continuation of SET after three months 
of treatment without functional improvement, was only preferred by 60.0% of the 
respondents.
Most respondents did not consider a maximum walking distance of <100m or age 
older than 80 years a contraindication for SET. However, in patients with a significant 
iliac artery stenosis (70.8%), patients with a coinciding chronic pulmonary condition 
(e.g. COPD) (65.9%) or chronic heart failure (69.8%), SET was less frequently thought 
to be useful. 
As additional treatment before or after angioplasty for CLI, SET was thought to be 
useful by 71.9% of the respondents while 64.8% would recommend SET as an adjunct 
to bypass surgery.
42
CHAPTER 3 | When is supervised exercise therapy indicated for intermittent claudication? 




SET is more effective than a single walking advice 100 (89/89)
In addition to CVRM, SET is the primary treatment for IC 96.7 (88/91)
Community-based SET is as effective as hospital-based SET 93.3 (84/90)
Feedback of the physical therapist contributes to patient 
management
85.6 (77/89)
Continuation of SET is useful if patients do not improve in the 
first 3 months of treatment
60.0 (54/86)
SET for intermittent claudication is useful in:
- patients with a maximal walking distance of <100m 84.4 (76/85)
- patients older than 80 years 81.8 (72/81)
- patients who underwent angioplasty 81.1 (73/89)
- intermittent claudication caused by a significant iliac stenosis 70.8 (63/83)
- patients with not-decompensated chronic heart failure 69.8 (60/84)
- patients with a chronic pulmonary condition (e.g. COPD) 65.9 (60/87)
SET for critical limb ischemia is useful in addition to: 
- angioplasty 71.9 (64/84)
- peripheral bypass surgery 64.8 (57/86)
SET: supervised exercise therapy; IC: intermittent claudication; CVRM: cardiovascular risk management
Definition of successful conservative management
In total, 91 respondents gave 109 categorised answers to the open question; when is 
conservative management (cardiovascular risk management and SET) for IC considered 
successful? Patient satisfaction (63.3% of all answers) and progress in pain-free or 
maximal walking ability (26.6% of all answers) were the most prevalent criteria to 
determine successful conservative management (Table 3).
 
Invalidating IC
The decision to perform angioplasty for IC is determined by the interpretation of 
‘severely disabling’ or ‘invalidating’ IC. For this reason, respondents were asked which 
variables contributed to the decision to perform angioplasty with a multiple-answer 
question. Limitations in daily life (LDL), patient reported walking ability (WA-P) and 
walking ability determined in the vascular laboratory (WA-V) were possible answer 
options. Respondents could also mention other factors influencing their decision 
to perform angioplasty. The combination of LDL, WA-P and WA-V was thought to 
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contribute the most to choosing an angioplasty (32.2%) followed by LDL alone (23.3%), 
LDL in combination with WA-P (20.0%) and LDL in combination with WA-V (12.2%) 
(Table 4). Other mentioned responses were anatomic location of the stenosis/occlusion 
(n=3), type of stenosis (n=2), effect of three months of SET (n=1), cardiopulmonary 
condition (n=1) and patency of the procedure (n=1). LDL alone or in combination with 
WA-P or WA-V was mentioned in 87.8% of all answers (n= 79/90). Walking ability 
(WA-P or WA-V) was mentioned in 76.7% of all answers (n=69/90). Therefore the 
patient’s LDL seems to be more contributing to the decision to perform an angioplasty 
then the patient’s walking ability.
TABLE 3 When is conservative therapy considered successful in IC?
% n
Patient satisfaction 63.3 (69/109)
Progress in pain-free or maximal walking ability 26.6 (29/109)
Progress in quality of life 2.8 (3/109)
Increased ankle-brachial index 2.8 (3/109)
No further decline in pain-free or maximal walking ability 1.8 (2/109)
Adjustment of patient’s lifestyle 1.8 (2/109)
ADL recovery 0.9 (1/109)
IC: intermittent claudication; ADL: activities of daily living
TABLE 4 Determinants for angioplasty in invalidating IC
% n
LDL + WA-P + WA-V 32.2 (29/90)
LDL 23.3 (21/90)
LDL + WA-P 20.0 (18/90)
LDL + WA-V 12.2 (11/90)
WA-P + WA-V 5.6 (5/90)
WA-P 5.6 (5/90)
WA-V 1.1 (1/90)
IC: intermittent claudication; LDL: Limitations in Daily Life; WA-P: Patient reported Walking Ability;  
WA-V: Vascular Laboratory determined Walking Ability
Content of SET
Most participants agreed that supervised walking exercise (100%) and lifestyle 
interventions (84.4%) should be part of supervised exercise rehabilitation. Assessment 
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of medication adherence, side effects and blood glucose levels was not thought to be 
contributing to supervised exercise rehabilitation (Table 5)
TABLE 5 Supervised exercise rehabilitation should contain…
Agreement
% n
Supervised walking exercise 100 (90/90)
Lifestyle interventions (e.g. smoking cessation, dietary advice) 84.4 (76/90)
Supervised alternative exercise (e.g. cycling, strength training) 62.2 (56/90)
Cardiopulmonary risk assessment 54.4 (49/90)
Assessment of used medication 45.6 (41/90)
Assessment of medication adherence 32.2 (29/90)
Assessment of drug side effects 22.2 (20/90)
Assessment of blood glucose levels (in case of DM type 2) 18.9 (17/90)
DM: diabetes mellitus
DISCUSSION
The TASC II Inter-Society Consensus for the Management of Peripheral Arterial Disease 
recommends SET as part of the initial treatment for all patients with PAOD.5 As shown 
in our study, the vast majority of Dutch vascular surgeons and fellows in vascular 
surgery have a positive attitude towards SET as treatment option for IC and even CLI. 
More than three-quarters of new patients with IC are estimated to be referred for SET. 
Results could be influenced by responder bias, most likely in favour of a positive attitude 
towards SET. Therefore, the found attitude towards SET may in fact be less positive 
in real life. In a study on the use of SET in the United Kingdom, a large spread in 
proportion of patients referred for SET was found.9 Furthermore, only 24% of resident 
surgeons had access to supervised exercise in the UK. In the Netherlands, community-
based physical therapists are readily available and can provide SET according the 
guidelines of the Royal Dutch Society for Physical Therapy, although not all physical 
therapists are adequately schooled. 
 
Besides limited availability of qualified therapists providing SET, the infrastructure of the 
health care system can also be a reason for underutilisation of SET. If patients need to 
pay a significant amount of SET treatments one might argue that angioplasty would be 
more attractive from a patient point-of-view. In the Netherlands, the first 12 treatments 
in 2011 (20 treatments in 2012) are covered by an additional health care insurance. 
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The basic health care insurance covers all additional SET treatments for IC until one 
year of training. Since most patients have an additional health care insurance, SET 
does not lead to any additional costs for the patient in the Netherlands. However, in 
other countries this could surely be one of the reasons of SET underutilization. 
This study showed that the criteria not to refer for SET are largely based on existence of 
major comorbidity (e.g. pulmonary, cardiac) or a significant iliac stenosis causing IC. 
Apparently, the respondents did not consider SET to be successful in these particular 
patients. This could be explained by concern of major complications or the belief that 
SET is ineffective to improve walking ability or quality of life in these particular patients. 
Nonetheless, COPD has shown to be present in 16% of all patients with PAOD for 
which pulmonary rehabilitation (PR) is strongly indicated to increase physical 
functioning, reduce hospital admissions, reduce respiratory symptoms and improve 
ADL-activities.10,12 PR consists primarily of supervised aerobic exercise (e.g. treadmill 
walking, cycling) in a moderate to severe intensity. Although treatment regimens of PR 
are not identical to SET for IC, a significantly improved health-related quality of life and 
walking distances were found for PR after 12 months of exercise.13 
Coronary artery disease has shown to be present in 46-58% of all patients with PAOD, 
of which 22% even had active ischemia.10,14 For these coronary conditions, requiring 
hospitalisation or cardiac revascularisation procedures, cardiac rehabilitation in the 
form of a moderate intensity aerobic exercise training was associated with a 21-
34% decrease in 5-year mortality.15 Likewise for congestive heart failure, cardiac 
rehabilitation is also advised with a class Ib recommendation.16 For these patients 
exercise training resulted in a modest (11%) reduction in the adjusted risk for all-cause 
mortality.17 
Exercise training also appears to be safe in patients with coronary heart disease. In a 
systematic review, more than 2 million exercise hours, performed by 51.000 patients 
with coronary heart disease, were analysed.18 In total, 21 cardiac arrests (of which 3 
fatal) and 8 nonfatal myocardial infarctions (MI) were found, equivalent to 1 cardiac 
arrest per 112.000 exercise hours, 1 acute MI per 300.000 exercise hours and 1 
fatality per 800.000 exercise hours. It is questionable whether these rates are higher 
than the naturally occurring rates of these events. It is clear that SET should be offered 
to patients with coexistence of IC and congestive HF, chronic pulmonary conditions 
or coronary conditions, although patient monitoring and exercise intensity should be 
adjusted to the patient’s conditions. 
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In case of a significant iliac artery stenosis causing IC, studies comparing SET to 
angioplasty are lacking. Currently, in the Netherlands, the multicenter randomised 
controlled SUPER trial is enrolling 300 patients to investigate which treatment modality 
should be performed: SET and deferred angioplasty (in case of SET failure) or immediate 
angioplasty.19 The complementary effects of SET and angioplasty have been described 
previously. In the MIMIC trial, patients with femoropopliteal and aorto-iliac arterial 
disease were randomised to receive either PTA or no PTA against a background of SET 
and best medical therapy.20 The maximum walking distance after 24 months of follow up 
was 38% greater in the PTA group for the femoropopliteal trial (95%; CI 1-90)(p=0.04) 
and 78% greater in the PTA group for the aorto-iliac trial (95%; CI 0-216) (p=0.05). 
No benefits were found regarding health-related quality of life. Although more studies 
are needed to determine the effect of SET for this particular group of claudicants, SET 
seems to show beneficial effects when combined with a vascular intervention. 
Although there is little evidence yet, SET may also be effective as adjuvant to a 
revascularisation procedure in patients with invalidating IC or CLI. Kruidenier et al. 
performed a RCT to investigate the effects of SET after angioplasty for patients with 
all stages of PAOD.21 They found that SET following angioplasty was more effective in 
increasing maximum walking distance than angioplasty alone. Badger et al. evaluated 
the efficacy of an exercise program after arterial bypass surgery for short distance 
intermittent claudication or CLI.22 SET resulted for this group in an increased maximum 
walking distance of 175% compared to 4% for the group with usual care. Although not 
all included patients had CLI, these studies indicate that SET could be a useful adjunct 
after angioplasty or bypass surgery. In this study, SET was considered by 71.9% of 
the respondents in addition to angioplasty and 64.8% in addition to bypass surgery. 
Although more evidence is needed, SET seems to have a role in the treatment of CLI. 
One might argue that besides smoking cessation, regaining physical activity in patients 
with PAOD, is the most important determinant to reduce major cardiovascular events 
and mortality. Healthy individuals engaging in moderate-intensity physical activity 
(150min/wk) had a 14% lower coronary heart disease risk compared with 20% 
reduction in those engaging 300min/wk of exercise.23 Therefore, any physical activity is 
probably better than none and additional benefit occurs with more physical activity. The 
respondents agreed that lifestyle interventions, such as a minimal intervention strategy 
for smoking cessation, should be integrated in SET to further reduce progression of 
atherosclerosis, cardiovascular events and even mortality. Given the frequent contacts 
of physical or exercise therapist, a future role as lifestyle coaches for these specialists 
is conceivable. 
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Currently, in the Netherlands, a nationwide network (ClaudicatioNet) of vascular 
surgeons and physical therapists is being implemented. National coverage should 
exist in 2015. In this concept, physical therapists are trained in providing SET and 
lifestyle interventions tailored to the patient’s needs. To remain network participation 
they need to comply with quality standards such as reporting patient progress to a 
national database, complying with audits and continuous medical education. After 
completion of a regional network, vascular surgeons are expected to refer only to those 
physical therapists, accredited by ClaudicatioNet. Results are eagerly awaited for, but 
this initiative will further improve the quality of conservative management of PAOD in 
the Netherlands. 
CONCLUSION
SET is considered an important component of the management of PAOD. Conditions 
that are perceived as contraindications for SET, including cardiopulmonary morbidity, 
are in fact additional indications for participation in an exercise program. Limited 
availability of qualified therapists and financial barriers in healthcare systems can add 
to this underuse. Ideally, therapists providing SET would also play a role in lifestyle 
management of patients with PAOD.
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ABSTRACT 
Background
According to international guidelines and literature, all patients with intermittent 
claudication should receive an initial treatment of cardiovascular risk modification, 
lifestyle coaching, and supervised exercise therapy. In most studies, supervised exercise 
therapy consists of treadmill or track walking. However, alternative modes of exercise 
therapy have been described and yielded similar results to walking. Therefore, the 
following question remains: Which exercise mode gives the most beneficial results?
Objectives
Primary objective: To assess the effects of different modes of supervised exercise therapy 
on the maximum walking distance (MWD) of patients with intermittent claudication. 
Secondary objectives: To assess the effects of different modes of supervised exercise 
therapy on pain-free walking distance (PFWD) and health-related quality of life scores 
(HR-QoL) of patients with intermittent claudication.
Search methods
The Cochrane Peripheral Vascular Diseases Group Trials Search Coordinator searched 
the Cochrane Peripheral Vascular Diseases Group Specialised Register (July 2013); 
CENTRAL (2013, Issue 6), in The Cochrane Library; and clinical trials databases. The authors 
searched the MEDLINE (1946 to July 2013) and Embase (1973 to July 2013) databases 
and reviewed the reference lists of identified articles to detect other relevant citations.
Selection criteria
Randomised controlled trials of studies comparing alternative modes of exercise 
training or combinations of exercise modes with a control group of supervised walking 
exercise in patients with clinically determined intermittent claudication. The supervised 
walking programme needed to be supervised at least twice a week for a consecutive 
six weeks of training.
Data collection and analysis
Two authors independently selected studies, extracted data, and assessed the risk of 
bias for each study. Because of different treadmill test protocols to assess the maximum 
or pain-free walking distance, we converted all distances or walking times to total 
metabolic equivalents (METs) using the American College of Sports Medicine (ACSM) 
walking equation.
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Main results
In this review, we included a total of five studies comparing supervised walking exercise 
and alternative modes of exercise. The alternative modes of exercise therapy included 
cycling, strength training, and upper-arm ergometry. The studies represented a sample 
size of 135 participants with a low risk of bias. Overall, there was no clear evidence of 
a difference between supervised walking exercise and alternative modes of exercise in 
maximum walking distance (8.15 METs, 95% confidence interval (CI) -2.63 to 18.94, 
P = 0.14, equivalent of an increase of 173 metres, 95% CI -56 to 401) on a treadmill 
with no incline and an average speed of 3.2 km/h, which is comparable with walking 
in daily life.
Similarly, there was no clear evidence of a difference between supervised walking 
exercise and alternative modes of exercise in painfree walking distance (6.42 METs, 
95% CI -1.52 to 14.36, P = 0.11, equivalent of an increase of 136 metres, 95% CI 
-32 to 304).
Sensitivity analysis did not alter the results significantly. Quality of life measures showed 
significant improvements in both groups; however, because of skewed data and the 
very small sample size of the studies, we did not perform a meta-analysis for health-
related quality of life and functional impairment.
Authors’ conclusions
There was no clear evidence of differences between supervised walking exercise and 
alternative exercise modes in improving the maximum and pain-free walking distance 
of patients with intermittent claudication. More studies with larger sample sizes are 
needed to make meaningful comparisons between each alternative exercise mode 
and the current standard of supervised treadmill walking. The results indicate that 
alternative exercise modes may be useful when supervised walking exercise is not an 
option for the patient.
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PLAIN LANGUAGE SUMMARY
Modes of exercise training for intermittent claudication
Intermittent claudication is a cramping leg pain that develops during exercise and is 
relieved by a short period of rest. It is caused by inadequate blood flow to the muscles 
of the leg because of atherosclerosis (hardening and narrowing of the arteries). 
Intermittent claudication is closely associated with other vascular diseases, such as a 
heart attack or stroke. Therefore, all patients with intermittent claudication should receive 
cardiovascular risk management and lifestyle coaching to reduce cardiovascular risk 
factors.
To improve the walking capacity and quality of life, supervised exercise therapy is 
the primary treatment according to the current scientific evidence. Community-based 
supervised exercise appears to be at least as effective as programmes provided in 
a hospital setting. In the literature, supervised exercise therapy usually consists of 
treadmill walking. However, alternative modes of exercise therapy (e.g. cycling, 
strength training) have been described, with beneficial effects on walking capacity and 
quality of life. Therefore, the following question remains: Which exercise mode gives 
the most beneficial results?
The present review shows that there are few studies comparing alternative modes of 
exercise training to the standard of supervised walking exercise. The review authors 
identified five studies that randomised a total of 135 participants. The alternative modes 
of exercise therapy included cycling, strength training, and upper-arm ergometry. 
Comparing these alternative modes of exercise with supervised walking exercise 
showed no clear evidence of a difference in maximum or pain-free walking distance 
between the groups. Quality of life measures showed significant improvements in both 
groups; however, we could not make a direct comparison because of limited data. 
This review shows that alternative modes of exercise therapy seem to yield similar 
results to supervised walking therapy. Therefore, they may be considered useful when 
supervised walking exercise is not an option for the patient. However, more randomised 
controlled trials are needed to make a meaningful comparison between the different 
modes of exercise therapy.
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BACKGROUND
Description of the condition
Peripheral arterial occlusive disease (PAOD) is a chronic arterial occlusive disease 
caused by progressive atherosclerosis. Several arterial segments can be affected, such 
as the aorta; iliac; and femoral, popliteal, and tibial arteries in the limbs. The most 
common symptom is intermittent claudication (IC), defined as a cramping pain in the 
muscles of the leg(s) that occurs during exercise and is relieved by a short period of 
rest. Because of this condition, patients have a diminished maximum and pain-free 
walking capacity, leading to diminished health-related quality of life.1
The incidence of IC increases with age, with an annual incidence rate of 0.7%, 3.9%, 
and 10.6% among 35- to 44-year-old men, 45- to 54-year-old men, and 55- to 
64-year-old men, respectively.2 In women, the incidence rates are approximately 50% 
lower.2 IC restricts patients’ activity and mobility and considerably reduces their health-
related quality of life.1,3 In addition, because of the ongoing generalised atherosclerotic 
process, IC is closely associated with cardiovascular morbidity and mortality. Patients 
with IC have a five-year all-cause mortality rate of 10% to 15% and a 20% chance of 
a non-fatal cardiovascular event.4 When IC progresses to critical limb ischaemia, an 
even higher mortality rate of 25% after one year is found.5
Description of the intervention
Because of the serious health risks, all patients with IC should receive a multicomponent 
therapy consisting of cardiovascular risk modification, lifestyle coaching, and exercise 
therapy.5 Several randomised controlled trials and systematic reviews compared 
walking exercise supervised by a physical or exercise therapist to non-supervised 
exercise, usual care, placebo, single walking advice, endovascular interventions, or 
bypass surgery.6-10 
The current evidence supports supervised exercise therapy as the primary treatment 
for improvement of walking capacity and health-related quality of life in patients 
with IC. Furthermore, community-based supervised exercise appears to be at least as 
efficacious as programmes provided in a hospital setting.11-13 However, less attention 
has been paid to the mode of (supervised) exercise. Besides walking, alternative modes 
of supervised exercise training, such as cycling, upper-extremity cycle ergometer 
exercise and strength training exist and are associated with a significantly improved 
walking capacity.14-16 
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How the intervention might work
A number of potential mechanisms have been suggested for the reduced functional 
capacity in IC, such as blood flow limitation due to arterial obstruction, disruption of 
endothelial function, altered skeletal muscle phenotype by mitochondrial dysfunction, 
increased blood viscosity, and inflammatory activation.17 Exercise has the potential 
to reverse these pathological events and thereby interrupt the clinical course toward 
disability.17
Why it is important to do this review
In most studies, supervised exercise programmes involve treadmill or track walking that 
is of sufficient intensity to bring on claudication pain. Walking exercise is alternated 
with rest over the course of a 30- to 60-minute session. Exercise therapy for IC is 
recommended at least three times a week for three months, although there does not 
seem to be a clear dose-response relationship between exercise volume or intensity 
and symptom relief.5,18 Unfortunately, some groups of patients with IC are not capable 
of completing the exercise protocol because of concomitant comorbidities, such as 
arthrosis, chronic obstructive pulmonary disease, stroke, or cardiac complaints. For 
these patients, an adjusted protocol or alternative exercise regime may be proposed.
Recently, a systematic review comparing any mode of exercise, whether supervised or 
unsupervised, was published.18 It suggested that alternative modes of aerobic exercise, 
other than walking, appear equally beneficial compared to walking exercise, while the 
effects of progressive resistance training and upper body exercise seem only promising. 
The effect size of each exercise mode was calculated and compared to the effect size of 
walking exercise. However, because of heterogeneity, no meta-analysis was performed 
on specific randomised controlled trials (RCTs) comparing the standard of supervised 
walking exercise to alternative exercise regimes.
Therefore, the question regarding which exercise mode gives the most beneficial results 
in walking distance, health-related quality of life, or both, in patients with IC remains 
to be answered. Previous Cochrane systematic reviews focused on the effect of exercise 
compared with usual care and the value of a supervised exercise programme in 
relation to non-supervised exercise.7,19 This systematic review will determine the effect 
of alternative exercise modes by analysing randomised controlled trials comparing 
the current standard of supervised walking exercise to alternative modes of exercise. 
Studies focusing on this research topic are increasing, implicating the need for a 
regular update of this review in the upcoming years.
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OBJECTIVES
Primary objective: To assess the effects of different modes of supervised exercise therapy 
on the maximum walking distance (MWD) of patients with intermittent claudication. 
Secondary objectives: To assess the effects of different modes of supervised exercise 
therapy on pain-free walking distance (PFWD) and health-related quality of life scores 
(HR-QoL) of patients with intermittent claudication.
METHODS
Criteria for considering studies for this review
Types of studies
We included parallel-group, randomised controlled trials (RCTs) comparing 
(combinations of) alternative modes of exercise training (for example, ergometry, 
strength training, aerobic exercise, etc.) with supervised walking exercise in patients 
with IC. We excluded crossover, factorial, or cluster RCTs.
Types of participants
The study population consisted of adults (18 years and older) with clinically determined 
IC, according to Fontaine stage II or Rutherford stages 1 to 3, who were considered 
for conservative treatment. We excluded studies of participants with asymptomatic 
lower-limb atherosclerosis identified by testing. When studies described a mixture 
of asymptomatic and symptomatic participants, we contacted the authors to ask if a 
subanalysis was available. If not, we excluded these studies.
Types of interventions
We included all RCTs comparing alternative modes of exercise training (e.g. arm 
ergometry, strength training, cycling, etc.) or combinations of exercise modes with 
a control group of supervised walking exercise. Supervised walking exercise needed 
to be supervised at least twice a week for a consecutive six weeks of training. We 
excluded studies reporting an exercise programme with a duration of less than six 
weeks of training or with less than two supervised walking sessions a week. 
Since different types of alternative exercise modes are associated with an increased 
walking capacity, we combined all studies with different alternative exercise modes 
in one analysis. However, to analyse the effect of each individual or combined 
alternative exercise modes, we performed a subgroup analysis on the exercise mode 
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(or combination) if more than one study was available. We excluded all types of 
mechanical intermittent compression treatments as we did not consider them to be 
exercise training. Furthermore, we did not include studies comparing different types of 
walking exercise (supervised versus unsupervised, community versus hospital-based) 
or comparisons of different walking protocols (low- versus high-frequency training, 
low- versus high-intensity training, different treadmill exercise protocols).
Types of outcome measures
Primary outcomes
The primary outcome measurement was the maximum walking distance (MWD) 
measured by a treadmill test. Outcome measurements needed to be available at 
baseline and after at least six weeks of follow up. In case of different treadmill test 
protocols, we converted walking times or distances to total metabolic equivalents (total 
METs or sum of METs during the walking period).
Secondary outcomes
Secondary outcome measurements were the pain-free walking distance
(PFWD) and health-related quality of life (HR-QoL) scores. Besides a baseline 
measurement, results needed to be available after at least six weeks of follow up. In 
case of different treadmill test protocols, we converted walking times or distances to 
METs.
Search methods for identification of studies
Electronic searches
We did not use language restrictions. The Cochrane Peripheral Vascular Diseases 
Group Trials Search Coordinator (TSC) searched the Cochrane Peripheral Vascular 
Diseases Group Specialised Register (last searched July 2013) and the Cochrane 
Central Register of Controlled Trials (CENTRAL) 2013, Issue 6, part of The Cochrane 
Library, www.thecochranelibrary.com. The Specialised Register is maintained by 
the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, 
CINAHL, AMED, and through handsearching relevant journals. The full list of the 
databases, journals and conference proceedings which have been searched, as well 
as the search strategies used are described in the Specialised Register section of the 
Cochrane Peripheral Vascular Diseases Group module in The Cochrane Library www.
thecochranelibrary.com. 
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The TSC searched the following trial databases (July 2013) for details of ongoing and 
unpublished studies using the terms exercise and claudication:
• The World Health Organization International Clinical Trials Registry (ICTRP) platform 
(apps.who.int/trialsearch/).
• The US National Institutes of Health Ongoing Trials Register (www.clinicaltrials.gov).
• The metaRegister of Controlled Trials (www.controlledtrials.com/isrctn/).
Searching other resources
The authors searched MEDLINE (1946 to 15 July 2013) and Embase (1973 to 15 
July 2013). We reviewed the reference lists of articles identified by the above search 
strategies to identify other relevant citations.
Data collection and analysis
Selection of studies
GJL and FF independently selected trials for this review. SS and JT confirmed the 
suitability of selected trials for inclusion in the review. We sought additional information 
for included trials, if necessary.
Data extraction and management
GJL and FF independently extracted data using a standard data collection form created 
for this review. We entered the data into Review Manager (RevMan 5.2). We resolved 
disagreements between the review authors by discussion. SS acted as arbiter if no
consensus was achievable. The extracted study data consisted of the following:
1. study characteristics, including study design, method of randomisation, exclusions 
postrandomisation, publication year, country, and study period;
2. baseline characteristics, including number of participants, losses to follow up, mean 
age, gender distribution, and inclusion and exclusion criteria;
3. type of interventions, including mode(s) of exercise, duration of programme, number 
of sessions, number of supervised sessions, and exercise protocol; and
4. the mean maximum walking distance or time, mean painfree walking distance or 
time, and mean quality of life scores at baseline and follow-up periods.
Assessment of risk of bias in included studies
The authors (GJL and FF) assessed the risk of bias for each study as described in the 
Cochrane Handbook for Systematic Reviews of Interventions 20 for each of the following 
domains:
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1. randomisation/sequence generation;
2. allocation concealment;
3. blinding (of participants, personnel, and outcome assessors);
4. incomplete outcome data;
5. selective outcome reporting; and
6. publication and other sources of bias.
Measures of treatment effect
To analyse treatment effect, we assessed the MWD, PFWD, and HR-QoL scores after 
participation in the exercise programme. In the case of different treadmill test protocols, 
we converted walking times or distances to total METs (sum of METs during the walking 
period) using the American College of Sports Medicine (ACSM) walking equation.21 
The ACSM walking equation includes the time, speed, and inclination of the treadmill 
test. Since direct conversion of the walking times or distances to METs was not possible 
because of the absence of individual participant data, we simulated a new dataset 
for each study. We used post intervention walking distances and variances from 
the intervention and control group to simulate a new dataset assuming a normal 
distribution. For each simulated individual, we calculated the number of METs using the 
ACSM walking equation. We used the summary measures (mean METs and variances) 
from each simulated dataset as post intervention outcomes from the included studies.
Unit of analysis issues
We searched for RCTs with at least six weeks’ duration of training and a parallel-group 
design. We included no crossover trials in this review. In assessment of the primary and 
secondary outcomes, we considered the participant the unit of analysis.
Dealing with missing data
We expected missing standard deviations for walking distances. In the case of missing 
data, we requested data from the original investigators, if appropriate. We did not 
impute missing outcome data for the primary and secondary outcomes.
Assessment of heterogeneity
For all the outcome measures, we assessed statistical heterogeneity by calculating the 
Q-statistic or Chi2 test (P < 0.10 considered as heterogeneous) and the I2 statistic (I2 
statistic greater than 50% considered as moderate to substantial risk of heterogeneity) in 
order to assess to what degree the data from the included studies were heterogeneous.20 
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Assessment of reporting biases
In case of sufficient studies (> 10 studies), we planned to assess publication bias with 
a funnel plot with the maximum walking distance on the X axis and the standard 
error of each study on the Y axis.20 If there is bias, for example, because smaller 
studies without statistically significant effects remain unpublished, this will lead to an 
asymmetrical appearance of the funnel plot. In this situation, the effect calculated by 
the meta-analysis will tend to overestimate the intervention effect. Therefore, we also 
planned
to evaluate funnel plot asymmetry using Begg and Egger tests 22,23 performed with Stata 
statistical software.24
Data synthesis
To analyse treatment effect, we used the DerSimonian and Laird random-effects 
model. This model takes the variance between studies and the variance within a study 
into account.25 We summarised the data of each study in forest plots and calculated 
summary estimates with a 95% confidence interval. We considered a two-sided P 
<0.05 as statistically significant, except for the test of publication bias for which the 
recommended levels are P <0.10. We performed analyses using RevMan 5.2.
Subgroup analysis and investigation of heterogeneity
We performed a subgroup analysis of each type of alternative exercise mode if we 
found more than one trial comparing the specific exercise mode with walking exercise. 
Furthermore, because most studies and international guidelines advise a 12-week 
supervised exercise programme, we reported outcomes both at the end of training and 
at 12 weeks of training. Finally, we performed a subgroup analysis on the combination 
of alternative exercise modes in relation to supervised walking exercise.
Sensitivity analysis
We examined individual study effects on the results by removing each study one at a 
time to examine whether removing a particular study would significantly change the 
results. In addition, we planned to perform sensitivity analyses on the methodological 
quality of the studies. We planned to exclude studies with apparent methodological 
flaws and risk of bias and examine whether removing these studies significantly 
changed results.
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RESULTS
Results of the search
FIGURE 1. Study flow diagram
Figure 1. Study flow diagram
7Modes of exercise training for intermittent claudication (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
We identified 10 publications comparing an alternative exercise regime to supervised 
walking exercise for IC. Of these 10 publications, we identified five primary 
studies.15,16,26-28 These five randomised controlled trials published in peer-reviewed 
journals fulfilled the inclusion criteria, and we considered these for inclusion in this 
review. Five addition l pu licati ns describe  the results of three of the primary studies 
more extensively.29-33
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Three trials compared supervised walking exercise to an exercise or progressive 
resistance regime 26-28; one trial compared arm ergometry to supervised walking 
exercise 16 and one trial compared cycling exercise to supervised walking exercise.15 
These five trials randomised a total of 184 participants with IC, with 135 participants 
randomised to the treatment arms relevant to this review. The number of participants 
per study was small, with a variation of between 29 and 45 participants. The mean 
age of the participants in the included trials varied between 62.0 and 71.7 years, and 
all trials included both men and women. The trials were conducted in the United States 
(3), Brazil (1), and Australia (1). 
Enrolment criteria were rather homogeneous. All trials included participants if a 
declination in ankle brachial index was present with coinciding limiting or disabling 
symptoms of IC. One trial 26 assessed claudication symptoms by a questionnaire (San 
Diego Claudication Questionnaire). In all trials, the presence of critical limb ischaemia 
was an exclusion criterion. Participants were also excluded if the exercise capacity 
was limited by another factor than IC (e.g. angina, chronic obstructive pulmonary 
disease, arthrosis). In three of the five trials, claudication symptoms needed to be 
stable for, respectively, three months 27 six months 28, or more than 12 months.15 Two 
trials 27,28 excluded participants if a revascularisation procedure was performed in 
the previous year. One RCT 16 excluded participants if a coronary or lower-extremity 
revascularization procedure was performed within the past three months. The two 
remaining trials 26,15 excluded participants if they recently underwent surgery or a 
cardiovascular event. Treatment duration varied between studies ranging from six 
weeks’ training 15,12-week training 16,27,28, to 24-week training periods.26
Excluded studies
After title/abstract screening, we excluded 3626 studies. After full text assessment, 
we excluded another 18 studies for various reasons. We excluded three studies as 
they were not randomised controlled trials.34-36 We excluded four studies 37-40 as they 
were meeting posters with a limited description of the methods and results; no articles 
of these meeting posters were published yet. We excluded nine studies 40-48 because 
they did not assess (adequate) supervised exercise therapy according to our inclusion 
criteria for this review. Five studies 41,43,44,46,49 did not report the primary and secondary 
outcome measures of this review. We excluded one study 50 because the outcome 
measures were unclearly described. We tried to contact the authors but did not receive 
additional information. We excluded one study 51 because we did not consider the 
intervention (pole walking) an alternative exercise regime in comparison to supervised 
walking.
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Risk of bias in included studies
See Figure 2 for a summary of the risk of bias in each included study.








































































































































McDermott 2009 + + + + ? + ?
Regensteiner 1996 ? ? + ? + + +
Ritta-Dias 2010 + + + + + + +
Sanderson 2006 + ? + ? + + +
Treat-Jacobson 2009 + ? + + + + +
+ ?
Allocation
Two studies described adequate sequence generation and allocation concealment by 
means of computer randomisation. 26,28 Two studies an adequate sequence generation, 
but did not describe the allocation concealment. 15,16 One study did not describe the 
randomisation process. 27
Blinding
In the included studies, participants and direct personnel could not be blinded to the 
intervention (exercise). For this reason, bias could be introduced. However, since all 
studies experienced the same limitation, we considered the risk of bias to be low for all 
studies. Detection bias can be avoided by blinding the outcome assessors. Three studies 
achieved this.16,26,28
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Incomplete outcome data
Most studies well-described reasons for missing data, and we considered these 
plausible and well distributed among the groups. One study addressed asymptomatic 
participants with PAOD as well as symptomatic participants.26 After contacting the 
authors, we derived the data of the sole symptomatic group with IC. However, it is 
unclear which of the missing data described in the article related to the symptomatic 
group. For this reason, we considered the incomplete outcome data in this study to be 
unclear.
Selective reporting
All studies described relevant outcomes. For three studies, we retrieved additional 
outcome data by contacting the authors.15,16,26
Other potential sources of bias
Since we identified only five studies, we could not detect publication bias with a funnel 
plot. Additional Begg and Egger tests did also exclude any indication of publication 
bias (Begg: adjusted Kendall’s score = 4, P = 0.462; Egger: bias 1.11, 95% confidence 
interval (CI) 0.43 to -2.77, P = 0.430). One of the studies did not describe the baseline 
characteristics of the subgroup of participants with intermittent claudication.26 This was 
due to the study setting. (The study included participants with asymptomatic as well as 
symptomatic peripheral arterial disease.) However, we identified no other potential 
sources of bias in the included trials.
Effects of interventions
Walking exercise versus alternative exercise
Maximum walking distance [METs]
Data for the maximum walking distance (MWD) obtained at the end of each study 
were available in all of the included trials, with a total sample size of 135 participants. 
We calculated the pooled treatment effect after standardising the reported walking 
distances. For this reason, we converted all distances to metabolic equivalents (METs) 
using the American College of Sports Medicine (ACSM) formulas for metabolic 
calculations. We considered the impact of heterogeneity as low with an I2 statistic of 
13%. At the end of training, the pooled MWD increased with an overall non-significant 
effect size of 8.15 METs (95% confidence interval (CI) -2.63 to 18.94, P = 0.14) in 
favour of walking exercise. This is the equivalent of an increase of 173 metres (95% CI 
-56 to 401metres) on a treadmill with no incline and an average speed of 3.2 km/h, 
which is comparable with walking in daily life (Analysis 1.1). However, because of 
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the width of the CI of the pooled MWD, we could not identify any clear evidence of 
difference between interventions.
Furthermore, we calculated the effect size after 12 weeks of training. After this 
follow-up period, data from three trials on MWD were available with a sample size 
of 74 participants.16,27,28 We considered the impact of heterogeneity as moderate to 
substantial with an I2 statistic of 52%. In these trials, the pooled MWD increased with a 
non-significant effect size of 13.05 METs (95% CI -11.43 to 37.54, P = 0.30) in favour 
of walking exercise. This correlates with 276 metres (95% CI -242 to 795 metres) on a 
treadmill with no incline and an average speed of 3.2 km/h (Analysis 1.2).
ANALYSIS 1.1. Comparison 1Walking exercise versus alternative exercise, Outcome 1 Maximum 







1 Maximum walking distance at
the end of the study
2 41 Mean Difference (IV, Random, 95% CI) 9.31 [-12.77, 31.40]
2 Pain-free walking distance at the
end of the study
1 Mean Difference (IV, Random, 95% CI) Totals not selected
An lysis 1.1. Comparison 1 Walking exercise versus alternative exercise, Outcome 1 Maximum walking
distance at the end of training.
Review: Modes of exercise training for intermittent claudication
Comparison: 1 Walking exercise versus alternative exercise
Outcome: 1 Maximum walking distance at the end of training





N Mean(SD)[METs] N Mean(SD)[METs] IV,Random,95% CI IV,Random,95% CI
Ritta-Dias 2010 15 58.9 (33.6) 15 66.5 (39.9) 14.9 % -7.60 [ -34.00, 18.80 ]
McDermott 2009 17 41.2 (18.2) 16 35.9 (18.2) 49.3 % 5.30 [ -7.12, 17.72 ]
Sanderson 2006 13 77.3 (34.8) 15 67.7 (47.4) 11.5 % 9.60 [ -20.95, 40.15 ]
Treat-Jacobson 2009 13 66.2 (38) 12 51.2 (24.9) 16.5 % 15.00 [ -10.00, 40.00 ]
Regensteiner 1996 10 73.5 (53) 9 33.8 (27.7) 7.8 % 39.70 [ 2.20, 77.20 ]
Total (95% CI) 68 67 100.0% 8.15 [ -2.63, 18.94 ]
Heterogeneity: Tau2 = 21.21; Chi2 = 4.57, df = 4 (P = 0.33); I2 =13%
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
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Pain-free walking distance [METs]
Data for the pain-free walking distance (PFWD) obtained at the end of each study 
were available in four of the five included trials, with a total sample size of 116 
participants.15,16,26-28 We calculated the effect after converting the reported walking 
distances to standardised METs. We considered the impact of heterogeneity as 
moderate with an I2 statistic of 49%. At the end of training, the PFWD increased with 
an overall non-significant effect size of 6.42 METs (95% CI -1.52 to 14.36, P = 0.11) in 
favour of walking exercise. This is the equivalent of an increase of 136 metres (95% CI 
-32 to 304 metres) on a treadmill with no incline and an average speed of 3.2 km/h, 
which is comparable with walking in daily life (Analysis 1.3). However, because of 
the width of the CI of the pooled PFWD, we could not identify any clear evidence of a 
difference between interventions. 
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ANALYSIS 1.2. Comparison 1Walking exercise versus alternative exercise, Outcome 2 Maximum 
walking distance after 12 weeks of training.
Analysis 1.2. Comparison 1 Walking exercise versus alternative exe c se, Outcome 2 Maximum walking
distance after 12 weeks of training.
Review: Modes of exercise training for intermittent claudication
Comparison: 1 Walking exercise versus alternative exercise
Outcome: 2 Maximum walking distance after 12 weeks of training





N Mean(SD)[METs] N Mean(SD)[METs] IV,Random,95% CI IV,Random,95% CI
Ritta-Dias 2010 15 58.9 (33.6) 15 66.5 (39.9) 36.4 % -7.60 [ -34.00, 18.80 ]
Treat-Jacobson 2009 13 66.2 (38) 12 51.2 (24.9) 38.1 % 15.00 [ -10.00, 40.00 ]
Regensteiner 1996 10 73.5 (53) 9 33.8 (27.7) 25.5 % 39.70 [ 2.20, 77.20 ]
Total (95% CI) 38 36 100.0 % 13.05 [ -11.43, 37.54]
Heterogeneity: Tau2 = 246.89; Chi2 = 4.26, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Furthermore, we calculated the effect size after 12 weeks of training. After this follow-
up period, data for two trials for PFWD were available, with a sample size of 55 
participants.16,28 We considered the impact of heterogeneity as low with an I2 statistic 
of 0%. In these trials, the pooled PFWD increased with a non-significant effect size 
of 2.37 METs (95% CI -5.81 to 10.56, P = 0.57) in favour of walking exercise. This 
correlates with 50 metres (95% CI -123 to 224 metres) on a treadmill with no incline 
and an average speed of 3.2 km/h (Analysis 1.4).
Health-related quality of life (HR-QoL) and functional impairment
Two of the included studies described HR-QoL and functional impairment.26,27 One 
study used the Medical Outcomes Study (MOS) SF-20; another study used the SF-36 
Physical Functioning score to collect HR-QoL data.26,27 Both studies used the Walking 
Impairment Questionnaire (WIQ) to describe functional impairment. 
Data on HR-QoL and functional impairment (WIQ) from one study, with a total sample 
size of 19 participants, showed an increase in HR-QoL with a significant effect size 
of 26.50% (95% CI 2.67 to 50.33, P = 0.03) in favour of walking exercise.27 WIQ 
distance score increased with an effect size of 2.00% (95% CI -16.04 to 20.04, P = 
0.83) in favour of walking exercise. WIQ speed score decreased with an effect size 
of -4.50% (95% CI -27.34 to 18.34, P = 0.70) in favour of alternative exercise. WIQ 
stair-climbing score decreased with an effect size of -29.50%(95% CI -51.65 to -7.35, 
P = 0.009) in favour of alternative exercise. Unfortunately, both the SF-36 Physical 
Functioning score and WIQ data from the second study were not normally distributed. 
SF-36 Physical Functioning score improved in both the strength (n = 14) and treadmill 
walking group (n = 17), with a median of, respectively, 12.5 points (interquartile range 
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= -5.00 to 20.00) and 10.0 points (interquartile range = 5.00 to 20.00), P = 0.811.26 
WIQ distance score improved in both the strength (n = 15) and treadmill walking 
group (n = 15), with a median of, respectively, 14.0 points (interquartile range = 
1.56 to 26.6) and 7.46 points (interquartile range = -0.36 to 25.0), P = 0.431. WIQ 
speed score improved in both the strength (n = 15) and treadmill walking group (n = 
16), with a median of, respectively, 3.26 points (interquartile range = -7.61 to 26.1) 
and 1.63 points (interquartile range = -3.80 to 28.8), P = 0.736. WIQ stair-climbing 
score improved in the strength training group (n = 15), with a median of, respectively, 
12.5 points (interquartile range = 4.17 to 25.0), while we saw no improvement in the 
median score in the treadmill walking group (n = 16, median score of 0.00 points, 
interquartile range = 0.00 to 14.6), P = 0.136. Because of the skewed data of one of 
the studies and the small sample size of both studies, we did not transform these data 
to perform a meta-analysis of the two studies.26
ANALYSIS 1.3. Comparison 1Walking exercise versus alternative exercise, Outcome 3 Pain-free 
walking distance at the end of training. 
Analysis 1.3. Compari on 1 Walking exerc se versus al ernative xercise, Outcome 3 P i -free walking
distance at the end of training.
Review: Modes of exercise training for intermittent claudication
Comparison: 1 Walking exercise versus alternative exercise
Outcome: 3 Pain-free walking distance at the end of training





N Mean(SD)[METs] N Mean(SD)[METs] IV,Random,95% CI IV,Random,95% CI
Ritta-Dias 2010 15 32.8 (21.4) 15 37 (26.4) 15.1 % -4.20 [ -21.40, 13.00 ]
Treat-Jacobson 2009 13 16.8 (15.4) 12 12.5 (7.2) 30.4 % 4.30 [ -5.01, 13.61 ]
McDermott 2009 17 18.8 (15.4) 16 14.4 (9.4) 32.3 % 4.40 [ -4.25, 13.05 ]
Sanderson 2006 13 31.6 (22.8) 15 12.1 (6.2) 22.2 % 19.50 [ 6.72, 32.28 ]
Total (95% CI) 58 58 100.0% 6.42 [ -1.52,14.36 ]
Heterogeneity: Tau2 = 31.43; Chi2 = 5.89, df = 3 (P = 0.12); I2 =49%
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours Alternative Favours Walking
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ANALYSIS 1.4. Comparison 1Walking exercise versus alternative exercise, Outcome 4 Pain-free 
walking distance after 12 weeks of training.
Analysis 1.4. Comparison 1 Walking exercise versus alternative exercise, Outcome 4 Pain-free walking
distance after 12 weeks of training.
Review: Modes of exercise training for intermittent claudication
Comparison: 1 Walking exercise versus alternative exercise
Outcome: 4 Pain-free walking distance after 12 weeks of training





N Mean(SD)[METs] N Mean(SD)[METs] IV,Random,95% CI IV,Random,95% CI
Ritta-Dias 2010 15 32.8 (21.4) 15 37 (26.4) 22.7 % -4.20 [ -21.40, 13.00 ]
Treat-Jacobson 2009 13 16.8 (15.4) 12 12.5 (7.2) 77.3 % 4.30 [ -5.01, 13.61 ]
Total (95%CI) 28 27 100.0% 2.37[-5.81,10.56]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.73, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours Alternative Favours Walking
Analysis 1.5. Comparison 1 Walking exercise versus alternative exercise, Outcome 5 Change in health-
related quality of life at the end of training.
Review: Modes of exercise training for intermittent claudication
Comparison: 1 Walking exercise versus alternative exercise
Outcome: 5 Change in health-related quality of life at the end of training





N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
Regensteiner 1996 10 24 (20.9686) 9 -2.5 (30.5724) 26.50 [ 2.67, 50.33 ]
-200 -100 0 100 200
Favours Alternative Favours Walking
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Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Sensitivity analysis
We performed a sensitivity analysis to assess whether excluding an individual study 
would significantly change the main results on MWD and PFWD at the end of the study. 
For MWD, removing any individual study did not alter the results significantly, although 
by removing one study, the MWD increased almost significantly, in favour of walking 
exercise, with an overall effect size of 10.16 METs (95% CI -0.40 to 20.71, P = 0.06).28 
This is the equivalent of an increase of 215 metres (95% CI - 8 to 439 metres) on a 
treadmill with no incline and an average speed of 3.2 km/h. 
For PFWD, removing one of the studies did not alter the results significantly, although 
by removing one study 28, the PFWD increased almost significantly in favour of walking 
exercise, with an overall effect size of 8.30 METs (95% CI -0.26 to 16.86, P = 0.06). 
This is the equivalent of an increase of 176 metres (95% CI -6 to 357 metres) on a 
treadmill with no incline and an average speed of 3.2 km/h. We did not perform a 
sensitivity analysis on the methodological quality of the studies because of the limited 
number of studies.
Walking exercise versus strength training
Maximum walking distance [METs]
Data for MWD obtained at the end of each study were available in three of the five 
included trials, with a total sample size of 82 participants.26-28 We considered the 
impact of heterogeneity as moderate to substantial with an I2 statistic of 52%. At the 
end of the study, the pooled MWD increased with an overall non-significant effect size 
of 8.11 METs (95% CI -11.68 to 27.90, P = 0.42) in favour of walking exercise. This is 
the equivalent of an increase of 172 metres (95% CI -247 to 591 metres) on a treadmill 
with no incline and an average speed of 3.2 km/h, which is comparable with walking 
in daily life (Analysis 2.1).
Furthermore, we calculated the effect size after 12 weeks of training. After this follow-
up period, data for two trials for MWD were available, with a sample size of 49 
participants.27,28 We considered the impact of heterogeneity as substantial with an I2 
statistic of 76%. The pooled MWD increased with a non-significant effect size of 14.10 
METs (95% CI -32.10 to 60.29, P = 0.55) in favour of walking exercise. This correlates 
with 299 metres (95% CI -680 to 1277 metres) on a treadmill with no incline and an 
average speed of 3.2 km/h (Analysis 2.2).
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ANALYSIS 2.1. Comparison 2 Walking exercise versus strength training, Outcome 1 Maximum 
walking distance at the end of training.
Analysis 2.1. C mpa ison 2 Walking ex cise versus strength training, Outcome 1 Maximum walking
distance at the end of training.
Review: Modes of exercise training for intermittent claudication
Comparison: 2 Walking exercise versus strength training
Outcome: 1 Maximum walking distance at the end of training





N Mean(SD)[METs] N Mean(SD)[METs] IV,Random,95% CI IV,Random,95% CI
Ritta-Dias 2010 15 58.9 (33.6) 15 66.5 (39.9) 29.8 % -7.60 [ -34.00, 18.80 ]
McDermott 2009 17 41.2 (18.2) 16 35.9 (18.2) 50.8 % 5.30 [ -7.12, 17.72 ]
Regensteiner 1996 10 73.5 (53) 9 33.8 (27.7) 19.4 % 39.70 [ 2.20, 77.20 ]
Total (95% CI) 42 40 8.11[-11.68,27.90]
Heterogeneity: Tau2 = 160.49; Chi2 = 4.13, df = 2 (P = 0.13); I2 =52%
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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ANALYSIS 2.2. Comparison 2 Walking exercise versus strength training, Outcome 2 Maximum 
walking distance at 12 weeks of training.
Analysis 2.2. Comparison 2 Walking exercise versus strength training, Outcome 2 Maximum walking
distance at 12 weeks of training.
Review: Modes of exercise training for intermittent claudication
Comparison: 2 Walking exercise versus strength training
Outcome: 2 Maximum walking distance at 12 weeks of training





N Mean(SD)[METs] N Mean(SD)[METs] IV,Random,95% CI IV,Random,95% CI
Ritta-Dias 2010 15 58.9 (33.6) 15 66.5 (39.9) 54.1 % -7.60 [ -34.00, 18.80 ]
Regensteiner 1996 10 73.5 (53) 9 33.8 (27.7) 45.9 % 39.70 [ 2.20, 77.20 ]
Total (95% CI) 25 24 14.10[-32.10,60.29]
Heterogeneity: Tau2 = 844.87; Chi2 = 4.09, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 2.3. Comparison 2 Walking exercise versus strength training, Outcome 3 Pain-free walking
distance at the end of training.
Review: Modes of exercise training for intermittent claudication
Comparison: 2 Walking exercise versus strength training
Outcome: 3 Pain-free walking distance at the end of training





N Mean(SD)[METs] N Mean(SD)[METs] IV,Random,95% CI IV,Random,95% CI
Ritta-Dias 2010 15 32.8 (21.4) 15 37 (26.4) 20.2 % -4.20 [ -21.40, 13.00 ]
McDermott 2009 17 18.8 (15.4) 16 14.4 (9.4) 79.8 % 4.40 [ -4.25, 13.05 ]
Total(95%CI)3231 100.0%2.66[-5.06,10.39]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours Strength Favours Walking
32Modes of exercise training for intermittent claudication (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
100.0%
ANALYSIS 2.3. Comparison 2 Walking exercise versus strength training, Outcome 3 Pain-free 
walking distance at the end of training.
Analysis 2.3. Comparison 2 Walking exercise versus strength training, Outcome 3 Pain-free walking
distance at the end of training.
Review: Modes of exercise training for intermittent claudication
Comparison: 2 Walking exercise versus strength training
Outcome: 3 Pain-free walking distance at the end of training





N Mean(SD)[METs] N Mean(SD)[METs] IV,Random,95% CI IV,Random,95% CI
Ritta-Dias 2010 15 32.8 (21.4) 15 37 (26.4) 20.2 % -4.20 [ -21.40, 13.00 ]
McDermott 2009 17 18.8 (15.4) 16 14.4 (9.4) 79.8 % 4.40 [ -4.25, 13.05 ]
Total (95% CI) 32 31 2.66[-5.06,10.39]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours Strength Favours Walking
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Copyright © 14 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Pain-free walking distance [METs]
Data for the PFWD at the end of the study were available in two of the included 
trials, with a total sample size of 63 participants.26,28 We considered the impact of 
heterogeneity as low with an I2 statistic of 0%. At the end of the study, the pooled PFWD 
increased with an overall non-significant effect size of 2.66 METs (95% CI -5.06 to 
10.39, P = 0.50) in favour of walking exercise. This is the equivalent of an increase of 
56 metres (95% CI -107 to 220 metres) on a treadmill with no incline and an average 
speed of 3.2 km/h, which is comparable with walking in daily life (Analysis 2.3).
Walking exercise versus a combination of exercise modes
Maximum walking distance [METs]
Two trials analysed the effect of a combination of exercise modes in relation to 
supervised walking exercise on the MWD.16,27 One trial compared a combination 
of walking exercise and arm ergometry to sole walking exercise.16 The second trial 
compared a combination of walking exercise and strength training to sole walking 
exercise.27 In total, the two trials had a sample size of 41 participants for analysis of the 
MWD at the end of the studies. We considered the impact of heterogeneity as low with 
an I2 statistic of 0%. The pooled MWD increased with an overall non-significant effect 
size of 9.31METs (95%CI -12.77 to 31.40, P = 0.41) in favour of sole walking exercise. 
This is the equivalent of an increase of 197 metres (95% CI -270 to 665 metres) on a 
treadmill with no incline and an average speed of 3.2 km/h, which is comparable with 
walking in daily life (Analysis 3.1). 
Pain-free walking distance [METs]
Data for PFWD obtained at the end of each study were available in one of the included 
trials with a total sample size of 25 participants.16 At the end of this study, the PFWD 
increased with an overall non-significant effect size of 3.30 METs (95% CI -6.01 
to 12.61, P = 0.49) in favour of sole walking exercise. This is the equivalent of an 
increase of 70 metres (95% CI - 127 to 267 metres) on a treadmill with no incline and 
an average speed of 3.2 km/h, which is comparable with walking in daily life.
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DISCUSSION
Summary of main results
We included five randomised controlled trials (RCTs) in this review, with a total of 135 
participants. We could not find any clear evidence of a statistical difference in maximum 
or pain-free walking distance when comparing supervised treadmill walking with an 
alternative exercise regime. Furthermore, sensitivity analysis did not significantly alter 
the results. Regarding quality of life, two studies described health related quality of 
life and functional impairment.26,27 However, the data in one of the two studies were 
not normally distributed.26 Therefore, we could not make any meaningful comparison 
between studies.
Overall completeness and applicability of evidence
Although the topic of this review is contemporary 18, this review identified only five 
RCTs, with a total of 135 participants. The five RCTs described only three alternative 
exercise modes: strength training 26-28, arm-ergometry 16, and cycling exercise 15. In 
total, three of the five studies 26-28 compared strength training to supervised treadmill 
walking, for which we performed a subanalysis. Eventually, more studies are needed to 
make meaningful comparisons between each alternative exercise mode and the current 
standard of supervised treadmill walking. Therefore, the applicability of the current 
evidence is limited.
Quality of the evidence
The risk of bias of the included studies was, in general, low (see Figure 2), reflecting 
good methodological quality of the included studies. We could not detect publication 
bias because we could not assess asymmetry in a funnel plot with the limited number 
of studies. The quality of this review is however limited because of the small sample 
size of 135 participants. At analysis, we experienced some heterogeneity in Analysis 
1.2, Analysis 2.1, and Analysis 2.2 using the I2 statistic and in Analysis 2.2 using the 
Q-statistic or Chi2 test. Sensitivity analysis did not significantly alter the results of the 
review.
Potential biases in the review process
We tried to limit all potential biases in the review process. To limit bias and make 
a meaningful comparison, we standardised maximum walking distance (MWD) and 
pain-free walking distance (PFWD) from each study by converting walking distances 
to total metabolic equivalents (METs) according to the American College of Sports 
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Medicine (ACSM) formulas for metabolic calculations.21 However, direct conversion 
of the walking times or distances to METs was not possible due to the absence of 
individual participant data. We therefore simulated a new dataset for each study to 
make a meaningful comparison. It is unclear to what extent this could have biased our 
findings.
We excluded one study solely because it did not report the correct outcome measures.49 
Although we were careful to ascertain that relevant outcomes were not available 
because they were not measured rather than not reported, this could be a potential bias 
in the review process. In future updates, we will pay further attention to this potential 
source of bias.
Agreements and disagreements with other studies or reviews
We agree with a previous published systematic review 18 that there was no clear 
evidence of difference between alternative exercise modes and supervised walking 
exercise for intermittent claudication. Results seem promising, but additional studies 




Few studies were found and there was no clear evidence of a difference between 
supervised walking exercise and alternative exercise modes. More studies with larger 
sample sizes are needed to make meaningful comparisons between each alternative 
exercise mode and the current standard of supervised treadmill walking. The results 
indicate that alternative exercise modes may be useful when supervised walking 
exercise is not an option for the patient.
Implications for research
More studies are urgently needed to make meaningful comparisons between each 
alternative exercise mode and the current standard of supervised treadmill walking.
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ABSTRACT
Objectives
Reduced physical activity (PA) is associated with a higher mortality rate and more 
rapid functional decline in patients with intermittent claudication (IC). The newest 
generation of accelerometers can assess both direction and intensity of activities three-
dimensionally and may also adequately calculate energy expenditure in daily life. 
The aim of this study was to quantify daily PA level and energy expenditure of newly 
diagnosed patients with IC and healthy controls. PA outcomes are compared with 
contemporary public health physical activity guidelines.
Methods 
Before initiating treatment, 94 patients with newly diagnosed IC and 36 healthy controls 
were instructed to wear a tri-axial seismic accelerometer for 1 week. Daily PA levels (in 
metabolic equivalents, METs) were compared with the ACSM/AHA public health PA 
minimum recommendations (≥64 METs·min·day, in bouts of ≥10 minutes). A subgroup 
analysis assessed the effect of functional impairment on daily PA levels.
Results
Data from 56 IC patients and 27 healthy controls were available for analysis. Patients 
with IC demonstrated significantly lower mean daily PA levels (±SD) than controls 
(387 ± 198 METs·min vs. 500 ± 156 METs·min, p =0.02). This difference was solely 
attributable to a subgroup of IC patients with the largest functional impairment (WIQ-
score < 0.4). Only 45% of IC patients met the public health physical activity guidelines 
compared with 74% of the healthy controls (p =0.01).
Conclusions
More than half of patients with IC do not meet recommended standards of PA. 
Considering the serious health risks associated with low PA levels, these findings 
underscore the need for more awareness to improve physical exercise in patients with 
IC.
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INTRODUCTION
Intermittent claudication (IC) is closely associated with cardiovascular and 
cerebrovascular disease.1-3 Compared with healthy adults, IC patients are burdened 
with a low health-related quality of life and functional impairment during daily 
activities.4,5 A reduced exercise capacity and lower daily free-living physical activity 
(PA) level are both strong predictors of long-term mortality. In contrast, higher PA levels 
are associated with less functional decline.6-9
The ACSM/AHA have issued recommendations on types and amounts of PA needed 
for (older) adults to improve and maintain health.10 Specific recommendations are 
provided that apply to adults >65 years of age or to adults aged 50-64 years with 
chronic conditions or physical functional limitations.11 All adults are advised to engage 
in moderate-intensity aerobic exercise for a minimum of 30 minutes on 5 days a 
week, or vigorous-intensity aerobic PA for a minimum of 20 minutes on 3 days a 
week. Activities should be performed in bouts of at least 10 minutes. Combinations 
of moderate- and vigorous-intensity aerobic PA can also be performed to meet these 
recommendations.
Metabolic equivalents (METs) are used by the ACSM/AHA as a means to express 
the energy expenditure or energy costs of physical activities. The total amount of PA 
is a function of its intensity, duration, and frequency. Accordingly, vigorous intensity 
activities (>6.0 METs) performed for a particular duration and frequency generate 
greater energy expenditure than moderate-intensity activities (3.0-6.0 METs) of the 
same duration and frequency. When combining the recommendations on moderate- 
and vigorous-intensity physical activity, the daily minimum goal of PA should be in the 
range of 64-107 METs·min.10,11
In the literature, PA is defined and determined in different ways. Frequently used 
definitions of PA are “time spent in different activities (sedentary/ambulatory), 
number of steps, duration of walking events or the score on a specific exercise test 
or questionnaire”.8,12-15 PA objectively measured by energy expenditure is seldom 
performed in patients with IC.15-17 Regularly described methods for PA measurement 
are PA questionnaires, pedometers, or activity monitors. However, only the last 
method is found capable of adequately assessing energy expenditure.18,19 The 
newest generation of activity monitors is based on tri-axial accelerometer techniques 
measuring accelerations in three dimensions that can be converted to intensities and 
METs. In contrast to unilateral accelerometers (or vertical accelerometers), tri-axial 
accelerometers also measure activities that do not include vertical movement. As such, 
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PA is determined more precisely as demonstrated with high correlations between 
indirect calorimetry and generated MET output at different walking speeds.18,20,21 To 
our knowledge, no studies are available on the use of a tri-axial accelerometer in 
patients with IC compared with healthy adults. 
The purpose of this prospective observational study was to objectively determine the 
PA using a tri-axial accelerometer in patients with IC and healthy adults. Furthermore, 
the number and percentage of participants meeting the lower limit of the ACSM/AHA 
recommendations for PA and public health are determined. It was hypothesised that 
healthy adults had a higher PA level and complied more frequently with these minimum 
recommendations than IC patients.
MATERIALS & METHODS
Participant selection
Patients with clinical manifestations of IC were recruited at the outpatient clinic of 
Vascular Surgery of the Catharina Hospital, Eindhoven and Maxima Medical Center, 
Veldhoven/Eindhoven, The Netherlands. Healthy individuals recruited from family or 
friends of healthcare workers served as controls. All subjects gave written informed 
consent and all procedures described in this study were approved by the Medical 
Ethical Committee, Catharina Hospital, Eindhoven.
Eligibility assessment
IC group
Patients without any previous history of peripheral arterial occlusive disease (PAOD) 
presenting with new onset clinical manifestations of IC underwent an ankle-brachial 
index (ABI) measurement using standard equipment. Patients with values below 0.90 at 
rest or a drop in value of more than 0.15 after a standard treadmill test were considered 
eligible. Exclusion criteria included serious cardiopulmonary limitations (NYHA class 3-4), 
critical limb ischemia or previous lower-limb amputation, use of walking aids, psychiatric 
instability or other serious comorbidity which possibly limited the patient’s walking ability. 
Control group
Healthy volunteers aged >45 years without a history of PAOD, cardiac or pulmonary 
disease were included if they were able to walk without any limitations or walking aids. 
Participants were excluded if an ABI measurement was below 0.90 at rest or decreased 
more than 0.15 after a standard treadmill test.
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Functional impairment and health-related quality of life scores
After consenting to the study specifics, a Dutch validated version of the Walking 
Impairment Questionnaire (WIQ), 12-item Short Form Physical Functioning Summery 
(SF-12 PCS) and 12-item Short Form Mental Functioning Summery (SF-12 MCS) were 
assessed prior to treatment in the IC patients and in controls.22,23 Evidence based 
conservative treatment was subsequently started in the IC group. Each patient received 
cardiovascular risk management including antiplatelet therapy and a statin. 
Physical activity monitoring
Dynaport tri-axial seismic accelerometer
Both groups of study participants were asked to wear a tri-axial seismic accelerometer 
(Dynaport MoveMonitor, McRoberts B.V., The Hague, The Netherlands) during a 1 week 
time period. The Dynaport MoveMonitor (size 84mm x 50m x 8mm; weight 55 g) contains 
three orthogonal piezo-capacitive acceleration sensors, each measuring at a sample rate 
of 100Hz. The accelerometer has a direct current response to the Earth’s gravitational 
field, and used a seismic or a proof mass suspended by a spring structure in a case. The 
case has a micro USB connection and a rechargeable battery and stores the raw data on 
a Micro-SD card. The Dynaport MoveMonitor is placed in a belt that is strapped around 
the waist. It is positioned at the base of the lumbar column just cranial to the buttocks. 
The Dynaport technology is validated for counting steps, detecting time spent in different 
activities, activity-related energy expenditure and assessment of reproducibility.18,21,24-28 
Monitoring protocol
All participants were instructed to correctly wear the Dynaport MoveMonitor for 7 
consecutive days. As the device is not waterproof, participants were asked to take off 
the device when taking a shower or a bath. Furthermore, to achieve better compliance, 
participants were instructed not to wear the device during sleeping.
They were instructed to perform their regular daily activities during this week. Supervised 
exercise therapy (SET) was initiated after this one week monitoring period in IC 
patients. SET was provided by a specialised physical therapist in a community-based 
setting. According to the quality standards and guidelines of the Dutch ClaudicatioNet 
Network and Royal Dutch Society for Physical Therapy, the physical therapist assessed 
the pain-free walking distance (PFWD) and maximum walking distance (MWD) at 
baseline according to a standardised graded treadmill protocol.29,30
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Outcomes
Primary outcomes
 • The daily PA level (measured in METs·min)
 • The daily PA level performed in bouts of >10 minutes moderate- or vigorous-
intensity PA (measured in METs·min)
 • The number and percentage of participants meeting the lower limit of the ACSM 
recommendation for PA and public health (67 METs·min a day)
 
Secondary outcomes
 • The average daily time spent in different activities (Lying, Standing, Sitting, Walking, 
Shuffling) and the time spent not wearing the device
 • The average daily number and highest number of steps walked in one period (top 
period of steps) 
 • The average daily time spent in light-, moderate- or vigorous-intensity activity. 
Sedentary activity is activity with an intensity of <1.5 METs, light activity is activity 
with an intensity of 1.5-3 METs, moderate activity is activity with an intensity of 3-6 
METs and vigorous activity is activity with an intensity of 6-9 METs.
Data Analysis
Daily checks were made to assure proper use of the device. By definition, the device 
was worn correctly if it detected at least 20 steps and if it was ‘worn’ ≥10 hours and 
‘not worn’ for ≥5 hours a day. Participants with less than 5 days of correctly wearing 
the device were arbitrarily excluded from analysis. Daily average outcomes were 
determined for each participant depending on the number of ‘correctly worn days’. 
Subgroup analysis
The IC group was divided into two subgroups according to the WIQ score (<0.4 or ≥0.4) 
in order to evaluate the hypothesis that IC patients with more functional impairment 
have a lower daily PA level. The WIQ-score was used because it takes both the patient’s 
effort to walk and his perceived impairment into account, while estimated or treadmill 
walking distances do not reflect walking distances in daily life.31 A lower WIQ-score 
reflects higher functional impairment. A cut-off value of 0.4 was arbitrarily chosen to 
establish even groups.
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Statistical analyses
All analyses were performed using IBM SPSS Statistics Version 21 (SPSS Inc., Chicago, 
IL, USA). Categorical variables are presented as frequencies with percentages. 
Nominal variables are depicted as the mean ± standard deviation in case of a normal 
distribution. Statistical differences between the groups were calculated with a Pearson 
Chi-Square test for categorical variables, an Independent sample T-test for continuous 
variables between two groups and a One-Way between-groups ANOVA for continuous 
variables between more than two groups. In case of significant differences between more 
than two groups, post-hoc Tukey tests were performed to assess a possible significant 
difference between groups. A p-value <0.05 was used for statistical significance.
Univariable and multivariable linear regression analysis were used to evaluate which 
pre-specified variables predicted daily level of physical activity.  In the univariable 
regression analysis, each variable is included in a separate regression analysis. In the 
multivariable regression analysis, all statistically significant variables, identified by the 
univariable regression analysis, are included in one regression analysis, using the enter 
method. Included pre-specified variables were age, BMI, sex, resting ABI, IC symptoms 
of both legs, cardiac history, pulmonary history, WIQ score, SF-12 PCS score, SF-12 
MCS score, and maximal walking distance measured at baseline.  Multivariable linear 
regression analysis using the backward elimination method was used to identify the 
variables included in the final regression equation. The backward method starts with all 
the variables in the equation and in every step variables that do not have a statistically 
significant influence are excluded. The criterion for removal from the regression model 
was a p-value of more than 0.10.  The quality of the regression models was expressed 
with the R2  (explained variance) for linear regression analysis. 
RESULTS
Group baseline characteristics
A total of 130 participants were considered eligible (IC, n=94; controls, n=36). 
Analysis of the accelerometer data demonstrated that 56 IC patients and 27 controls 
met all criteria of a correctly worn device. A significant group difference regarding 
age, number of correctly worn days, resting ABI, WIQ-score, SF-12 PCS score and 
MWD was found between both groups. (Table 1) 
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Time spent in different activities or intensity-levels
IC patients spent almost 8.5 hours a day sitting (508 ± 108 minutes), more than 2.5 
hours a day standing (165 ± 60 minutes), more than 2 hours a day lying (132 ± 
101 minutes), 1 hour a day walking (65 ± 33 minutes) and 21 ± 12 minutes a day 
shuffling. (Table 2) Compared to the control group a significant difference was found 
in the time spent sitting and ‘device not worn’. A significant group difference was also 
found regarding vigorous-intensity activities (IC: 4 ± 8 vs. Controls: 11 ± 10 minutes 
a day, p=0.002). 
Step analysis
Daily number of steps in the IC subgroups was significantly fewer compared to the 
control group (IC subgroup 1: 4663 ± 3104 vs. IC subgroup 2: 5761 ± 2371 vs. 
Controls: 6682 ± 2701, p=0.03). The highest number of steps walked in one period 
(top period of steps) was also significantly lower in IC patients (IC subgroup 1: 1601 ± 
1414 vs. IC subgroup 2: 2546 ±1894 vs. Controls: 4584 ± 4680, p<0.001). 
TABLE 2 Average duration of different daily activities and intensity levels
IC group (n = 56) Control group (n= 27)
P-value a
Mean S.D. Mean S.D.
Lying (hours:min) 2:12 101 2:10 62 0.92
Sitting (hours:min) 8:28 108 9:20 80 0.03
Standing (hours:min) 2:45 60 2:33 47 0.34
Walking (hours:min) 1:05 33 1:16 29 0.14
Shuffling (hours:min) 0:21 12 0:26 12 0.10
Not Worn (hours:min) 9:13 50 8:16 47 <0.001
Light activity (hours:min) 1:18 33 1:33 55 0.13
Moderate activity (hours:min) 1:23 37 1:35 29 0.11
Vigorous activity (hours:min) 0:04 8 0:11 10 0.002
Note. a Independent Sample T-test, Light activity = activity with an intensity of 1.5-3 METs,  
Moderate activity = activity with an intensity of 3-6 METs, Vigorous activity = activity with an intensity  
of 6-9 METs)
Daily physical activity level
A statistically significant difference (p = 0.02) in both daily PA level and daily PA in 
bouts of >10 minutes of moderate- or vigorous intensity exercise, was found between 
the IC subgroups and the control group. (Figure 1, 2) Post-hoc analyses showed that 
this difference was solely due to a significant difference between IC subgroup 1 (WIQ 
86
CHAPTER 5 | Physical activity monitoring in patients with intermittent claudication
< 0.4) and the control group (p=0.018). In contrast, no significant difference in daily PA 
level was found between IC subgroup 2 (WIQ ≥ 0.4) and the control group (p=0.28).
FIGURE 1. Daily physical activity level (mean ± S.D.)

















FIGURE 2. Daily physical activity level in bouts >10 min of moderate or vigorous activity (median, 
I.Q.R.)
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Analysis of the number of participants achieving the lower (67 METs·min a day) and 
upper (107 METs·min a day) limit of the ACSM minimum recommendations showed 
a significant difference (lower limit: p=0.01, higher limit: p=0.02) between the IC 
subgroups and the control group in favour of the healthy controls. (Figure 3) 






































Achieved lower limit of ACSM recommendations (67 METsmin a day) 









Prediction model for daily physical activity level
Univariable regression analysis revealed that age, a previous history of pulmonary 
disease, MWD and the WIQ, SF-12 MCS and SF-12 PCS score, all independently 
influenced the daily PA level. (Table 3) Multivariable regression analysis including five 
variables (age, pulmonary history, SF-12 PFS, SF-12 MFS, MWD) explained 53% 
(p<0.001) of the variance in daily PA level: 
Daily PA level of IC patients (METs·min) = 369.23 – 7.65 x Age + 4.73 x SF-12 PCS 
score + 6.53 x SF-12 MCS score + 0.18 x MWD (– 138.65 if pulmonary history is 
present)
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DISCUSSION
This study hypothesized that IC patients would demonstrate a lower PA level and would 
comply less frequently to the lower limit of the ACSM/AHA recommendations for PA 
and public health compared to healthy adults. In a two-day assessment of PA using a 
vertical accelerometer and a pedometer, one other study found that daily PA level of IC 
patients was 42%-45% lower compared to healthy subjects of similar age.17 Also using 
a vertical accelerometer, a second study demonstrated that patients with peripheral 
arterial occlusive disease (PAOD) had markedly lower PA levels compared to non-
PAOD participants (803 ± 364 kcal/wk vs. 1750 ± 1296 ± kcal/wk).15 Ever since the 
ACSM/AHA issued minimum recommendations on PA and public health were issued, 
studies describing to what extent IC patients meet these criteria in relation to healthy 
adults were not performed. 
The present study using newest generation of tri-axial accelerometers found that fewer 
than half of IC patients meet the ACSM/AHA minimum recommendations while more 
than one-quarter of older healthy adults do not meet these criteria. 
Moreover, the daily level of PA of IC patients (387 ± 198) is much lower compared 
to healthy adults (500 ± 156). IC patients reporting substantial functional impairment 
(WIQ score <0.4) had the lowest mean daily PA level of all groups. Interestingly, the 
PA group difference was solely attributed to this subgroup. Only minor functional 
impairment in IC patients apparently does not result in lower daily PA level. 
A tri-axial accelerometer allows for separately identifying various activities such as 
sitting, standing, lying or walking. The present study found significant group differences 
regarding time of sitting and ‘not wearing the device’. Healthy adults appear to sit 
approximately one hour longer and might sleep less compared to IC patients. In 
contrast, walking time did not differ among groups, although the daily number of steps 
and highest number of steps were significantly lower in the IC group. This difference is 
possibly explained by a slower walk pace or cadence associated with IC. A previous 
study also suggested that patients with IC take fewer steps and have a lower daily 
average cadence compared to healthy adults.32 
Variables influencing daily PA level in IC patients were hitherto not identified. 
The present study revealed that age, previous history of pulmonary disease, MWD 
and the WIQ, SF-12 MCS and SF-12 PCS score all independently influence these 
levels. Pulmonary history appeared the strongest factor. However, patient with serious 
pulmonary conditions (affecting the patient’s walking ability) were excluded from this 
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study. Therefore, the effect of pulmonary history on the daily PA level in an IC patient 
is probably underestimated. Patients with COPD are markedly inactive in daily life 
compared to healthy adults.33 Therefore, physicians need to realize that patients with 
IC and COPD are much less active compared to IC patients without pulmonary history 
or healthy adults. 
A low daily PA level is generally considered a strong predictor of mortality and 
functional decline in patients with IC.6-9 More than light-intensity weekly PA improves 
5-year survival rate significantly compared to light-intensity or no physical activity.7 
For this reason, one could argue that the PA level is a valid outcome parameter in 
evaluating treatment effects of any intervention for IC. Current outcome parameters 
including maximum- or pain-free walking distances only describe the patient’s exercise 
capacity while it does not reflect to what extent this capacity is used. In contrast, daily 
PA levels, provide objective information on the frequency, duration and intensity 
of exercise. Combined with a functional impairment score such as the WIQ-score, 
physicians may objectively monitor the patient’s treatment progress.
Future studies should focus on the effects of different treatment strategies on PA.
A rehabilitation program such as supervised exercise therapy (SET) improves walking 
performance and functional impairment. Most programmes promote, besides 
supervised sessions, daily home-based exercise in order to increase the patient’s 
daily PA. No studies have substantiated the effect of SET on the daily level of PA yet. 
Therefore, accelerometer studies before and after different treatment strategies may 
shed light on these issues. 
Study limitations
The present study is limited by the number of excluded participants. In total, 38 
participants in the IC group (40.4%) and nine controls (25.0%) were excluded because 
the device was not correctly worn for ≥5 days. By definition, a correctly worn day was 
considered a day that the device was worn for ≥10 hours, not worn for ≥5 hours, and 
with at least 20 steps. These strict criteria were a priori determined to prevent bias. For 
instance, if a participant wore the device for only 5 hours one day, unrepresentative 
data on the overall person’s PA would have been collected. The high dropout rate may 
have potentially biased the PA results, most likely by overestimating the current PA level 
in IC patients. Lack of motivation or misunderstanding the monitoring protocol could 
have led to incorrect use. A substantial number of participants said they had forgotten 
the end date of the monitoring period. In a few instances, participants fell asleep with the 
device still strapped to their waist. In our monitoring protocol, participants were asked 
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to remove the device before sleeping to improve compliance. If the device was worn 
during the night, that day was considered by definition “not correctly worn”. We are 
not sure if compliance could have been higher if participants wore the device constantly. 
In future studies, regular checkups by phone calls could be employed as a means of 
increasing compliance and checking the understanding of the monitoring protocol. 
For clinical practice one could consider a shorter monitoring period, providing results 
are summarised in an average daily PA level. However, the accuracy of PA results 
from a shorter monitoring period should first be validated since these could vary. Only 
a few measurement failures with the tri-axial accelerometer were experienced. The 
Dynaport Move-Monitor may fail if the battery is not fully charged or if the device is 
worn backwards. The device indicates if it is fully charged, minimising the chance of 
human errors. However, in a handful of cases the device did not measure for 7 days 
because the investigators replaced the original SD cards with new ones. The new SD 
cards appeared to consume more battery energy than the original ones. Therefore the 
device could only measure for 5 or 6 days. Besides this error, we did not experience 
device malfunction. The investigators explicitly explained how to wear the device to 
minimise the chance that participants might wear the device backwards. This could be 
explained quite easily since the device is worn correctly if the word ‘McRoberts’ on the 
outside of the device could be read. Therefore this error did not occur during any of 
the worn days. 
Another study limitation is the lack of an age-matched control group. Although groups 
were initially matched for age and sex, a significant difference in age was present 
between the IC and control group once the IC group drop out rate appeared high. 
However, a sensitivity analysis including healthy adults aged ≤60 years (n =14) 
revealed no significant difference in daily PA level in comparison to 13 other healthy 
adults aged >60 years (526 ± 160 METs·min vs. 471 ± 151 METs·min, p = 0.37) 
although these groups may have been underpowered.
CONCLUSIONS
More than half of patients with IC do not meet the minimum recommendations for PA 
and public health. Compared with healthy adults, they have a significantly lower daily 
PA level. PA differences are due to an IC subgroup with severe functional impairments. 
Because a low PA level is considered a strong predictor of mortality and functional 
decline, all health-care workers should actively encourage physical activities in IC 
patients. Future studies should assess the effects of treatment strategies including 
supervised exercise therapy on daily PA levels.
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ABSTRACT
Objectives
Intermittent claudication (IC) is associated with a reduction in physical activity (PA) 
and a more rapid functional decline leading to a higher mortality rate compared to 
healthy individuals. Supervised exercise therapy (SET) is known to increase the walking 
capacity of IC patients. However, it is unclear whether SET increases PA. The aim of 
this study was to investigate the effect of SET on PA levels and ambulatory activities in 
patients with IC.
Design & Methods
Newly diagnosed IC patients were requested to wear an activity monitor one week 
prior to and one week immediately following 3 months of SET. Primary outcome was 
the percentage of patients meeting the minimum recommendations of PA (ACSM/
AHA public health, ≥67METs·min·day, in bouts of ≥10 min) at baseline and after 3 
months of SET. Additionally, daily PA level (metabolic equivalents, METs·min), duration 
of ambulatory activities, daily number of steps, pain free walking distance (PFWD), 
maximal walking distance (MWD) and SF-36 health surveys were compared before 
and after SET.
Results
Data of 41 participants were available for analysis. A higher number of participants 
met the ACSM minimum recommendation for PA at the 3 months follow up (baseline: 
43%; 3 months: 63%, p= .003). Despite significant increases in PFWD (baseline: 210m; 
3 months: 390m, p=.001), MWD (baseline: 373m; 3 months: 555m, p=.002) and 
physical functioning score (SF-36) following SET, no increase in mean daily PA level 
was found (395 ± 220 vs. 411 ± 228 METs·min, p=.43). Furthermore, total number of 
steps and time spent in ambulatory activities did not change following SET.
Conclusion
Three months of SET for intermittent claudication leads to more patients meeting the 
ACSM/AHA public health minimum recommendations of PA. Assessment of PA may be 
incorporated as outcome parameter in future research comparing different treatment 
modalities for peripheral arterial disease.
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INTRODUCTION
Most patients with intermittent claudication (IC) demonstrate a limited exercise 
performance and have increased risks on cardio- and cerebrovascular events, reduced 
quality of life (QoL) and higher mortality rates.1 Primary treatment of IC includes 
supervised exercise therapy (SET) as suggested by several international guidelines.1-3 
SET significantly improves the maximal and pain-free walking distances and is cost-
effective.4-8 However, the question arises whether effectiveness of PAD treatment 
modalities should be evaluated on the basis of changes in walking capacity only. 
Individuals who are regularly physically active report better overall health, lower health 
care expenditures and fewer mobility limitations than their sedentary counterparts.9,10 
The American Heart Association (AHA) and the American College of Sports Medicine 
(ACSM) provide specific recommendations of various types of activity to stimulate the 
elderly. Tailored recommendations are provided that apply to adults with clinically 
significant chronic conditions or functional limitations that affect mobility and activity.11
Guidelines suggest to engage in moderate-intensity aerobic exercise for a minimum of 
30 minutes during five days a week, or a minimum of 20 minutes of vigorous-intensity 
activity on three days each week, or some combination of the two.11 Activities should 
be performed in bouts of at least 10 minutes. Intensity of effort is assessed in absolute 
terms by estimating the actual metabolic cost of a given activity and assigning intensity 
accordingly.12 A metabolic equivalent (MET) is an estimate of oxygen consumption 
at rest. A three-MET activity would be an activity that utilizes roughly three times the 
amount of resting energy expenditure. Accordingly, vigorous intensity activities (>6.0 
METs) performed for a particular duration and frequency generate greater energy 
expenditure than moderate-intensity activities (3.0-6.0 METs) of the same duration 
and frequency. When combining the recommendations on moderate- and vigorous-
intensity physical activity (PA), the daily minimum goal of physical activity (PA) should 
be in the range of 64-107 METs·min.11 
Recent studies demonstrated that free-living daily PA levels in IC patients are lower 
compared to healthy controls.13-16 However, PA is scantly used as an outcome parameter 
in trials concerning IC treatment.15,17-21 It may be relevant to study the potential beneficial 
effects of SET on PA level and exercise behaviour in IC patients. If PA levels improve 
following SET, cardiovascular risk reduction and improved quality of life may follow on 
the long term.22,23 Although SET has proven effective in improving walking distances 8,19, 
one can question whether an increased walking capacity is of benefit during the 
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patient’s daily life activities. In other words, when an IC patient is able to walk further, 
this finding does not necessarily implicate that PA levels and/or exercise behavior 
are positively influenced. A potential goal of future PAD treatment should perhaps be 
aimed at increasing physical activity.
The aim of this study is to assess the effect of a SET program on PA and walking 
behavior in an IC population. In addition, we hypothesize that a SET induced increased 
walking distance would improve PA levels in IC patients.
METHODS
The present study was executed between January 2013 and September 2013. The 
study was conducted following a previous study that was executed to quantify daily PA 
levels and energy expenditure in newly diagnosed IC patients.16 
Patients were recruited from a population presenting with new onset manifestations of 
IC at outpatient departments of Vascular Surgery of the Catharina Hospital, Eindhoven 
and Maxima Medical Centre, Veldhoven/Eindhoven, The Netherlands. Following 
history taking and a physical examination, patients suspected of IC underwent an 
ankle-brachial index (ABI) measurement using standard equipment. Patients with 
values below 0.90 at rest or a drop in value of more than 0.15 after a standardised 
treadmill test (at 3.2 km/h and a 10% incline) were considered eligible.
Exclusion criteria were serious cardiopulmonary limitations (NYHA class 3-4), critical 
limb ischemia or previous lower-limb amputation, use of walking aids, psychiatric 
instability or other serious comorbidity which possibly limited the patient’s walking 
ability. Patients who were treated with invasive revascularizations during follow up 
were excluded as well.
Subjects that were willing to participate provided a written informed consent. All 
procedures described in this study were approved by the Medical Ethical Committee, 
Catharina Hospital, Eindhoven.
Study protocol
All participants received a detailed instruction on all specifics regarding proper 
handling and wearing of the DynaPort MoveMonitor (McRoberts BV, The Hague, the 
Netherlands) and were asked to wear the device correctly for 7 consecutive days. As 
the device is not waterproof, participants were instructed to remove the device when 
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taking a shower or a bath. Participants were also asked to perform their normal daily 
activities during this week and not to wear the device during sleeping. A 3 months 
period of SET was commenced immediately after the first week monitoring period. 
Patients were referred to a local physical therapist, which were trained in providing 
SET according to the Royal Dutch Society for Physical Therapy guidelines and the Dutch 
ClaudicatioNet quality standards.24
The educational program ensured that all patients received SET according to the 
guidelines of the Royal Dutch Society for Physical Therapy.25 The physical therapist 
assessed a baseline and a 3 months pain-free walking distance (PFWD) and maximum 
walking distance (MWD) using a standardised graded treadmill protocol (walking 
at 3.2 kilometer per hour (km/h) with a 0% incline that increases by 2% every 2 
minutes till a maximum of 10%).26,27 Patients were tested for a maximum of 30 minutes 
(1600m). Evidence-based cardiovascular risk management including antiplatelet and 
statin therapy was standardly initiated, in case patients were not taking this medication 
already. After 3 months, SET outcome was discussed with the patient followed by a 
second 7-day period of wearing the DynaPort MoveMonitor.
Monitoring of physical activity and walking impairment
The DynaPort MoveMonitor, a tri-axial seismic accelerometer, was used to measure 
PA. The DynaPort MoveMonitor was placed in a belt that was strapped around the 
waist. It was positioned at the base of the lumbar column just cranial to the buttocks. 
This accelerometer was chosen because of an optimal correlation between indirect 
calorimetry and generated MET output whereas walking speed was correctly measured 
in a population with chronic obstructive pulmonary disease.28 Moreover, this activity 
monitor was recently validated in an IC population.29 The device consists of a tri-
orthogonal orientated piezo-capacitive acceleration sensor, a rechargeable battery 
and removable SD card to store the acceleration data. The raw acceleration data lend 
itself to a pattern recognition approach using logical algorithms (MoveMonitor analysis 
software, version 2.6) for the classification of postures (lying, sitting and standing) 
and motions (locomotion and shuffling). General and specifics of the software were 
provided in several previously published articles.16,30-31 A Dutch validated version of the 
Walking Impairment Questionnaire (WIQ) and a 36-item Short Form Health Survey 
version 2 (SF-36) were assessed at baseline and after the 3 months of SET treatment.32-34
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Primary outcomes
 • Percentage of participants meeting the ACSM lower limit recommendation for PA 
and public health (67 METs·min a day)
 • Percentage of participants meeting the ACSM higher limit recommendation for PA 
and public health (107 METs·min a day)
Secondary outcomes
 • Daily PA level (measured in METs·min)
 • Daily PA level performed in bouts of >10 minutes of moderate or vigorous intensity 
(measured in METs·min)
 • Mean time spent per day during different activities (in minutes; lying, standing, 
sitting, walking, shuffling, locomotion, not wearing the device)
 • Mean number of steps walked in one period and maximal number per day (top 
period of steps)
 • Activity per day (in minutes; sedentary activity: intensity <1.5 METs; light: 1.5-3 
METs; moderate: 3-6 METs; vigorous: 6-9 METs)
Data Analysis
Data checks per patient for each study day were deemed necessary to assure proper 
use of the device. By definition, the device was ‘worn correctly’ during a day if it 
detected a minimum of 20 steps and if it was ‘worn’ ≥9 hours and if it was ‘not worn’ 
for ≥5 hours a day. Moreover, patients were arbitrarily excluded from analysis if the 
device was worn during less than 5 days, to filter out incorrect or unrepresentative data. 
Mean time that was spent per day was determined for each participant depending on 
the number of ‘correctly worn days’. Analysis was performed on patients with both a 
correct baseline and follow-up measurement.
Statistical analyses
All analyses were performed using IBM SPSS Statistics Version 21 (SPSS Inc., Chicago,
IL, USA). Categorical variables are presented as frequencies with percentages. A 
Pearson Chi-Square test was used to identify differences for categorical variables. 
To obtain an impression of the distribution, values were analyzed for skewness and 
kurtosis. Nominal normally distributed variables are depicted as the mean ± standard 
deviation (SD), while non-normally distributed values are reported as median ± 
interquartile range (IQR).
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Statistical differences between the included and excluded study populations were 
analysed with an independent Students T-test, while differences between time periods 
were calculated with a paired sample T-test or with Pearson correlation coefficients for 
continuous normal distributed variables. A Wilcoxon signed-rank test or Spearman’s 
rho were utilized for non-normal distributed continuous variables. A p-value <0.05 
was used for statistical significance.
RESULTS
Baseline characteristics
A total of 126 IC patients wore the device correctly at baseline and were considered 
eligible for this study (Figure 1). Analysis of the accelerometer data demonstrated 
that 17 subjects did not wore the device correctly for ≥5 days at follow up. In six 
cases the internal memory card malfunctioned and data were not stored, another 
eight participants refused a follow up measurement and another 38 subjects were 
lost to follow up (36.5%). As a consequence, data of 57 participants could be used 
for analysis (45.2%), of which 10 patients received a vascular intervention during the 
study period and 6 did not receive SET due to inadequate health care insurance. The 
present study reflects the results obtained from 41 patients (35.3% of the total study 
population). Baseline characteristics regarding both the included and excluded study 
population are depicted in Table 1.
ACSM recommendations in IC patients
A total of 18 participants achieved the lower limit of the ACSM recommendations
(67 METs·min a day) and 12 of them even met the ACSM upper limit (107 METs·min a 
day) as well at baseline line. The number of participants meeting the lower limit of the 
ACSM recommendations was significantly lower at baseline (n=18, 43%) compared to 
the numbers at 3 months of follow up (n=26, 63%, p=.003, Figure 2). Of the initial 18 
participants that achieved the lower limit of the ACSM recommendations at baseline, 
16 achieved the lower limit at follow up (Figure 2) again, while the remaining other 
two did not. From the 12 participants who achieved the higher limit of the ACSM 
recommendations at baseline (29%), eight achieved the higher limit again after 3 
months (Figure 2). In total 14 subjects met the ACSM higher limit (34%).
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FIGURE 1. Study population flowchart. 




- Not correct worn follow up measurement (n=17)
- refused a follow-up measurement (n=8)
- loss to follow up (n=38)
- SD card failure (n=6)
Eligible patients for analysis
(n=57)
Included patients for analysis
(n=41)
Not a solely SET regimen
- SET plus vascular surgery (n=10)
- “go home and walk advice” (n=6)
Note. Correct worn = the device was “worn correctly” during a day if it detected a minimum of 20 steps 
and if it was “worn” for ≥ 9h and “not worn” for ≥ 5h a day; SD = secure digital; SET = supervised exercise 
therapy.
FIGURE 2. Adherence to the American College of Sports Medicine’s (ACSM) minimum 


























Note. *p < .05.
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TABLE 1 Baseline characteristics






Male (N - %) 20 (48.8%) 49 (57.6%) .45
Both legs symptomatic (N - %) 19 (46.3%) 38 (44.7%) .29
Age (years) (mean ± SD) 69 ± 11 68 ± 10 .42
BMI (kg/m2) (mean ± SD) 27.4 ± 4.1 26.7 ± 4.0 .37
Worst ABI in rest (mean ± SD) 0.61 ± 0.20 a 0.63 ± 0.19 d .50
Worst ABI after effort (mean ± SD) 0.43 ± 0.21 b 0.44 ± 0.22 e .85
Duplex right leg c
No leasions 6 (14.6%) n/a
Aortoiliac 6 (14.6%) n/a
Femoropopliteal 12 (29.3%) n/a
Combination 5 (12.2%) n/a
Duplex left leg c
No leasions 10 (24.4%) n/a
Aortoiliac 4 (9.8%) n/a
Femoropopliteal 12 (29.3%) n/a
Combination 5 (12.2%) n/a
Pulmonary history (N - %) 9 (22.0%) 16 (18.8%) .81
Cardiac history (N - %) 10 (24.4%) 29 (34.1%) .33
Note. BMI = body mass index; ABI = ankle-brachial index; NA = not available. a Values based on 29 
patients. b Values based on 38 patients. c Values based on 82 patients. d Values based on 30 patients. e 
Values based on 73 patients.
Daily level of physical activity in IC patients
Mean daily PA level (in METs·min) was normally distributed. No significant difference in 
mean daily PA level was found after 3 months of SET (baseline: 395 ± 220 METs·min vs. 
3 months: 411 ± 228 METs·min, p=.43; Figure 3). Moreover, daily PA levels performed 
in bouts of >10 minutes were also not significantly different after 3 months (p=.13; 
Figure 3). No significant correlation coefficients were found between the change in 
mean daily PA (METs·min) or mean daily PA in bouts and the increase in MWD (Δmean 
daily PA vs. ΔMWD: r=.21, p=.19; Δmean daily PA in bouts vs. ΔMWD: r=.30, p=.06).
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TABLE 2 Mean daily activities and duration at different intensity levels at baseline and at the 
3-month follow up.





Device worn correctly (days) 7 (6 – 7) 7 (6 - 7)
Time worn (min) 910 (880 – 1006) 932 (899 – 1043) .06
Lying (min) 139 (72 – 270) 182 (99 – 270) .27
Sitting (min) 462 (390 – 580) 512 (397 – 607) .24
Standing (min) 151 (108 – 221) 168 (123 – 209) .40
Walking (min) 64 (40 – 87) 61 (42 – 88) .87
Shuffling (min) 20 (13 – 25) 17 (13 – 32) .70
Locomotion (min) 89 (61 – 116) 82 (60 – 125) .84
Not Worn (min) 529 (434 – 559) 509 (397 – 541) .11
Steps (mean ± SD) 5732 (3187) 5805 (3336) .43 b
Top period consecutive steps 
(mean ± SD)
1914 (1473) 2390 (1904) .03 b
Light activity (min) 66 (50 – 91) 64 (51-91) .29
Moderate activity (min) 83 (59 – 107) 81 (58 – 106) .81
Vigorous activity (min) 1.3 (0.4 – 6.2) 0.9 (0.4 – 7.9) .97
Note. IQR = interquartile range; light activity = activity with an intensity of 1.5-3.0 metabolic equivalents 
(METs); moderate activity = activity with an intensity of 3.1-6.0 METs; vigorous activity = activity with an 
intensity of 6.1-9.0 METs. a Wilcoxon signed rank test. b Paired t test. 
FIGURE 3. Mean daily physical activity (PA) level at baseline and at 3-month follow up.
Note. Mets = metabolic equivalents. *Data were normally distributed and analyzed with a paired t test. 
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Time consumption and intensity of various activities
Table 2 depicts the time consumption and intensity of the various daily activities of 
IC patient. Data was non-normally distributed. No significant changes were found 
after 3 months of SET. Analysis of the intensity levels did also not show any significant 
differences between baseline and 3-months values (Table 2). However, the mean 
maximal number of consecutive steps (top period of steps), which was normally 
distributed, was significantly higher after 3 months of SET (1914 ± 1473 vs. 2390 ± 
1904, p<.05).
Walking distances and quality of life
PFWD, MWD and total WIQ score significantly improved following SET (Table 3).
Moreover, quality of life as reflected by SF-36 scores showed a significant increase 
in the physical functioning (PF) and the bodily pain (BP) role (Table 3). No significant 
correlation was found between the increase in both quality of life roles and an 
improvement in maximal walking distance (ΔPF vs. ΔMWD: r=-.07, p=.75; ΔBP vs. 
ΔMWD: r=.08, p=.73).
TABLE 3 Quality of life and walking distances at baseline and at the 3 month follow up.





PFWD (m) b 210 (113 – 300) 390 (230 – 580) .001
MWD (m) c 373 (254 – 631) 555 (320 – 825) .002
WIQ total score d 0.33 (0.16 – 0.58) 0.54 (0.41 – 0.78) <.001
SF-36 d
physical functioning 36.0 (25.5 – 43.9) 38.1 (33.9 – 46.5) .002
physical role 42.2 (30.5 – 48.9) 39.8 (32.8 – 52.0) .12
bodily pain 41.4 (37.2 – 49.3) 46.1 (37.2 – 50.3) .04
general health 41.7 (36.8 – 49.3) 44.8 (38.2 – 51.8) .06
vitality 49.0 (43.5 – 61.5) 52.1 (45.8 – 60.7) .35
social role 45.9 (35.0 – 56.8) 51.4 (40.5 – 56.8) .11
emotional role 48.1 (40.3 – 55.9) 44.2 (36.0 – 55.9) .34
mental health 52.8 (44.0 – 61.3) 55.6 (42.3 – 58.5) .85
Note. Note. IQR = interquartile range; PFWD = pain free walking distance; MWD = maximal walking 
distance; WIQ = Walking Impairment Questionnaire; SF-36 = Short Form Health Survey version 2.
a Values based on 34 patients. b Values based on 40 patients. c Values based on 39 patients. d Wilcoxon 
signed rank test.
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DISCUSSION
In line with the upcoming interest in studying potential associations between daily PA 
and their impact on cardiovascular risk reduction and mortality 35-41, this study assesses 
the effect of SET on proportions of IC patients meeting the ACSM lower and higher limit 
recommendation for PA and public health. Several studies registered activity levels in 
IC patients.15,17-21 However, this parameter was never considered as a primary outcome 
value. McDermott et al. showed in a 7-day measurement model that IC patients 
significantly improved their PA levels (in activity units) after 6 months of home-based 
exercise.21 These findings might in part be confirmed by the present results. Although 
our study was based on a shorter follow up period and based on supervised therapy, 
SET increased the percentage of IC patients achieving the lower and higher limit of 
daily PA level as recommended in the international ACSM guideline.11 However, firm 
conclusions cannot be drawn, since some patients did show a decline in PA level and 
mean values for ambulatory activities (e.g. walking time, total number of steps) were 
not influenced after a period of SET. Probably large variations in activities per patient 
(duration as well as intensity) and between patients in combination with our relatively 
small study population could have caused this contradiction. Therefore further research 
is necessary to optimize the determination of PA levels in patients suffering from IC. 
However from our results it may be argued that a 3-month SET program may have 
beneficial effects on increasing daily PA in an IC population.
It was hypothesized that an increased walking capacity would result in an improved 
PA level of IC patients. Although both the percentage of patients meeting the ACSM 
limits and walking capacity significantly improved after 3 months of SET, no significant 
correlation between the change in PA levels and the increase in walking distance was 
found. Therefore one may argue that components of a SET program other than an 
increased walking capacity do influence daily PA. Our findings might suggest that 
solely focusing on improvement of walking capacity has a limited value in optimizing 
SET treatment efficacy. It appears that patients who are able to walk further (because 
of a decrease in IC symptoms), will not use this capacity to walk more often, longer or 
with probably more intensity in daily life. 
The effect of SET on quality of life is still subject to debate.8 A recently published meta-
analysis found a positive trend in improved quality of life after three months of SET, 
although only the SF-36 “general health” role appeared significantly increased.8 In 
addition, McDermott et al. found no group differences in changes in the SF-12 PCS 
or MCS subscales.21 In contrast, we found a significant increase in both the physical 
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functioning and the bodily pain role after three months of SET. Although patients 
showed an increased walking capacity, no significant correlation in the change of SF-
36 values was found. This finding was recently confirmed by others reporting that the 
improvement in self-efficacy, satisfaction with functioning, pain acceptance and social 
functioning after six months of home-based walking exercise compared to a non-
exercising control group was independent of walking performance.42 In combination 
with our finding that walking capacity might be of diminished value, a shift in SET 
treatment paradigm seems necessary. Future research should therefore focus on the 
optimization of SET programs other than increasing walking capacity alone (intrinsic 
motivation, life-style, patient satisfaction and expectations, social functioning, etc.).
Unfortunately a number of participants were lost to follow up which may have 
potentially resulted in a selection bias. However, this is probably not the case as any 
differences regarding baseline characteristics between the study group and excluded 
patients were found. Furthermore both study groups were a representative reflection 
of the general PAD population encountered in a vascular outdoor clinic. An important 
reason for this substantial loss to follow up is the fact that 56 of the 126 included 
patients were recruited from a previous performed study.16 Only 23 of these 56 
patients were eligible for inclusion, because in the other patients the 3 months follow 
up period was already expired. Furthermore, introducing the Dynaport MoveMonitor 
from a research setting to daily practice in our patient outdoor clinic may boost wear 
compliance, as was observed in comparable research concerning COPD patients.43 
Unfortunately, a reliable sub-analysis between revascularization and SET treatment 
could not be performed as only 16 participants did receive such a treatment. Future 
research is needed to identify the effect of different IC treatment modalities on daily PA 
levels and ambulatory activities.
CONCLUSION
A 3-month SET program increases the number of patients achieving the ACSM/AHA 
public health minimum recommendations for physical activity (PA). The general focus 
of increasing solely walking capacity seems ancillary to other elements of supervision. 
Further research is needed to determine the optimal content of a SET program. In 
concert with the interest in factors such as sedentary activities and cardiovascular event 
risks, exercise behavior and PA might be included as outcome parameter in future PAD 
research and eventually clinical practice.
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ABSTRACT
Introduction
Intermittent claudication (IC) is a manifestation of peripheral arterial occlusive disease. 
Besides cardiovascular risk management, supervised exercise therapy (SET) should be 
offered to all patients with IC. Outdated guidelines, an insufficient number of specialised 
physiotherapists (PT’s), lack of awareness of the importance of SET by referring 
physicians and misguided financial incentives, all seriously impede the availability of a 
structured SET programme in the Netherlands.   
Description of care practice
By initiating regional care networks, ClaudicatioNet aims to improve the quality of care 
for patients with IC. Based on the chronic care model as conceptual framework, these 
networks should enhance the access, continuity and (cost-) efficiency of the health care 
system. With the aid of a national database, healthcare professionals will be able to 
benchmark patient results while ClaudicatioNet will be able to monitor quality of care 
by way of functional and patient reported outcome measures. 
Discussion
The success of ClaudicatioNet is dependent on several factors. Vascular surgeons, 
general practitioners and coordinating central caregivers will need to team up and 
work in close collaboration with specialised PT’s.  A substantial task in the upcoming 
years will be to monitor the quality, volume and distribution of ClaudicatioNet PT’s. 
Finally, misguided financial incentives within the Dutch Healthcare system need to be 
tackled.
Conclusion
With ClaudicatioNet, integrated care pathways are likely to improve in the upcoming 
years. This should result in achieving optimal quality of care for all patients with 
intermittent claudication.
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INTRODUCTION
Peripheral arterial occlusive disease (PAOD) is an expression of systemic atherosclerosis. 
Plaque formation causes progressive narrowing and hardening of the arteries in the 
legs. The manifestation of PAOD is variable, with some patients being asymptomatic 
and others developing tissue loss that ultimately necessitates amputation of the affected 
limb.1 The prevalence of PAOD is estimated to be 1.6% to 4.5% in the general population 
and as high as 19.1% in the Dutch population aged 55 years and older.2-6 
Intermittent claudication (IC), the mildest symptomatic manifestation of PAOD, is defined 
as pain in the muscles of the leg during exercise that is relieved by a short period of 
rest. IC is reported in 4.5% to 32.5% of all patients with PAOD.2,3,5 For IC, a five-year 
mortality rate of 19.2% is described, of which 70% is due to cardiovascular causes. 
Non-fatal cardiovascular events (e.g. myocardial infarction, stroke) in patients with IC 
are found in 29% at five years of follow-up.7 The prevalence of cerebrovascular disease 
in patients with IC is about 25–50%.8
Numerous consensus documents provide recommendations for diagnosis and 
management of patients with PAOD, including the American College of Cardiology/
American Heart Association (ACC/AHA) and Trans-Atlantic Inter-Society Consensus 
on Management of Peripheral Arterial Disease (TASC II) guidelines on PAOD.1,9 These 
guidelines identify patients with IC as a high-risk population who require intensive 
risk factor modification. Blood pressure levels, glucose, and cholesterol metabolism 
should all be optimised. Attention should be paid to smoking cessation since smoking 
is considered the most important modifiable vascular risk factor. Antiplatelet therapy 
and the use of a statin is indicated for all IC patients to reduce the risk of cardiovascular 
events.10,11
The primary symptomatic treatment for IC is exercise therapy, which was first suggested 
by Erb in 1898.12-13 In a Cochrane review of systematic reviews, Watson et al. 
described an overall improvement in maximal walking time with a mean difference 
of 5.12 minutes (95% confidence interval 4.51 – 5.72) in favour of exercise therapy 
compared with usual care or placebo.14 Exercise therapy consisted of all sorts of 
exercise prescriptions, including walking advice and unsupervised exercise regimes. 
Further benefit of exercise therapy was seen in the reduction of cardiovascular risk 
factors including hypercholesterolemia, hypertension, and diabetes mellitus.15 Given 
its clear benefits, the importance of exercise therapy is highlighted in contemporary 
international guidelines.1,9
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In daily practice, lack of specific individual guidance and the absence of uniform 
supervision appear to be important barriers concerning the initiation and continuation 
of exercise therapy.16 For this reason, exercise programmes under supervision of a 
physiotherapist (PT) are considered beneficial. A Cochrane review by Bendermacher 
et al. showed that supervised exercise therapy (SET) was superior to a non-supervised 
exercise program. The maximum walking distance increased by an additional 150 
meters in patients treated with SET compared to non-supervised exercise programmes.17
In a cohort study, community-based SET appeared to be as effective as hospital-based 
SET.18 Compared to outpatient hospital-based SET, community-based SET has the 
advantage of providing a larger capacity of care, in most cases being feasibly close 
to the patient’s home environment with reduced transport costs. With this body of 
evidence, it is clear that SET should be offered eventually to all patients with IC. 
PROBLEM STATEMENT
For the Dutch situation, there are several reasons as to why a structured SET programme 
is not offered to all patients with IC.   
Outdated guidelines of referring physicians
In The Netherlands, the diagnosis of IC is determined by a general practitioner 
or a vascular surgeon. In all cases, the general practitioner (GP) has to initiate 
cardiovascular risk management according to the 2011 Dutch multidisciplinary 
guideline ‘Cardiovascular Risk Management’.19 Both general practitioners as vascular 
surgeons are expected to start conservative symptomatic treatment for patients with IC, 
according to contemporary international guidelines for PAOD.1,9 However, guidelines 
of the Dutch Association of General Practitioners and Dutch Society for Vascular 
Surgery are in an urgent need of an update since SET is not advocated as initial 
treatment for patients with IC.20,21
Outdated arguments not to refer for a SET programme
A quarter of new patients with IC, seen by a vascular surgeon, do not receive SET, as 
recently described in a national survey.22 The referral rate of GP’s is unknown, although 
this will most probably be low given the small impact IC has on the general practice of a 
GP. Vascular surgeons who do refer for SET (75,4 %) mentioned arguments why not to 
refer for SET in certain cases. These arguments are: existing significant cardiopulmonary 
comorbidity; an aortoiliac stenosis or occlusion causing IC; and limited availability of 
sufficiently specialised PT’s.22 Nevertheless, only the limited availability of PT’s seems 
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to be a valid argument. The remaining arguments appear to be outdated by current 
literature.
Furthermore, in case of severe or invalidating IC, invasive vascular interventions are 
often performed without first awaiting the effects of a structured SET programme. If a 
better infrastructure of specialised PT’s exists, more patients would be able to receive 
SET from the onset. 
Referring to whom?
If indications and referrals for SET have been set in a proper way, the next question is 
to whom should be referred? More than 22.000 PT’s in the Netherlands should make 
it possible to provide SET according to the Royal Dutch Society for Physical Therapy 
guideline.23 However, the majority of these PT’s are not adequately schooled in providing 
SET and do not have sufficient experience to provide this form of therapy. Patients with 
IC suffer from a variety of comorbidities and modifiable lifestyle factors, potentially 
generating suboptimal results if these aspects are not addressed appropriately. When 
adequately trained, PT’s should ideally be able to perform individual training, recognise 
alarm symptoms (so called red and yellow flags) and even provide lifestyle counseling 
or monitor medication adherence. Volume criteria could have an influence on patient 
outcomes, since in general, more experience leads to better results. In order to achieve 
these better patient outcomes differentiation in the field of physical therapy is needed.
Misguided financial incentives
Not the least problem is the fact that the Dutch healthcare system does not stimulate 
use of conservative treatment for patients with IC, while invasive vascular interventions 
are fully compensated. The Dutch government determines the scope of coverage of the 
basic health care and health insurers are obligated to accept people for this insurance 
without any selection. For additional coverage to the basic health insurance package, 
a voluntary additional health care insurance can be acquired. Health insurers can 
determine the content and prices for their additional packages and can refuse 
acceptation for additional coverage for high-risk patients.  
In this system, services provided by the GP or vascular surgeon, such as cardiovascular 
risk management or invasive vascular interventions, are fully compensated by the basic 
healthcare insurance. However, for physiotherapy, the first 20 treatment sessions of SET 
(for IC) are not covered by the basic health care insurance and have to be paid by 
the patient himself or by an additional insurance (since January 1st, 2012). All further 
treatment sessions, for a total of 1 year, are covered by the basic health care insurance. 
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Therefore, in some cases, patients with IC have a financially driven interest to be 
treated by vascular surgeons who deliver invasive vascular interventions (for instance 
angioplasty or bypass surgery), in disregard of the associated risk of morbidity (<0.5 - 
10%) and even mortality (2-3% for bypass surgery).11 
To tackle some of the aforementioned shortcomings, the ClaudicatioNet concept was 
developed and launched in the Netherlands in 2011.
DESCRIPTION OF CARE INTERVENTION: CLAUDICATIONET
The goal of the ClaudicatioNet programme is to improve the quality of care for 
patients with IC by creating connectivity and collaboration between the various players 
(including the patient) within the Dutch healthcare system. In general, by initiating 
regional care networks, ClaudicatioNet aims to enhance the access, continuity and 
(cost-) efficiency of the health care system. Furthermore, it aims to improve patient 
responsibility, patient satisfaction and quality of life for all patients with PAOD in the 
Netherlands. 
Initiation of the ClaudicatioNet concept
The EXITPAD trial provided level Ib evidence to support supervision in conjunction with 
exercise therapy for patients with IC.24 The concept of ClaudicatioNet has been based 
on the methods and results of this trial. In particular, many logistical efforts to make 
this trial possible provided useful knowledge for the initiation of the ClaudicatioNet 
concept.
ClaudicatioNet started in 2011 to initiate regional care networks between specially 
trained PT’s, central caregivers and vascular surgeons. After initiation of a network, 
general practitioners are able to use the network’s infrastructure. In regional networks, 
transparent, synergistic and multidisciplinary care has to be provided, based on the 
guidelines of cardiovascular risk management, SET and the Innovative Care for Chronic 
Conditions (ICCC) framework of the WHO.1,9,19,25 In addition to these evidence-based 
guidelines, the Dutch Health Care Inspectorate has developed (on behalf of the Ministry 
of Health, Welfare, and Sport) a set of mandatory key performance indicators.26 To 
meet these indicators, hospitals need to have a network of trained PT’s capable of 
providing SET for patients with IC by 2012.
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The goal of ClaudicatioNet is to initiate the set up of regional networks throughout the 
Netherlands in a three years time period (January 2011 - December 2013). Since 
every network requires a three to four year period to expand to the desired level, 
full nationwide implementation should be achieved by 2016. The Dutch Society for 
Vascular Surgery, the Royal Dutch Society for Physical Therapy (KNGF), and the Dutch 
patient association for heart and vascular diseases (De Hart & Vaatgroep) currently 
support ClaudicatioNet. With these partners, broad backing is in place to successfully 
implement this integrated care concept. 
Creation of care chains
Ideally the care for PAOD patients is initiated by general practitioners and provided 
by health care professionals connected within horizontal primary care chains. In the 
Netherlands there are successfully operating and well-equipped primary care chains 
for diabetes and COPD that have proven to be able to deliver care conform national 
guidelines and care standards. However, at this moment the majority of the GP’s do not 
participate in structured programs focusing on vascular risk management and do not 
take a leading or supervising role in the management of IC. There is an urgent need to 
solve this problem since a well-organised SET programme is stated in all contemporary 
guidelines and is listed as a key performance indicator by governmental bodies. To 
overcome the present care gap for patients with IC, a feasible and realistic solution 
had to be found.  At this moment most patients are referred for SET by the 163 certified 
and practicing vascular surgeons in the Netherlands. A majority of these surgeons is 
motivated to contribute to the establishment of the ClaudicatioNet concept.
Therefore regional networks were chosen to set-up amongst vascular surgeons, central 
caregivers and PT’s. After initiation, GP’s will be able to use the network’s infrastructure. 
In a region of the country where there is sufficient experience in setting up health care 
chains, further integration with three Dutch primary care health clusters (DOH, PoZoB, 
SGE) is being explored. 
Both referring physicians and PT’s benefit from participating in ClaudicatioNet. For 
referring physicians an infrastructure for care delivery with the use of specialised PT’s 
becomes available. By only referring patients to PT’s connected to ClaudicatioNet, 
vascular surgeons, general practitioners, and Health Care Insurers are guaranteed 
transparent and standardised high quality treatment for each patient. For vascular 
surgeons, a regional network is enrolled by ClaudicatioNet, which complies with 
the mandatory key performance indicator established by the Dutch Health Care 
Inspectorate. 
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For PT’s, ClaudicatioNet will provide a trajectory of specialisation in PAOD. This 
trajectory could be complementary to existing PT specialisations in the field of 
chronic illness or cardiopulmonary rehabilitation. Because of the growing need for 
differentiation in the field of physical therapy, participation will be a strategic choice 
for each individual PT or group practice. Furthermore, it is expected that the number of 
referrals per PT will increase significantly since only a proportion of all available PT’s 
will participate in ClaudicatioNet and only these PT’s will receive referrals. However, 
each PT has to make an economic trade-off between the potential profit and required 
investments derived from the mandatory participation criteria. How many referrals will 
lead to an acceptable profit giving the necessary investments is as yet uncertain. The 
answer pertaining to the viability of the business model of the program for primary care 
PT’s is important with regard to the incentive to prolong future participation. Supply 
and demand of SET will evolve and reach equilibrium over time. 
Improving integrated care pathways by using the chronic care model 
The structure and working method of ClaudicatioNet is based on the internationally 
(WHO) accepted chronic care model that provides an evidence based, conceptual 
framework to improve the functional and clinical outcomes for people with chronic 
illness. The chronic care model describes the interacting system components which are 
important for providing good chronic illness care: self-management support; delivery 
system design; decision support and clinical information systems (Figure 1).27 The 
model also includes the organization of the health care system and other conditional 
factors like resources and policies.
ClaudicatioNet bridges the gap between different health care professionals (e.g. 
GP’s and their practice assistants, vascular surgeons, specialised nurses in vascular 
surgery and PT’s). Together they are able to provide the best standards of practice. 
Patients have a pivotal role in the care given. Specific information, treatment goals 
and obtained results need to be communicated to the patient. Many more treatment 
goals (lifestyle counseling, monitoring medication adherence) should ideally be 
reiterated and explained by all involved caregivers. However, the risk of health related 
information fatigue must be avoided. All of these elements ask for an integrated care 
approach. The chronic care model is used as a framework to improve the integrated 
care pathways and quality of care provided by all health care professionals (Figure 2).
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FIGURE 1. The Chronic Care Model 
Note. adapted from Epping-Jordan et al. Qual Saf Health Care 2004
Patients 
Patients are placed centrally in the care structure of the ClaudicatioNet concept, in 
which the patient his self-management is essential to yielding optimal patient outcomes. 
Health care professionals need to support and facilitate self-management and patient 
empowerment. In general, patients with IC have a low level of physical activity and 
in the majority of cases favour an unhealthy lifestyle (smoking, poor diet, lack of 
movement). An essential part of a successful SET program is self-initiated exercises 
between supervised training sessions. 
In addition to the provided services of the involved health care professionals, 
ClaudicatioNet will provide supporting patient information through an interactive 
patient web portal. With the aid of this web portal patients are directed to background 
patient information regarding their disease, SET and/or lifestyle influences. Patients 
will be to able to find a specialised ClaudicatioNet PT in the online care finder and after 
initiation of SET, patients will have the possibility to monitor their own progress (based 
on individual data within the ClaudicatioNet database) in a user-friendly dashboard. 
Automatic reminders and the use of the interactive mobile application ‘WalkMate’ 
should increase adherence of patient self-management. With this app it will be possible 
to find, meet and train with other patients.
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§    DIAGNOSING PAOD 
§    INITIATING CVRM 
§    DESIGNATING CENTRAL 
 CAREGIVER 
§    DIAGNOSING PAOD 
§    INDICATING TREATMENT FORM          
 (CONSERVATIVE / VASCULAR 
 INTERVENTION / COMBINATION) 
§    DESIGNATING CENTRAL  
 CAREGIVER 
§    SUPPLYING PATIENT INFORMATION  
 (PAOD, CVRM, PHYSICAL THERAPY,  
 LIFESTYLE CHANGES) 
§   COMPLETING STANDARD REFERRAL FORM 
§    COORDINATING CARE: 
§    CHOOSING PT WITH PATIENT 
§    COORDINATING NECESSARY 
 APPOINTMENTS WITH HEALTH CARE 
 PROFESSIONALS 
§    MONITORING OF PATIENT PROGRESS 
 AND CONTACTING GP / VASCULAR 
 SURGEON IN CASE OF DETORIATION 
PATIENT	  
§    TREATMENT ACCORDING CLAUDICATIONET 
 QUALITY STANDARDS 
§    USING STANDARD FEEDBACK FORM  
 (AT 3, 6 AND 12 MONTHS OF TRAINING) 
§    CONTACT WITH CENTRAL CAREGIVER IN CASE OF: 
§    NO THERAPY ADHERENCE 
§    PROGRESSION OF PAOD 
§    SUSPECTED DRUG NON-ADHERENCE 
§    SEVERE TRAINING LIMITATIONS DUE TO 
 LIFESTYLE FACTORS / COMORBIDITY 
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To evaluate the treatment provided by all the health care professionals, patients are 
asked to provide feedback on the number of treatment sessions, treatment protocol, 
facilities and expertise of individual health care professionals. Special attention will be 
paid to whether a patient receives training by a specialised PT. 
General practitioners and vascular surgeons 
General practitioners and vascular surgeons are the first caregivers to confront a 
patient with IC diagnosis and thus have the responsibility to diagnose compounding 
cardiovascular risk factors and attributing lifestyle factors. Ideally, GP’s diagnose IC 
and initiate cardiovascular risk management while vascular surgeons determine if a 
vascular intervention is necessary. The guideline from the Dutch General Practitioners 
Society leaves the possibility to refer to a vascular surgeon in case of doubt or lack 
of available resources to perform an ABI (ankle-brachial index). In these cases it is 
a vascular surgeon whom initiates or advices first line treatment. After diagnosing 
and indicating treatment the patient should be designated to a central caregiver to 
coordinate the essential care for each individual patient. Ideally this takes place in 
primary care setting. 
ClaudicatioNet necessitates that vascular surgeons only refer patients to a specialised 
ClaudicatioNet PT. Patients will be asked to provide feedback regarding the quality of 
care provided by the healthcare professional. Also, the number and origin of referrals 
will be monitored in the national ClaudicatioNet database and can, with the cooperation 
of health care insurers, be compared with the total number of patients with IC.
Central caregiver
Central caregivers (GP practice assistants or specialised vascular surgery nurses) play 
a major role in providing patient tailored management and coordination of given 
care from all involved caregivers. In an ongoing relationship with the patient, central 
caregivers provide integrated patient information regarding the condition, prognosis, 
influencing factors and treatment progress. Patients need to be supported in order 
to improve the management for their condition. Preferably, it is the patient and their 
central caregiver whom select a ClaudicatioNet PT. The central caregiver is responsible 
for the content and the process of the care given. He or she provides structure and 
follow-up according to the second component of the chronic care model. 
Besides these tasks, central caregivers perform lifestyle interventions, monitor therapy 
adherence and initiate contact with the GP or vascular surgeon in case of detoriation 
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of the patient his condition. Therefore, a central caregiver needs to work in close 
collaboration with all participating PT’s in the regional network. In order to improve 
the system design, ClaudicatioNet developed standardised SET referral forms and 
patient leaflets with information regarding the interactive patient web portal. Central 
caregivers will be able to monitor the progress of their patients with a user-friendly 
web-based dashboard connected to the ClaudicatioNet database.
Physiotherapists 
PT’s participating in ClaudicatioNet perform standardised and evidence based SET, 
perform lifestyle interventions (e.g. smoking cessation, dietary advice) and regularly 
(2-4 times a year) assess medication adherence - all in close collaboration with the 
central caregiver. Prior to participating in a regional ClaudicatioNet network, PT’s must 
meet the set inclusion criteria (Table 1).
TABLE 1 Inclusion criteria for aspiring PT’s 
· Completed the course ‘Intermittent Claudication’, certified by the Royal Dutch Society for 
Physical Therapy.
· Owns or works at a well equipped practice with a treadmill (with inclinometer), bicycle 
ergometer, reanimation protocol, automatic electronic defibrillator, internet connection, 
and yearly maintenance of equipment.
· Broad oriented PT that recognises, reports, and acts on other limitations (like COPD, 
arthrosis, gait) that influence the patient’s progress.
Prior to launching a regional network, a certified schooling programme on ‘Intermittent 
Claudication’, is provided by ClaudicatioNet for all aspiring PT’s. 
After inclusion, a PT is included in the online care-finder of ClaudicatioNet, which ideally 
should lead to a rise of the number of referrals. In a three year, step-wise program, 
PT’s need to comply with increasing quality standards to ensure continued participation 
and referrals (Table 2). One additional year can be spent if the requirements of any 
given step in the specialisation process cannot be met. This results in a total of four 
years to obtain full specialization. After meeting the final criteria, PT’s are considered 
to keep their knowledge up to date by attending the annual ClaudicatioNet congress 
once every two years and participating in lifelong learning activities through relevant 
schooling (15 dedicated study hours/year). 
ClaudicatioNet provides an ‘ask the expert’ module, if a PT is confronted with a 
complex situation in their daily practice. This module is part of the ClaudicatioNet 
website and facilitates discussion about treatment difficulties with an expert PT and 
relates to the decision support component of the chronic care model. To gain efficiency 
in the delivery system design, ClaudicatioNet equips PT’s with standard feedback 
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forms. These forms provide essential information as inventoried in a national survey 
amongst vascular surgeons.22
TABLE 2 Participation criteria
Step 1 Step 2 Step 3
Standard care: delivers 
transparent care according 
to protocol, provides 
feedback to vascular surgeon 
and has adequate patient 
administration.
Practice visitation: complies 
with quality indicators on 
transparency and quality of 
care, organisation of practice, 
portfolio, and patient 
administration.
Patient Follow-up System: 
works in the third year with a 
patient follow-up system that 
supplies data to the national 
ClaudicatioNet database. 
Schooling: attended 
continuous medical education 
(CME) on peripheral arterial 
disease or concomitant 
disease. In total, 15 credits 
should be obtained each 
year.  The ClaudicatioNet 
congress is mandatory every 
two years.
Schooling: attended 
continuous medical education 
(CME) on peripheral arterial 
disease or concomitant 
disease. In total, 15 credits 
should be obtained each 
year.  The ClaudicatioNet 
congress is mandatory every 
two years.
Schooling: attended 
continuous medical education 
(CME) on peripheral arterial 
disease or concomitant 
disease. In total, 15 credits 
should be obtained each 
year.  The ClaudicatioNet 
congress is mandatory every 
two years.
Progress: completed an 
electronic inquiry of all results 
and number of patients.
Portfolio: provided an 
updated personal portfolio for 
web use (care-finder module).
Course: completed the course 
‘Motivational Interviewing’ 
and is able to perform lifestyle 
intervention for each patient
The progress of each individual PT will be monitored and if necessary acted upon. 
Quality evaluation based on a clinical information system is possible once PT’s supply 
data (e.g. patient outcomes, number of treatment sessions, referral information) to 
the national ClaudicatioNet database. Recently a set of evidence based performance 
indicators has been developed.28 This data will be combined at regular intervals with 
measured feedback from patients (e.g. the number and content of training sessions, 
treatment provision by appropriate (certified) caregivers, satisfaction and perceived 
quality of care). With this data ClaudicatioNet will be able to monitor and improve 
future quality of care.  
ClaudicatioNet promotes networking between health care professionals by organising 
regional network meetings with PT’s, case managers, GPs and vascular surgeons. 
The goal of these meetings is to evaluate daily practice and exchange knowledge. 
ClaudicatioNet also organises an annual congress focusing on the management of 
PAOD. As part of the congress two parallel regional lunch programs, one specific 
for PT’s and one aimed at case managers are organised. This lunch program enables 
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both groups to discuss regional organisational aspects (for instance network meetings, 
regional schooling or other activities) and the coordination of regional care (for 
instance referral practice, quality of feedback).
DISCUSSION
Once ClaudicatioNet is operating nationwide, more patients with symptomatic PAOD, 
if not all, will benefit from standardised SET. This will lead to a reduced need for vascular 
interventions (percutaneous angioplasties or peripheral bypass operations). Morbidity 
and mortality due to these prevented interventions will cease to exist, resulting in a 
substantial population health gain. Prevention of costly interventions will also lead to 
a reduction of overall health costs. The promotion of life style activities by different 
caregivers as well as a structured, supervised and self-initiated, health stimulated 
exercise therapy will also have beneficial effects on the general health of patients. This, 
in turn, is likely to lead to reduced complications of existing comorbidities.
Health care insurers support this innovative concept and are willing to participate. 
A decline in the total number of vascular interventions has already been noted after 
the successful implementation of the first regional integrated care networks for IC. In 
the upcoming years, the number of patients admitted to ClaudicatioNet PT’s will be 
compared to historical data and to the total number of vascular interventions. Patient 
outcomes will be gathered in the ClaudicatioNet database and compared to existing 
data. It is through these means that the success of ClaudicatioNet will be determined. 
In our opinion, the existence of a central caregiver as an easily accessible contact 
person within the first regional network, already improved patient communication and 
interaction between health care providers.
Success of ClaudicatioNet is, however, dependent on several factors.  Vascular surgeons 
and GP’s will need to refer patients with IC to PT’s connected with ClaudicatioNet. Because 
ClaudicatioNet offers transparency of care with logistic support (referral packages, 
standardised feedback), ClaudicatioNet participation has evident advantages. Also, 
the mandatory key performance indicators of SET will help secure the collaboration 
of vascular surgeons to team up with ClaudicatioNet to launch a regional network. 
As mentioned previously, SET is not recommended in the current guidelines of the 
Dutch General Practitioners Society and Dutch Society for Vascular Surgery. Given the 
evidence provided in the current literature, adjustment of these guidelines is urgently 
needed to provide all patients with IC the best possible care. 
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Another critical success factor is nationwide coverage. To achieve this goal a sufficient 
number of PT’s will need to participate. Given the number of referrals and the supply 
and demand dynamics in each regional network, the volume of patients will determine 
the economic trade-off for the individual PT. When a PT chooses not to participate in 
ClaudicatioNet, more referrals are divided among the remaining PT’s. ClaudicatioNet 
will not actively interfere with the geographic distribution of participating PT’s. In the 
near future, supply and demand of SET will evolve and eventually create a balance 
within the market. In a worst-case scenario, regional coverage may not be fully 
achieved in some areas. Should this situation arise, ClaudicatioNet will subsequently 
try to recruit PT’s to those specific areas.  
Monitoring, updating and increasing the quality of ClaudicatioNet PT’s will be a 
substantial task in the upcoming years and also an essential success factor. Participating 
PT’s need to comply with a greater number of quality standards compared to non-
participating PT’s. It is necessary in our opinion to reward those PT’s whom provide 
excellent care according to the established quality standards. Compensation for those 
PT’s should be linear to the quality provided and, over time, Health Care Insurers 
should compensate only those PT’s who deliver excellent care standards.  To achieve 
this, a specific role needs to be played by Health Care Insurers. ClaudicatioNet will 
collaborate with these Health Care Insurers in order to accomplish this goal. 
Another topic of discussion is the financial compensation for patients. In our opinion, 
every patient admitted to ClaudicatioNet should be fully compensated for the conservative 
treatment programme by the mandatory Dutch basic health care insurance. In the 
current Dutch Health Care system, patients whom undergo a percutaneous vascular 
intervention or bypass surgery are fully compensated, in contrast to SET for which a 
financial contribution is still compulsory. To advocate this, we will argue for a system 
in which superior care is fully compensated compared to less-superior care. It is our 
objective to convince the Health Care Insurance Board (CVZ) of this necessity. 
Future research should assess if the ClaudicatioNet concept is an effective approach 
for patients with critical limb ischemia whom have undergone a percutaneous vascular 
intervention or peripheral bypass surgery. For IC, the initiation of a cost-effectiveness 
study of the ClaudicatioNet concept will be the next step to determine the scope of 
efficiency. 
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CONCLUSION
In the Netherlands, evidence based conservative treatment is not offered to all patients 
with IC. ClaudicatioNet was launched to improve the quality of care, access, continuity 
and (cost-) efficiency of the health care system. The chronic care model provides a 
conceptual framework of the structure and working method of ClaudicatioNet. With 
this care intervention, integrated care pathways are ought to be improved in the 
upcoming years. This should result in an optimal quality of care for all patients with 
intermittent claudication.
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ABSTRACT
Objectives
The aim of the study was to develop quality indicators (QIs) for physiotherapy 
management of patients with intermittent claudication (IC).
Design
As part of an international six-step method to develop QIs, an online survey Delphi-
procedure was performed.
Participants
Twenty-six experts were recruited to participate in this study. Twenty-four experts 
completed the Delphi procedure.
Results
Out of 83 potential QIs in the Dutch physiotherapy guideline on “Intermittent claudication”, 
consensus among the experts selected five indicators; 1) The physiotherapist measures 
the functional claudication distance and absolute claudication distance by performing 
a standardized treadmill test, 2) The outcome measures are assessed at baseline, 
after three months, six months, twelve months and at the end of the physiotherapy 
intervention, 3) The physiotherapist administers the Walking Impairment Questionnaire 
(WIQ), 4) The physiotherapist measures quality of life using the Euro Quality of Life-5D 
and 5)The physiotherapist checks non-compliance with medication use.
Conclusion
A final set of five indicators was derived from (1) an evidence-based guideline and (2) 
an expert Delphi procedure. This set of indicators should be validated before being 
implemented in clinical practice.
8131
Development of quality indicators for physical therapy in peripheral arterial occlusive disease | CHAPTER 8
BACKGROUND
The prevalence of peripheral artery occlusive disease (PAOD) in the general population 
of the Netherlands aged 55 years or older is 19.1% (CI 18.1 – 20.0).1 Socio-
demographic developments suggest an increase in the incidence and prevalence of 
PAOD in the next 15 years. PAOD implies an elevated risk of cardiovascular and 
cerebrovascular disease and higher mortality rates, as PAOD is a marker of generalised 
atherosclerotic disease.1-3 
The five-year mortality associated with intermittent claudication is 19.2%.4 When PAOD 
becomes symptomatic, patients often present with the typical symptoms of intermittent 
claudication (IC) such as “cramping,” “fatigue,” or “aching” in the calf of the leg, 
induced by walking and relieved by rest (1). IC is associated with a significantly lower 
quality of life, which can be improved with supervised exercise therapy (SET).5 
Evidence for the efficacy of SET for patients with IC has evolved rapidly, with a Cochrane 
review and multiple randomised controlled trials of good quality.6-8 Compared to 
walking advice or endovascular revascularisation, SET showed favourable effects in 
terms of walking distances, functional impairment and health-related quality of life 6, 9, 10, 
and seems to be cost-effective.11 Community-based SET seems as efficacious as hospital-
based SET.9 The intensity and duration of treatment are well described.12
In the Netherlands, SET is reimbursed by health insurance in patients with IC if it is 
provided by a trained and skilled physiotherapist. In 2003, the Royal Dutch Society for 
Physical Therapy (KNGF) published an evidence-based guideline on physical therapy 
for IC for physiotherapists in the Netherlands.13 This guideline was distributed among 
the Society’s members and is freely accessible on the internet. However, dissemination of 
guidelines does not guarantee sufficient implementation of each guideline or adherence 
to the (key) recommendations in clinical practice 14-16, and the use of quality indicators 
(QIs) has been suggested in order to obtain a valid and appropriate measure of guideline 
adherence.17 European quality standards have been developed for cardiovascular risk 
prevention and risk management in primary care and comprise 44 indicators.18,19 
However, QIs for the physical therapy management of IC are lacking. 
This article reports on a research project for the development of QIs for physical 
therapy interventions in patients with IC. The aim of the study was to develop a feasible 
set of QIs for physical therapy management of IC. Opinions of experts were explored 
to identify aspects that are relevant and important for patients with IC. 
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METHODS
Based on the guideline on “Intermittent claudication” of the Royal Dutch Society 
for Physical Therapy 13, we developed a set of QIs, using the first four steps of an 
international six-step method. (Table 1) 17, 22 
TABLE 1 Steps in the process of developing QIs for PT for patients with IC.
Step 1. Selection of relevant patient group and care process. 
Step 2. Deriving potential indicators from the national guideline
Step 3. Rating of the relevance of each potential indicator by an expert panel 
Step 4. Operationalisation of prioritised indicators into draft set of quality indicators.
Step 5. Practice-testing the initial set of indicators using clinical vignettes
Step 6. Establishing definitive indicator set
Deriving potential indicators from the guideline
Two authors (HG, EH) drew up a list of potentially suitable indicators from the national 
guideline recommendations and the literature. 
Rating the relevance of each potential indicator
Two of the authors (HG, EH) selected and invited experts (12 physiotherapists, 12 vascular 
surgeons and residents, 3 lecturers) for the expert panel. Expert physiotherapists were 
physiotherapists with over 5 years of experience in providing SET, working in primary 
care as well as in hospitals, and complying with the quality standards of the Dutch 
integrated care network “ClaudicatioNet”. The invited vascular surgeons and trainee 
vascular surgeons knew the effects of SET. The invited lecturers were experienced in 
teaching physiotherapists about intermittent claudication or conducting research into 
this disease.
The experts were invited to participate in a two-stage online survey Delphi procedure, 
and were asked to rate the potential indicators in terms of relevance for the quality of 
physical therapy intervention. They could also add further potential indicators, provided 
these were thoroughly substantiated. The QIs were rated on a nine-point Likert scale 
from 1 to 9, where 1 meant “not relevant at all” and 9 meant “very relevant”. After the 
first Delphi round, all potential indicators with a mean score >8 and a median score 
of 8 or 9 were presented in a second Delphi round, in which the experts remained 
blinded to the scores from the first Delphi round. The experts were invited to rate the 
indicators again on the same nine-point Likert scale, in order to obtain a feasible set of 
indicators. The experts were given the option of re-including indicators discarded from 
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the original set. After these two stages, the remaining indicators with a mean score >8 
or a median score of 8 or 9 were scored in a third Delphi round. Four experts of the 
expert panel with specific knowledge in measurability, were also asked to score the 
measurability of the remaining items on a 4-point scale (very relevant, relevant, some 
relevance, not relevant at all). 
Operationalisation of prioritised indicators into a draft set of QIs
Potential indicators emerging from the third Delphi round, which had been unanimously 
rated as very relevant or relevant by all four experts were included in the draft set. 
Good measurability of the indicators was the main requirement for inclusion in the final 
draft set of indicators. All experts were subsequently asked to endorse this final draft 
set of indicators.
Data analysis 
The cut-off values for the relevance of indicators from the Delphi procedure were 
determined using the Kolmogorov-Smirnov test to check for a normal distribution. In 
case of normal distribution, indicators with a mean score > 8, as judged by the experts, 
were selected as relevant. If the distribution was not normal, items with a median 
score of 8 or 9 on the nine-point Likert scale were selected as relevant indicators. This 
analysis was used for the first two Delphi rounds. In the third round, only items with a 
score of “very relevant” or “relevant” were selected. 
RESULTS
Eighty-three potential QIs were initially derived from the recommendations of the 
evidence-based guideline on “Intermittent Claudication” of the Royal Dutch Society 
for Physical Therapy. An expert panel of 27 physical therapists, vascular surgeons 
and researchers were asked to rate the relevance of the indicators and suggest further 
indicators. This round was completed by 26 experts (for the characteristics of the expert 
panel see Table 2). All ratings were normally distributed, and 27 of the 83 indicators 
were selected in this first Delphi round. 
After this first round, the same experts were asked to rate the relevance of the 27 
indicators again. This round was completed by 24 experts (12 PTs, 9 VSs and 3 lectures). 
Fourteen of the 27 indicators then remained, and 11 of the indicators discarded in 
round one were re-included in the set of indicators. A total of 13 indicators were 
selected in this second Delphi.  
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In the third Delphi round, two expert physical therapists and two expert vascular 
surgeons scored the indicators in terms of measurability. Only the indicators that were 
rated as “very relevant” or “relevant” were adopted as a new draft set of indicators. 
This reduced the number of indicators to five (Table 3). A systematic representation of 
the entire Delphi process is provided in Figure 1. 
FIGURE 1. Overview of Delphi rounds and methods
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TABLE 2 Characteristics of expert panel 
PTs 
(n=12)




Age (mean (range)) 48 (30-64) 39.5 (27-49) 53 (48-57)







Years of experience with PAOD 
(mean (range))
20.2 (6-37) 8.7 (0-20) 24.7 (10-34)
Number of patients in last 3 months 9.8 (0-40) 86 (0-250) 0
Note. PTs=physiotherapists, VSs=vascular surgeons
TABLE 3 Set of five quality indicators that resulted from three Delphi rounds. 
Nr Indicator Comments
1 The physiotherapist measures the 
functional claudication distance and 
absolute claudication distance by 
performing a standardised treadmill test.
 
2 The outcome measures are assessed at 
baseline, after three months, six months 
and twelve months and at the end of the 
physical therapy intervention.
3 The physiotherapist administers the 
Walking Impairment Questionnaire (WIQ)
4 The physiotherapist measures quality of life 
using the Euro Quality of Life-5D
5 The physiotherapist checks non-compliance 
with medication use
28.5% of the experts regarded this as very 
relevant, but measurability is moderate. 
Nevertheless, it was considered important 
as a quality indicator 
DISCUSSION
This is the first report on a research project for the development of QIs for physical 
therapy intervention in patients with IC, for which QIs were so far lacking. In accordance 
with international standards for the development of QIs 17, 22 potential indicators were 
initially derived from an evidence-based guideline, while further potential indicators 
could be added in an expert Delphi procedure. This resulted in a set of five QIs, three 
of which were derived from the guideline, while two were added by the experts. 
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The indicators “The physiotherapist administers the Walking Impairment Questionnaire 
(WIQ)” and “The physiotherapist measures quality of life using the Euro QoL-5D (EQ-
5D)” were added by the experts, thoroughly substantiated, in the first Delphi round. 
These two indicators were rated as relevant in the second and third Delphi rounds. The 
indicators “The physiotherapist checks non-compliance with medication use” and “The 
physiotherapist supports smoking cessation” were added in the first Delphi round and 
were rated as very relevant in the second round. In the third Delphi round, however, 
the indicator “The physiotherapist supports smoking cessation” was assessed as poorly 
measurable, so it was initially excluded. 
Comparison with other quality indicator sets for cardiovascular disease 
A direct comparison of the set of QIs proposed here with similar sets of QIs for 
physical therapy management of IC is not possible, as to our knowledge, this is the first 
publication describing QIs for physical therapy for IC. However, a comparison can be 
made with QIs for cardiovascular risk management, as Ludt et al. described the EPA-
cardio instrument, which measures the quality of cardiovascular risk management in 
European primary care.19 This instrument includes patient questionnaires about physical 
activity, lifestyle, eating and smoking habits. The EPA-cardio instrument corresponds to 
some extent with the lifestyle indicators presented in our study.  
A multidisciplinary guideline for vascular risk management was developed in the 
Netherlands in 2006. This guideline is based on the chronic care model.21 The indicator 
“The physiotherapist checks non-compliance with medication use” in the present study 
is in line with this multidisciplinary guideline, in that it endorse the need for good 
interdisciplinary communication and well-informed patients. 
Comparison with other quality indicators for physical therapy
Until now, QIs to assess adherence with the recommendations of the Dutch physical 
therapy guidelines have only been systematically developed for the guidelines on 
Parkinson’s disease 28 and osteoarthritis of the hip and knee.29 These QIs were selected 
in a procedure involving experts in a Delphi procedure, similar to that employed in the 
present study. 
Limitations
This study was subject to certain limitations. In the process of formulating potential 
indicators, the experts did not take into account the level of evidence underlying the 
recommendations. As a result, recommendations based on single studies and expert 
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opinion (levels 3 and 4) were also included. It is a matter of debate whether a minimum 
level of evidence is required for recommendations to be included in sets of QIs. Another 
limitation is the fact that we derived indicators from the evidence-based guideline on 
“Intermittent claudication” of the Royal Dutch Society for Physical Therapy, which 
is based on literature up to 2002. Physical therapy research in PAOD is evolving 
rapidly and new evidence since then has been mainly found to favour SET, making the 
recommendations from the 2003 guideline even stronger. We believe that our use of 
the expert Delphi procedure has resulted in an up-to-date set of indicators. 
Another weakness of this study might be the measurability of some indicators. The 
expert group was aware of the poor measurability of some indicators, and therefore 
excluded some indicators like “Offers a prognosis”, “Provides good aftercare”, 
“supports smoking cessation” and “promotes an active lifestyle”. 
In a demand-driven or client-centered care system, services should meet the patients’ 
needs and preferences. 20, 21 Our study did not focus on quality assurance (e.g. through 
QIs) from the patient’s perspective.
Implications for further research
More research is needed to validate our proposed set of indicators. This could be 
done by checking randomly sampled patient files, using case vignettes or developing 
a questionnaire incorporating the indicators from the set.17, 28 In order to describe 
content-validity it is important to clarify also what the patients’ needs are and what 
these needs imply for the development of QIs for physical therapy in the treatment of IC. 
The clinical implications of this study seem very promising, as the use of this set of 
quality indicators enables further examination of adherence to the guideline for 
physical therapy for patients with IC. 
CONCLUSION
A set of five quality indicators was derived from an evidence-based guideline, and an 
expert Delphi procedure. This set of indicators should be validated before it can be 
used for implementation in clinical practice. 
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MAIN FINDINGS
Limited availability and reluctance of SET
Although contemporary guidelines clearly prescribe supervised exercise therapy (SET) as 
a first-line treatment in intermittent claudication (IC), many patients do not receive SET. 1-4 
The reason for this is multifactorial and lies with the doctor, who should prescribe SET 
as a first line treatment, the healthcare insurer, who should reimburse SET as a first-
line treatment, and the patient, who should be willing to comply with SET as a first-line 
treatment. Other possible factors that contribute to the limited referral rate of SET are 
limited SET availability, misinterpretation of potential SET indications, patient resis-
tance, professional self-interest and issues regarding the reimbursement of SET by the 
patient’s healthcare insurance plan.4
In this thesis, we presented the results of a cross-sectional survey study that assessed the 
current opinion of Dutch vascular surgeons and fellows in vascular surgery regarding 
SET as a treatment option for IC. We specifically wanted to find out to what extent and 
on which criteria Dutch vascular surgeons decide to offer or deny SET to IC patients. 
Participants received a 25-question survey, which they could complete either during the 
Annual Meeting of the Dutch Society for Vascular Surgery or on a secure website. We 
showed that the respondents would refer 75% of newly diagnosed patients with IC for 
SET. Although the study had a response rate of 51% of all Dutch vascular surgeons, the 
results could have been influenced by responder bias, most likely in favor of a positive 
attitude towards SET. Therefore, the estimated three quarters of IC patients that were 
referred for SET may in fact be less in real life. A study on 2009 invoice data of a Dutch 
healthcare insurance company with 3.4 million members showed that only 14% of IC 
patients received SET, whereas 28% were primarily treated with an invasive interven-
tion. The remaining 58% did not receive either of these two treatment regimens within 
3 months of diagnosis.5
These results were also confirmed in a study on the use of SET in the UK. This study 
found a large spread in the proportion of patients referred for SET.3 Furthermore, 
only 24% of UK surgeons had access to SET. In the Netherlands, with over 20,000 
physical therapists, community-based availability of SET is not a problem. However, 
the question is whether each physical therapist is capable of providing SET according 
to the guidelines of the Royal Dutch Society for Physical Therapy. To ensure optimal SET 
availability, continuity, cost-efficiency and quality of care, ClaudicatioNet was initiated 
in the Netherlands. This integrated care network ought to improve both access to and 
quality of SET. 
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Our study showed that respondents did not refer for SET in the presence of significant 
cardiopulmonary comorbidity and aortoiliac stenosis or occlusion causing IC, since 
they did not consider SET to be safe for these indications. However, these arguments 
for not referring for SET seem to be outdated. In both cardiac and pulmonary re-
habilitation programs, patients with congestive heart failure and chronic obstructive 
pulmonary disease undergo supervised aerobic exercise (e.g. treadmill walking and 
cycling) in a moderate to severe intensity.6-12 Also, exercise rehabilitation is consid-
ered safe for coronary heart disease, leading to a decreased 5-year all-risk mortality 
rate.9-12 SET can safely be prescribed given its exceedingly low all-cause complication 
rate. Routine cardiac screening is not required before commencing SET.13 Therefore, 
there is no reason why SET should not be offered to patients with coexistence of IC 
and congestive heart failure or chronic pulmonary or coronary conditions. Nonethe-
less, physical therapists should adjust patient monitoring and exercise intensity to each 
patient’s condition. 
There are several explanations why SET is not as effective in aortoiliac disease as en-
dovascular revascularisation. First, patients with aortoiliac disease have more ischemic 
muscle mass while walking, and consequently they are more often symptomatic than 
those with a more distal obstruction.14 Therefore, patients with aortoiliac disease might 
experience less improvement with exercise training. Second, surgeons have consider-
ably more experience with stent revascularization in the aortoiliac segment, and the 
results are more predictable and durable than those observed in the femoropopliteal 
artery segment.15-19 However, results demonstrate that for aortoiliac disease, SET re-
sulted in a superior treadmill walking distance after 6 months compared to percutane-
ous transluminal angioplasty (PTA) with stent revascularization, even though a non-
significant improvement of disease-specific quality of life was found in favor of PTA.20 
With this evidence, there is no reason why SET should not be offered to patients with IC 
caused by aortoiliac disease. Also, from a practical standpoint, initiation of SET should 
not be delayed by diagnostics of disease location, since there is no evidence that this 
has any consequences for the initiation of primary conservative treatment in IC. 
Another possible explanation for the limited use of SET could be patient resistance. 
Many IC patients want a quick solution for their problem. Therefore they prefer a swift 
vascular intervention over lifestyle changes and a lengthy exercise program. Vascular 
surgeons may try to convince patients of the benefits of SET. However, if a patient re-
fuses, a vascular intervention is readily available. This in turn is closely related to the 
final obstacle for referring for SET, which is professional self-interest. Vascular surgeons 
are remunerated for the execution of interventions. They opt for these invasive treat-
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ments in the conviction that they optimally serve their patients, but at the same time this 
decision is in line with their professional self-interest, since vascular interventions lead 
to higher reimbursements than SET. Moreover, invasive treatments are opportunities to 
train or improve skills. Also, vascular interventions are encouraged by the medical in-
dustry’s emphatic promotion of new invasive techniques, whereas SET lacks promotion.
The reluctance to refer for SET may also be explained by the fact that the conservative 
treatment for patients with IC is not stimulated by the Dutch health care system. In this 
system, the scope of coverage for basic health care is determined by the Dutch govern-
ment, and health insurers are obligated to accept applicants for this insurance without 
any selection. For additional coverage a voluntary additional health care insurance 
can be acquired, but the content and prices for these additional packages are deter-
mined by health insurers, who can refuse to accept high-risk patients who apply for 
additional coverage. 
Under the current coverage for basic health care, some patients with IC have a finan-
cially driven interest to refrain from SET and to be treated by invasive vascular interven-
tions, in disregard of the associated risks of morbidity or mortality. Basic health care 
insurance fully compensates services provided by the general practitioner or vascular 
surgeon, such as cardiovascular risk management or invasive vascular interventions. 
However, for IC, the first 20 treatment sessions of SET are not covered by basic health 
care insurance and have to be paid by the patient himself or by an additional insurance. 
Basic health care insurance does cover all further treatment sessions, for a total of 1 
year. This provision suggests that the value of SET for IC patients is officially recognized, 
but it does not benefit patients who are unable to afford the first 20 sessions of SET. 
The ideal situation for both the patient and the healthcare system would be a stepped-
care approach, in which SET is prescribed first and vascular intervention is only ap-
plied in case of SET failure. Implementation of such a stepped-care model may lead 
to a significant annual saving up to 33 million euro of healthcare resources in the 
Netherlands. Hence, healthcare insurers should invest in this stepped-care program. 
Vascular surgeons should restrict vascular interventions to cases of SET failure, and 
should be reimbursed accordingly. Further cost-efficiency could be achieved if gen-
eral practitioners coordinate conservative treatment and only refer patients in need 
of vascular intervention. This can be achieved by more integrated collaboration with 
vascular laboratories and vascular surgeons in regional care networks. ClaudicatioNet 
provides a clear framework to create nationwide coverage of these regional integrated 
care networks.
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As this thesis showed, the causes of the limited availability of SET and the reluctance 
to refer for SET are multifactorial and require a drastic change in the views of general 
practitioners, vascular surgeons, healthcare insurers and patients in order to optimize 
both the quality and the cost-efficiency of healthcare for IC patients. More attention 
should be paid to evaluating the quality of SET. Furthermore, individual patients might 
benefit from patient-tailored exercise modes.
Modes of exercise training
A number of potential mechanisms have been suggested that may explain why ex-
ercise (in general) might benefit patients with IC. Reduced functional capacity in IC 
might be due to blood flow limitation caused by arterial obstruction, disruption of 
endothelial function, altered skeletal muscle phenotype by mitochondrial dysfunction, 
increased blood viscosity, and inflammatory activation.21 Exercise, independent of its 
mode, has the potential to reverse these pathological processes and thus to interrupt 
the clinical course toward disability. Animal models of arterial insufficiency indicate 
that exercise training augments peripheral arterial supply. 22-25 In rodent models, exer-
cise stimulated gains in collateral blood flow after femoral occlusion through collateral 
enlargement. 22,26,27 Collateral growth induced by exercise reflects vascular structural 
remodeling, a process that depends on both growth factor activity and increased nitric 
oxide bioavailability via shear stress stimulation of endothelial nitric oxide synthase. 
22,26,28 In contrast to animal models, studies in patients with IC have not convincingly 
demonstrated that exercise training produces clinically relevant gains in peripheral 
blood flow. A recent meta-analysis of 7 exercise training studies demonstrated no 
change in the resting ankle-brachial index, a cumulative measure of blood supply to 
the lower extremities.29
As has been observed in coronary arteries, endothelial dysfunction could also lead 
to peripheral arterial vasoconstriction and limit vasodilator responses to flow, which 
would tend to exacerbate blood flow limitation during exercise. 30-32 Consistent with 
these potential links between vascular function and functional status, a number of stud-
ies have demonstrated impaired endothelial vasodilator responses in IC. SET increased 
endothelium-dependent flow- mediated dilation of the brachial artery by 65% in el-
derly patients with IC.33 The capability of exercise to reverse endothelial dysfunction 
may reflect sustained increases in shear-stress that stimulate nitric oxide bioactivity. A 
study in patients with coronary disease showed that exercise rehabilitation induced fa-
vorable effects on coronary endothelial function which were associated with increased 
endothelial nitric oxide synthase expression and activation.34 As impaired endothelial 
function predicts higher risk for cardiovascular events among patients with IC, the 
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exercise-induced improvement in vasodilator function may have the potential to reduce 
cardiovascular risk.35,36
Altered skeletal muscle energetics in IC has been linked to mitochondrial dysfunction. 
Intermediate metabolites of substrate oxidation, including acylcarnitines, accumulate in 
the blood and muscles of IC patients and are consistent with impaired metabolism at 
the mitochondrial level.37 Abnormal mitochondrial function may interfere with skeletal 
muscle oxygen utilization and may accelerate endothelial damage.38,39 Exercise train-
ing has the potential to enhance skeletal muscle metabolism and mitochondrial func-
tion. In IC patients, exercise training has been shown to restore carnitine metabolism in 
association with improved treadmill walking.37,40 Whether exercise training improves 
mitochondrial energy production or calf muscle characteristics in IC remains to be 
evaluated.
Furthermore, inflammation may accelerate functional impairment in IC by favoring 
plaque growth and inducing skeletal muscle injury. Endothelial inflammatory activation 
reduces nitric oxide bioavailability and may impede vasodilatory function during exer-
cise.41 Physical activity may have favorable effects on IC by suppressing inflammatory 
activation. While acute bouts of exercise increase inflammatory markers in claudicants, 
chronic exercise training appears to curb inflammation.42 A 3-month exercise program 
including treadmill exercise ameliorated neutrophil activation in patients with IC.43 It 
remains to be determined whether reduced inflammation produced by chronic exercise 
training underlies increased walking ability and translates to decreased events.
In a systematic review we assessed the effects of different exercise modes. The five in-
cluded RCTs described only three alternative exercise modes: strength training, arm er-
gometry, and cycling exercise. Although data were limited, we showed that alternative 
modes of exercise therapy seem to yield results similar to those of supervised walking 
therapy. Therefore, these alternative modes may be considered useful for some groups 
of patients with IC who are not able to complete the exercise protocol because of 
concomitant comorbidities, such as arthrosis, chronic obstructive pulmonary disease, 
stroke, congestive heart failure or coronary artery disease.  
Our systematic review was limited by the small sample size of 135 participants. How-
ever, sensitivity analysis did not significantly alter the results of this review. We tried 
to limit all the potential biases in the review process. In general, the risk of bias of the 
included studies was low, reflecting the good methodological quality of the included 
studies. We could not detect publication bias, because the number of studies was too 
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limited to assess asymmetry in a funnel plot. To limit bias and make a meaningful com-
parison, we standardised the maximum walking distance and the pain-free walking 
distance in each study by converting walking distances to total metabolic equivalents 
according to the American College of Sports Medicine (ACSM) formulas for metabolic 
calculations.44 However, direct conversion of the walking times or distances to metabol-
ic equivalents was not possible due to the absence of individual participant data. We 
therefore simulated a new dataset for each study to make a meaningful comparison. It 
is unclear to what extent this could have biased our findings.
More studies are needed to make meaningful comparisons between alternative exer-
cise modes. Also, future research should clarify the potential mechanisms of different 
alternative exercise modes. In general, more randomized controlled trials of adequate 
size are needed to compare the different conventional and alternative exercise re-
gimes to the standard of supervised walking exercise. Besides reporting walking per-
formance, future trials should focus on the effect of the exercise mode on health-related 
quality of life. Exercise training studies in IC have most often used treadmill walking 
time or distance as the primary outcome. The use of such an objective measure may 
be of great importance to investigators and to clinicians, given its relationship to IC 
symptoms. However, a patient may judge the benefit of an intervention by its effects 
on health-related quality of life, which is composed of many dimensions and not just 
related to leg symptoms. The concept of health-related quality of life as a primary out-
come has clearly been adopted in the IRONIC trial.45 Nevertheless, in standard clinical 
practice, quality of life is yet to be integrated as a tool to measure the clinical success 
of any intervention in patients with IC. 
Physical activity monitoring
We conducted a prospective observational cohort study to assess the daily physical ac-
tivity (PA) level of IC patients and healthy adults. We showed that more than half of the 
patients with IC did not meet the minimum recommendations for PA and public health. 
Compared with healthy adults, they had a significantly lower daily PA level. IC patients 
reporting substantial functional impairment (WIQ score < 0.4) had the lowest mean 
daily PA level of all groups. Interestingly, the PA group difference was solely attributed 
to this subgroup. Apparently, a lower daily PA level does not occur in IC patients who 
only have minor functional impairments.
The outcomes of this study may have been influenced by incorrect monitoring, which 
could be due to lack of motivation or failure to understand the monitoring protocol. In 
our monitoring protocol, participants were asked to remove the device before sleeping 
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to improve compliance. In a few instances, participants fell asleep with the device still 
strapped to their waist. If the device was worn during the night, that day was marked 
by definition as “not correctly worn”. We are not sure if compliance could have been 
higher if participants had been instructed to wear the device constantly. Also, a sub-
stantial number of participants said they had forgotten the end date of the monitor-
ing period. For clinical practice, a shorter monitoring period could be considered. 
However, the accuracy of PA results from a shorter monitoring period should first be 
validated, since these results could vary.
A proportion of the cohort described in our study on monitoring PA was also included 
in a new study to determine the effect of SET on the daily PA level. We demonstrated 
that a 3-month SET program raised the number of patients who met the ACSM/AHA 
public health minimum recommendations for PA. The general focus of only increasing 
walking capacity seems ancillary to other elements of supervision. Exercise behavior 
and PA might be included as outcome parameters in future IC research and eventu-
ally in clinical practice. Unfortunately, a number of participants were lost to follow-up, 
which may potentially have resulted in a selection bias. However, bias was most likely 
limited, since no baseline differences were found between the study group and ex-
cluded patients. Furthermore, both study groups constituted a representative reflection 
of the general IC population encountered in a vascular outpatient clinic. Unfortunately, 
it was not possible to perform a reliable sub-analysis between revascularisation and 
SET treatment, as only 16 participants received a revascularisation. 
In patients with IC, a low daily PA level is generally considered a strong predictor of 
mortality and functional decline.46-48 For this reason, the PA level could be viewed as 
a valid outcome parameter for evaluating the treatment effects of any intervention for 
IC. Current outcome parameters including maximum or pain-free walking distances 
only describe the patient’s exercise capacity, while it does not reflect to what extent this 
capacity is used in daily life. In contrast, daily PA levels provide objective information 
on the frequency, duration and intensity of exercise. In combination with a functional 
impairment score, such as the Walking Impairment Questionnaire (WIQ) score, mea-
suring daily PA levels enables physicians to objectively monitor the patient’s progress 
during treatment. Therefore, future studies should include an objectively measured 
daily PA level as an additional outcome measure for IC. If proven to provide reliable 
and reproducible evidence, measuring daily PA levels might be a valid instrument to 
evaluate treatment indications and treatment progress in clinical practice.
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Quality indicators 
We described the use of an online Delphi-procedure to develop quality indicators for 
physiotherapy management. This is the first report on a research project for the devel-
opment of quality indicators for physical therapy in patients with IC. In accordance with 
international standards for the development of quality indicators, potential indicators 
were initially derived from an evidence-based guideline, while further potential indica-
tors could be added in an expert Delphi procedure. 49,50 Three quality indicators were 
derived from the guideline ‘Intermittent Claudication’ of The Royal Dutch Society for 
Physical Therapy, while two were added by the experts.51 This resulted in a set of five 
quality indicators: 1) The physiotherapist measures the functional claudication distance 
and absolute claudication distance by performing a standardized treadmill test; 2) The 
outcome measures are assessed at baseline, after three months, six months and twelve 
months, and at the end of the intervention; 3) The physiotherapist administers the WIQ; 
4) The physiotherapist measures quality of life using the Euro Quality of Life-5D; 5) The 
physiotherapist checks whether patients comply with the prescribed use of medication. 
This set of indicators should be validated before being implemented in clinical practice.
IMPLICATIONS FOR CLINICAL PRACTICE AND FUTURE RESEARCH
In this thesis we described to what extent and on which criteria (Dutch) vascular sur-
geons decide whether or not to refer IC patients for SET. Arguments not to refer for SET 
seem to be outdated. SET, including lifestyle coaching, should receive more emphasis 
in the current management of IC.
Clearly, some groups of patients with IC are not able to complete the exercise protocol 
because of concomitant comorbidities, such as arthrosis, chronic obstructive pulmo-
nary disease, stroke, or cardiac complaints. For these patients, an adjusted protocol 
or alternative exercise regime may be proposed. In this thesis we tried to answer the 
question which exercise mode produces the most beneficial results. A systematic review 
of studies on alternative modes of exercise therapy summarised the reported results of 
cycling, strength training, and upper-arm ergometry. We showed that these alternative 
modes of exercise therapy seem to yield results similar to those of supervised walking 
therapy. Therefore, these alternative modes may be considered useful if supervised 
walking exercise is not an option for the patient. However, few studies included in our 
review were found to be of good quality. More randomised controlled studies with 
larger sample sizes are needed to make meaningful comparisons between each alter-
native exercise mode and the current standard of supervised treadmill walking.
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In this thesis we used the newest generation of accelerometers to objectively assess 
the daily PA level of patients with IC. Results demonstrate that less than half of these 
patients met the current minimal PA recommendations. The quantified daily level of PA 
in IC was significantly lower than in healthy adults. Because a low PA level in IC is con-
sidered a strong predictor of mortality and functional decline, this paper emphasizes 
the need for more awareness of improving physical exercise in patients with IC. 
Furthermore, we describe the effect of SET on walking capacity, walking behavior, 
ambulatory activities and daily physical activity in IC patients. Results of this study 
demonstrate the promising results of measuring the daily PA level of IC patients with 
tri-axial accelerometry. PA can be considered a valid outcome parameter in evaluat-
ing treatment effects of any intervention for IC. Current outcome parameters including 
maximum- or pain-free walking distances only describe the patient’ s exercise capac-
ity, while it does not reflect to what extent this capacity is used in daily life. In contrast, 
daily PA levels provide objective information on the frequency, duration, and intensity 
of exercise. Combined with a functional impairment score, such as the WIQ score, 
measuring daily PA levels enables physicians to objectively monitor the patient’s prog-
ress during treatment. Future clinical studies on IC should focus on this relevant new 
outcome parameter. Furthermore, future studies should examine the effects of different 
treatment strategies on the daily PA level in IC.
In this thesis we describe the design of ClaudicatioNet, an integrated care network 
that aims to improve the quality of care for patients with IC by initiating regional care 
networks. Based on the chronic care model as a conceptual framework, these networks 
should enhance the access, continuity, efficiency and cost efficiency of the health care 
system. ClaudicatioNet bridges the gap between various health care professionals, 
such as general practitioners and their practice assistants, vascular surgeons, special-
ised nurses in vascular surgery, and physical therapists. Together they are able to pro-
vide the best standards of practice. Patients play a pivotal role in the care that is given. 
Specific information, treatment goals, and obtained results need to be communicated 
to the patient. Many more treatment goals (lifestyle counseling, monitoring of medica-
tion adherence) should ideally be explained and reiterated by all involved caregivers. 
All these elements indicate the need for an integrated care approach. 
The success of ClaudicatioNet is dependent on several factors. Vascular surgeons, gen-
eral practitioners and coordinating central caregivers will need to team up and work 
in close collaboration with specialized physical therapists. A substantial task in the up-
coming years will be to monitor the quality, volume, and distribution of ClaudicatioNet 
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physical therapists. Finally, misguided financial incentives within the Dutch health care 
system need to be tackled.
In this thesis we described the development of quality indicators for physiotherapy 
management in patients with IC. Consensus among experts selected five potential qual-
ity indicators. More research is needed to validate our proposed set of indicators. This 
could be done by checking randomly sampled patient files, using case vignettes or de-
veloping a questionnaire incorporating the indicators from the set. In order to describe 
content-validity, it is also important to clarify what the patients’ needs are and what 
these needs imply for the development of quality indicators for physiotherapy in the 
treatment of IC. After validation, these quality indicators could be used as an instrument 
to measure quality of physiotherapy management of IC in the Netherlands. With the 
initiation of ClaudicatioNet, clinical implications of this study seem very promising, as 
the use of this set of quality indicators enables quality evaluation and examination of 
adherence to the guidelines for physiotherapy regarding patients with IC. 
Additional future studies on IC should focus on how to manage patients with IC due 
to specific disease locations. For IC due to femoropopliteal disease, PTA and SET are 
found equally effective in improving walking distance and quality of life at a follow-up 
of 12 months.52 For aortoiliac disease, SET resulted in a superior treadmill walking dis-
tance after 6 months compared to PTA, while PTA achieved a non-significantly greater 
improvement of disease-specific quality of life.53 However, combining both treatments 
resulted in significantly better results in walking distance and disease specific quality 
of life for mixed aortoiliac and femoropopliteal disease, indicating a possible adjuvant 
benefit of combining both treatments.54-56 More research should confirm these findings 
and identify a possible difference between femoropopliteal and aortoiliac disease. 
Furthermore, costs of interventions can also play a decisive role in choosing the op-
timal intervention for patients with IC. Future research should also focus on the cost-
effectiveness of different treatment protocols for patients with IC, with a particular focus 
on a stepped-care protocol indicating the use of SET as first treatment option and PTA 
only in case of SET failure. 
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SUMMARY OF THE THESIS
The aim of this thesis was to describe methods for improving the conservative 
management of intermittent claudication (IC) in the Netherlands. To achieve this 
objective, several studies were conducted to elucidate all possible indications for 
supervised exercise therapy (SET), to introduce a possible future outcome measure and 
to describe how a stepped care conservative management of IC can be implemented in 
a chronic-care model for the general Dutch population. In this chapter we summarize 
the main findings of the studies.
Management of IC requires a multidisciplinary approach. Chapter 2 provides an up-
to-date overview of the current literature regarding cardiovascular risk management 
and SET, both of which are integrated parts of the treatment for patients with IC. The 
development of IC is accelerated by the same cardiovascular risk factors as known 
for other expressions of atherosclerotic disease (i.e. coronary heart disease and 
cerebrovascular disease).1 Treatment of IC should therefore consist of a multicomponent 
therapy of cardiovascular risk modification (1), including lifestyle coaching (2) and 
symptomatic treatment (3). The first two components aim to prevent cardiovascular 
events (myocardial infarction, stroke) and related morbidity and mortality. The current 
evidence supports the use of SET as the primary symptomatic treatment for IC. SET 
improves maximum walking distance and health-related quality of life and constitutes 
a marginal risk of co-morbidity or mortality. This is also illustrated by the inclusion of 
SET in contemporary international guidelines.2,3
Although SET is considered the primary treatment for IC, it seems underutilized in 
clinical practice, possibly due to a limited availability of physical or exercise therapists 
with specific knowledge on peripheral arterial disease or SET treatment protocol. 
Another explanation could be differences in the views on the indications for SET, such as 
concomitant significant cardiopulmonary comorbidity, patient’s age or aortoiliac artery 
obstruction as cause of IC. Chapter 3 documents current opinions of vascular surgeons 
and fellows in vascular surgery on SET as treatment option for IC. We specifically 
wanted to find out to what extent and on which criteria Dutch vascular surgeons decide 
to offer or deny SET to IC patients. We showed that the respondents would refer 75% of 
newly diagnosed patients with IC for SET. The criteria not to refer for SET were mostly 
based on the existence of major co-morbidity (e.g. pulmonary and cardiac complaints) 
or a significant iliac stenosis causing IC. Apparently, the respondents assumed that 
SET would not be successful in these particular patients. This could be explained by 
a concern for major complications or the belief that SET is ineffective in improving 
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walking ability or quality of life in these particular patients. Since the arguments for 
not referring for SET seemed to be outdated, we concluded that SET should receive 
more emphasis in clinical practice. Furthermore, vascular surgeons agreed that lifestyle 
management should ideally be integrated in IC treatment. 
Chapter 4 describes the results of a systematic review on different modes of (supervised) 
exercise therapy. In literature, SET usually consists of treadmill walking.3 However, 
alternative modes of exercise therapy (e.g. cycling, strength training) have been 
described, with beneficial effects on walking capacity and quality of life.4-6 Therefore, 
the following question remained: Which exercise mode provides the most beneficial 
results? We demonstrated that there are few studies comparing alternative modes of 
exercise training to the standard of supervised walking exercise. The review authors 
identified five studies which randomised a total of 135 participants. The alternative 
modes of exercise therapy included cycling, strength training, and upper-arm 
ergometry. Although limited data are available, we showed that alternative modes of 
exercise therapy seem to yield results that are similar to those of supervised walking 
therapy. Therefore, these alternative modes may be considered useful if supervised 
walking exercise is not an option for the patient. However, more randomised controlled 
trials are needed to make a meaningful comparison between the different modes of 
exercise therapy.
In Chapter 5 we hypothesized that IC patients had a reduced physical activity (PA) level 
compared to healthy adults. A reduced exercise capacity and PA level are both strong 
predictors of long-term mortality. In contrast, higher PA levels are associated with less 
functional decline.7-10 Weekly PA of more than light-intensity improves 5-year survival 
rate significantly more than light-intensity PA or no PA.8 For this reason, one could 
argue that the PA level is a valid outcome parameter in evaluating treatment effects of 
any intervention for IC. To objectively determine the PA level of IC patients and healthy 
adults we performed a prospective observational study using the newest generation of 
tri-axial accelerometers. We showed that more than half of the patients with IC did not 
meet the minimum recommendations for PA and public health. Compared with healthy 
adults, they had a significantly lower daily PA level. PA differences were due to an IC 
subgroup with severe functional impairments. Because a low PA level is considered 
a strong predictor of mortality and functional decline, all health-care workers should 
actively encourage PA in IC patients. 
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In Chapter 6 we assessed the effect of a SET program on daily PA levels and walking 
behavior. We hypothesized that a SET-induced increased walking distance would 
improve PA levels in IC patients. Although SET was proven to be effective in improving 
walking distances, one can question whether an increased walking capacity is 
of benefit during the patient’s daily life activities. In other words, if an IC patient is 
enabled to walk further, this does not necessarily imply that PA levels and/or exercise 
behavior are positively influenced. We demonstrated that a 3-month SET program 
increases the number of patients achieving the ACSM/AHA public health minimum 
recommendations for PA. The general focus of increasing walking capacity alone 
seems ancillary to other elements of supervision. Exercise behavior and PA might be 
included as outcome parameter in future IC research and eventually in clinical practice.
In the Netherlands, there are several reasons why not all patients with IC are offered 
an evidence-based conservative treatment, including SET. In Chapter 7 we describe 
the problem statement of the conservative management of IC in the Netherlands and 
provide a design for a national integrated care network (ClaudicatioNet) for patients 
with IC. Based on the chronic care model as a conceptual framework, regional care 
networks of general practitioners, vascular surgeons, central caregivers and physical 
therapists should enhance the quality of care, access, continuity, efficiency and costs of 
the health care system. With the aid of a national database, health care professionals 
will be able to benchmark patient results, while ClaudicatioNet will be able to monitor 
quality of care by means of functional and patient reported outcome measures. With 
this care intervention, integrated care pathways should be improved in the coming 
years, resulting in optimal quality of care for all patients with IC.
Chapter 8 describes the development of quality indicators for physiotherapy 
management of patients with IC. Quality indicators were developed using an online 
survey Delphi-procedure, based on an international six-step method to develop quality 
indicators. Out of 83 potential quality indicators mentioned in the Dutch physiotherapy 
guideline on “Intermittent claudication”, consensus among the experts selected five 
indicators: 1) The physiotherapist measures the functional claudication distance and 
absolute claudication distance by performing a standardized treadmill test; 2) The 
outcome measures are assessed at baseline, after three months, six months, twelve 
months and at the end of the intervention; 3) The physiotherapist administers the 
Walking Impairment Questionnaire (WIQ); 4) The physiotherapist measures quality of 
life using the Euro Quality of Life-5D; 5) The physiotherapist checks whether patients 
comply with the prescribed use of medication. This set of indicators should be validated 
before being implemented in clinical practice.
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SAMENVATTING VAN DE THESIS
Dit proefschrift heeft als doel methoden te beschrijven om de conservatieve behandeling 
van claudicatio intermittens (CI) in Nederland te optimaliseren. Om dit doel te bereiken 
werden diverse wetenschappelijke studies verricht naar de mogelijke indicaties van 
gesuperviseerde looptherapie (GLT), een nieuwe uitkomstmaat voor perifeer arterieel 
vaatlijden en de beschrijving van een geïntegreerd zorgmodel voor behandeling van 
CI. In dit hoofdstuk zullen we de belangrijkste resultaten van deze studies samenvatten.
De behandeling van CI vraagt om een multidisciplinaire benadering. De ontwikkeling 
van CI wordt versneld door dezelfde cardiovasculaire risicofactoren als die bekend 
zijn voor andere atherosclerotische vaatziekten (zoals coronaire hartziekte of het 
cerebrovasculair accident). 1 Behandeling van CI dient daarom te bestaan uit multipele 
componenten zoals cardiovasculair risicomanagement (1), leefstijladviezen (2) 
en symptomatische behandeling (3). De eerste twee componenten hebben als doel 
cardiovasculaire events te voorkomen (zoals een hartinfarct of beroerte), met de 
daarmee geassocieerde morbiditeit en mortaliteit. De derde component bestaat in 
de dagelijkse praktijk uit een vorm van looptherapie (waaronder GLT), een invasieve 
procedure (zoals een dotterbehandeling, al dan niet met stent, of bypass chirurgie) 
of een combinatie van beide. In hoofdstuk 2 wordt een overzicht gegeven van de 
wetenschappelijke literatuur betreffende cardiovasculair risicomanagement en GLT als 
conservatieve behandeling van CI. GLT verbetert de maximale loopafstand en kwaliteit 
van leven met een minimaal risico op comorbiditeit en mortaliteit. Om deze reden 
wordt GLT beschouwd als de primaire symptomatische behandeling van CI en is als 
zodanig opgenomen in diverse internationale richtlijnen. 2,3
Ondanks dat GLT beschouwd wordt als de primaire symptomatische behandeling van 
CI lijkt deze behandeling in de klinische praktijk minder vaak voorgeschreven dan 
verwacht. Mogelijk wordt dit veroorzaakt door een gebrek aan fysiotherapeuten met 
specifieke kennis van perifeer arterieel vaatlijden en/of het GLT trainingsprotocol. Een 
andere verklaring kan bestaan uit een verschil in denkwijze over de indicaties van GLT, 
zoals het voorschrijven van GLT bij patiënten met CI en significante cardiopulmonale 
comorbiditeit, een oudere leeftijd of een iliacale stenose als oorzaak van de klachten. 
In hoofdstuk 3 van dit proefschrift worden de resultaten beschreven van een in 
2011 uitgevoerde enquête, met een respons van 80 procent van de Nederlandse 
vaatchirurgen. De enquête onderzocht in welke mate en op welke gronden Nederlandse 
vaatchirurgen gebruik maakten van GLT in de klinische praktijk. Hoewel het merendeel 
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van de vaatchirurgen aangaf patiënten te verwijzen voor GLT, kreeg 25 procent van de 
patiënten geen GLT aangeboden. GLT werd door 30 procent van de vaatchirurgen niet 
zinvol geacht bij patiënten met CI op basis van een iliacale stenose of in combinatie 
met cardiopulmonale comorbiditeit. Deze argumenten blijken inmiddels achterhaald in 
de wetenschappelijke literatuur. 
De door vaatchirurgen opgegeven 75 procent patiënten die GLT aangeboden zouden 
krijgen, is waarschijnlijk positief gekleurd door sociaal wenselijke antwoorden. Een 
analyse van declaratie data van een grote zorgverzekeraar toonde dat slechts 14 
procent van de patiënten met CI primair GLT kreeg aangeboden. Daarentegen werd in 
27 procent primair gekozen voor een vasculaire interventie. De oorzaak voor deze van 
de richtlijn afwijkende verdeling is multifactorieel. De oorzaak ligt bij zowel patiënten, 
huisartsen, vaatchirurgen zorgverzekeraars als beleidsmakers.
Hoofdstuk 4 beschrijft de resultaten van een systematische review naar verschillende 
gesuperviseerde oefenvormen. In de literatuur bestaat GLT voornamelijk uit wandelen 
op een loopband. 3 Echter, alternatieve oefenvormen, zoals fietsen of krachttraining, 
zijn beschreven met eveneens positieve effecten op de loopcapaciteit en kwaliteit 
van leven. 4-6 De vraag die wij ons stelde luidde: Welke oefenvorm leidt tot de meest 
gunstige behandelresultaten? In dit hoofdstuk werden 5 studies beschreven die in 
totaal 135 deelnemers met CI randomiseerden. De alternatieve oefenvormen die 
beschreven werden zijn fietsen, krachttraining en arm-ergometrie. Ondanks een 
beperkt aantal studies, kon geconcludeerd worden dat alternatieve oefenvormen 
nagenoeg vergelijkbare resultaten lieten zien voor wat toename van loopcapaciteit, 
in vergelijking met de standaard GLT behandeling. Concluderend blijken alternatieve 
oefenvormen dan ook een goed alternatief voor GLT indien lopen als trainingsvorm 
niet mogelijk blijkt. 
In hoofdstuk 5 werd de hypothese opgeworpen dat patiënten met CI een verminderde 
fysieke activiteit (FA) hebben in vergelijking met gezonde volwassenen. Een verminderde 
oefencapaciteit en FA zijn beide sterke voorspellers van mortaliteit en functionele 
achteruitgang. 7-10 Wekelijkse FA van gemiddelde of hoge intensiteit, verbetert de 5-jaars 
overlevingskans significant in vergelijking met geen FA of FA van lichte intensiteit. 8 
Daarom kan beargumenteerd worden dat de FA een valide uitkomstmaat kan zijn om 
de behandelresultaten van interventies voor CI te evalueren. In dit hoofdstuk werd een 
prospectieve observationele studie verricht om de FA van zowel patiënten met CI als 
gezonde volwassenen te bepalen middels tri-axiale accelerometrie. Uiteindelijk bleek 
dat meer dan de helft van de patiënten met CI de minimum ACSM aanbevelingen 
10
165
Samenvatting | CHAPTER 10
voor FA niet haalden. In vergelijking met gezonde volwassenen hadden patiënten met 
IC een lagere FA. Deze verschillen bleken voornamelijk verklaard te worden door de 
subgroep van CI patiënten met meer functionele belemmeringen. 
In hoofdstuk 6 werd het effect van 3 maanden GLT op de dagelijkse FA geanalyseerd. 
Onze hypothese was dat een toename in maximale en pijnvrije loopafstand door GLT 
zou leiden tot een toegenomen FA. Hoewel GLT effectief is in het vergroten van de 
maximale en pijnvrije loopafstand is het de vraag of deze toegenomen loopafstand van 
meerwaarde is voor de dagelijkse fysieke activiteit. Met andere woorden, als een patiënt 
met CI verder kan lopen hoeft dit niet te betekenen dat zijn loopgedrag en daarmee 
fysieke activiteit zal toenemen. In onze studie demonstreerden wij dat na 3 maanden 
GLT het aantal patiënten dat voldeed aan de American College of Sports Medicine 
(ACSM) beweegnorm van fysieke activiteit wel degelijk significant toenam. GLT lijkt 
dan ook naast het verbeteren van de maximale en pijnvrije loopafstand, geschikt in het 
verbeteren van de dagelijkse FA. FA is als potentiële nieuwe uitkomstmaat eenvoudig 
objectiveerbaar middels triaxiale accelerometrie en kan zodoende gebruikt worden in 
toekomstig wetenschappelijk onderzoek en de klinische praktijk.
Er zijn verschillende redenen waarom niet alle patiënten met CI een bewezen effectieve 
conservatieve behandeling in de vorm van GLT krijgen aangeboden in Nederland. 
In hoofdstuk 7 worden de problemen rondom conservatieve behandeling van CI in 
Nederland uiteengezet. Tevens wordt de blauwdruk voor een nationaal geïntegreerd 
zorgnetwerk voor CI beschreven (ClaudicatioNet). In dit zorgnetwerk wordt een 
totaalpakket van conservatieve behandeling van CI aangeboden gebaseerd op een 
samenwerking tussen verwijzers en daartoe geschoolde fysiotherapeuten die GLT en 
leefstijlinterventies aanbieden. Transparantie en kwalitatief hoogwaardige zorg voor 
alle patiënten met CI is het doel. Participerende fysiotherapeuten dienen een driejarig 
specialisatietraject te doorlopen. Met behulp van een online monitoring systeem wordt 
inzicht verkregen in de kwaliteit van de deelnemende fysiotherapeut.
Hoofdstuk 8 beschrijft het ontwikkelen van kwaliteitsindicatoren voor de fysio-
therapeutische behandeling van patiënten met CI. De kwaliteitsindicatoren kwamen 
tot stand met behulp van een online uitgevoerde Delphi procedure gebaseerd op een 
internationale 6-stap methode voor het ontwikkelen van kwaliteitsindicatoren. Er werden 
83 potentiele kwaliteitsindicatoren uit de Nederlandse richtlijn ‘Claudicatio Intermittens’ 
van de Koninklijke Nederlandse Genootschap voor Fysiotherapie geïdentificeerd. 
Uiteindelijk kwamen de experts tot consensus en werden 5 kwaliteitsindicatoren 
geselecteerd: 1) de fysiotherapeut meet de maximale en functionele loopafstand gemeten 
166
CHAPTER 10 | Samenvatting
met een gestandaardiseerde loopbandtest; 2) de fysiotherapeut meet de functionele 
capaciteit middels de WIQ-vragenlijst; 3) de fysiotherapeut meet de kwaliteit van leven 
middels de EQ-5D vragenlijst; 4) de fysiotherapeut neemt de uitkomstmaten af bij 
start van de behandeling, na 3, 6, 12 maanden en bij einde van behandeling; 5) de 
fysiotherapeut controleert of de patiënt zijn medicatie adequaat gebruikt. Uiteindelijk 
zal deze set kwaliteitsindicatoren gevalideerd moeten worden voordat deze gebruikt 
kan worden in de klinische praktijk.
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VALORISATIE
Claudicatio intermittens (CI), ‘etalagebenen’ in de volksmond, is de eerste symptomatische 
uiting van perifeer arterieel vaatlijden (PAV). Patiënten met etalagebenen hebben 
slagaderverkalking in de slagaders van en/of naar de benen. Hierdoor wordt de 
bloedtoevoer verminderd en ontstaat zuurstoftekort in de beenspieren. Het gevolg is 
dat de beenspieren tijdens inspanning sneller verzuren met krampende pijn als gevolg. 
Een patiënt met CI kan slechts een bepaalde afstand lopen, doordat de pijn toeneemt 
en hij uiteindelijk genoodzaakt is te stoppen. Tijdens een korte rustperiode neemt de 
pijn geleidelijk weer af. 
PAV is een veelvoorkomend probleem en heeft in Nederland een prevalentie van 
ongeveer 19 procent bij de populatie van 55 jaar en ouder. Rond de 50 tot 80 procent 
van de patiënten met PAV heeft klachten van CI en zoekt hiervoor medische hulp. In 
de Nederlandse huisartsenpraktijk bedraagt de incidentie van CI 2.8 nieuw ontdekte 
ziektegevallen per duizend patiënten per jaar (mannen 2.7 promille, vrouwen 3.0 
promille). Dit loopt op van 0.4 promille bij 25 tot 44-jarigen tot 10.6 promille bij 
75-plussers. Gezien de actuele vergrijzing van de bevolking is de verwachting dat de 
incidentie en prevalentie van CI verder zullen toenemen.
Het hebben van CI is prognostisch ongunstig. Ruim een derde van de patiënten met CI 
heeft tevens aandoeningen van het hart of de bloedvaten naar hersenen. Ongeveer 
één op de vijf patiënten met CI overlijdt binnen vijf jaar ten gevolge van een hart- 
of herseninfarct. Binnen tien jaar na het begin van CI krijgt 43 procent ischemische 
hartziekte, 21 procent een ischemisch cerebrovasculair accident (iCVA) en 24 procent 
hartfalen. De levensverwachting van patiënten met CI is gemiddeld tien jaar korter dan 
die van niet aangedane personen. Daarmee is de kans op overlijden twee tot drie maal 
groter dan die van leeftijdsgenoten zonder PAV. Dit verhoogde risico geldt overigens 
ook voor mensen met asymptomatisch PAV.
Gezien de geschetste gevolgen van CI behoort behandeling te bestaan uit cardiovasculair 
risicomanagement (1), leefstijladviezen (2) en behandeling van de symptomen 
(3). Zoals beschreven in de gelijknamige NHG-standaard dient cardiovasculair 
risicomanagement geïnitieerd te worden door de huisarts van de patiënt. Idealiter 
zouden ook leefstijladviezen (zoals rookstopinterventies) hier deel uit van moeten 
maken. Het geven van leefstijladviezen op basis van motiverende gespreksvoering kost 
echter tijd en vereist adequate scholing. Doordat in de Nederlands gezondheidszorg 
geen eisen worden gesteld ten aanzien van het geven van leefstijladviezen, worden 
deze hoogstwaarschijnlijk niet in alle gevallen aangeboden. 
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Behandeling van symptomen van CI kan zowel met een conservatieve als invasieve 
behandeling geïnitieerd worden. Een conservatieve behandeling, in de vorm van 
gesuperviseerde looptherapie (GLT), bewerkstelligt op zijn minst een vergelijkbare 
verbetering van de maximale loopafstand als een invasieve behandeling zoals een 
dotterbehandeling of bypass chirurgie. Een invasieve behandeling gaat echter wel 
gepaard met een verhoogd risico op morbiditeit, mortaliteit en aanzienlijke kosten. Op 
basis van deze basale uitgangspunten zou de behandeling van claudicatio intermittens 
primair moeten bestaan uit een conservatieve behandelingsstrategie. De meest recente 
‘National Institute for Health and Care Excellence’ (NICE) richtlijn adviseert het gebruik 
van GLT dan ook als initiële behandeling voor alle patiënten met CI. 
Dit proefschrift heeft als doel methoden te beschrijven om de conservatieve behandeling 
van CI in Nederland te optimaliseren. Om dit doel te bereiken werden diverse 
maatschappelijke relevante wetenschappelijke studies verricht. 
In hoofdstuk 3 van dit proefschrift worden de resultaten beschreven van een in 
2011 uitgevoerde enquête, met een respons van 80 procent van de Nederlandse 
vaatchirurgen. De enquête onderzocht in welke mate en op welke gronden Nederlandse 
vaatchirurgen gebruik maakten van GLT in de klinische praktijk. Hoewel het merendeel 
van de vaatchirurgen aangaf patiënten te verwijzen voor GLT, kreeg 25 procent van de 
patiënten geen GLT aangeboden. GLT werd door 30 procent van de vaatchirurgen niet 
zinvol geacht bij patiënten met CI op basis van een iliacale stenose of in combinatie 
met cardiopulmonale comorbiditeit.  Deze argumenten blijken inmiddels achterhaald 
in de wetenschappelijke literatuur. 
De door vaatchirurgen opgegeven 75 procent patiënten die GLT aangeboden zouden 
krijgen, is waarschijnlijk positief gekleurd door sociaal wenselijke antwoorden. Een 
analyse van declaratie data van een grote zorgverzekeraar toonde dat slechts 14 
procent van de patiënten met CI primair GLT kreeg aangeboden. Daarentegen werd in 
27 procent primair gekozen voor een vasculaire interventie. De oorzaak voor deze van 
de richtlijn afwijkende verdeling is multifactorieel. De oorzaak ligt bij zowel patiënten, 
huisartsen, vaatchirurgen zorgverzekeraars als beleidsmakers.
Vanuit maatschappelijk perspectief zou de oplossing gevonden kunnen worden in 
een ‘stepped care’ model. Een model waarin iedere patiënt met CI initieel voor drie 
maanden GLT krijgt. Alleen die patiënten, waarbij dit traject niet tot het gewenste 
resultaat heeft geleid, komen in aanmerking voor een vasculaire interventie. De 
verwachting is dat hiermee veel minder vasculaire interventies nodig zullen zijn bij 
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deze patiëntenpopulatie. Als gevolg kan implementatie van een dergelijk ‘stepped 
care’ model dan ook leiden tot een aanzienlijke kostenbesparing voor de Nederlandse 
gezondheidszorg. Verdergaande kostenbesparing kan worden gerealiseerd als de 
diagnose CI en initiatie van GLT kan worden gerealiseerd vanuit de eerste lijn. Dit kan 
bereikt worden door ondersteuning bij de diagnostiek naar perifeer arterieel vaatlijden 
(PAV) dan wel samenwerkingsafspraken met de tweede lijn en gebruikmaking van de 
faciliteiten van een poliklinisch vaatlaboratorium. 
In dit proefschrift wordt in hoofdstuk 7 een conceptueel framework beschreven, 
ClaudicatioNet, waarmee landelijke dekking van regionale zorgnetwerken gecreëerd 
kan worden. In deze zorgnetwerken wordt een conservatieve behandeling van CI 
geboden door samenwerking tussen verwijzers en geschoolde fysiotherapeuten die 
GLT en leefstijlinterventies aanbieden. Transparantie en kwalitatief hoogwaardige zorg 
voor alle patiënten met CI is het doel. Hiertoe dienen participerende fysiotherapeuten 
een driejarig specialisatietraject te doorlopen. Door middel van een online monitoring 
systeem wordt inzicht verkregen in de kwaliteit van de deelnemende therapeut. De 
werkwijze van ClaudicatioNet maakt het mogelijk om ook voor andere chronische 
aandoeningen een ‘stepped care‘ model te implementeren in de Nederlandse 
gezondheidszorg 
Een andere invalshoek van dit proefschrift is het introduceren van een nieuwe 
uitkomstmaat voor wetenschappelijk onderzoek naar CI. In onderzoek naar CI wordt 
het effect van de conservatieve of invasieve behandeling gemeten door middel van de 
toename in maximale, functionele of pijnvrije loopafstand. Het is echter de vraag of een 
toename van de loopafstand leidt tot een hogere fysieke activiteit in het dagelijks leven. 
Symptoomverlichting is beter meetbaar door middel van een gezondheid gerelateerde 
kwaliteit van leven vragenlijst, al is een dergelijke vragenlijst van voldoende kwaliteit 
op dit moment nog niet beschikbaar. Naast symptoomverlichting lijkt een toename 
van fysieke activiteit essentieel voor patiënten met CI, aangezien fysieke activiteit 
geassocieerd is met een reductie in cardiovasculaire mortaliteit en morbiditeit. 
In hoofdstuk 5 en 6 wordt in twee studies beschreven hoe de fysieke activiteit van patiënten 
met CI in de klinische praktijk geobjectiveerd kan worden door gebruik te maken van 
tri-axiale accelerometrie. In de eerste studie werden 93 nieuw gediagnosticeerde 
patiënten met CI en 36 gezonde vrijwilligers gevraagd een dergelijke accelerometer 
gedurende 1 week te dragen. De patiënten met CI bleken een significant lagere 
fysieke activiteit te hebben in vergelijking met de gezonde controlegroep. Eveneens 
bleek dat meer dan de helft van de claudicanten niet voldeed aan de internationale 
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ACSM beweegnorm voor fysieke activiteit. Wetende dat een te lage fysieke activiteit 
geassocieerd is met een stijging van
gezondheidsrisico, is meer aandacht voor verbetering van de fysieke activiteit bij 
claudicanten noodzakelijk. 
In de tweede studie werd gekeken naar het effect van GLT op de fysieke activiteit bij 
een populatie nieuw gediagnosticeerde claudicanten. In vergelijking met het niveau 
van fysieke activiteit voorafgaand aan het traject GLT bleek het aantal claudicanten 
dat na een traject GLT wel voldeed aan de internationale ACSM beweegnorm voor 
fysieke activiteit toegenomen. Het lijkt dan ook aannemelijk dat GLT met incorporatie 
van leefstijladviezen, geïnitieerd door een daartoe getrainde  fysiotherapeut, leidt tot 
een toename van de fysieke activiteit. 
De toepasbaarheid van het meten van fysieke activiteit met accelerometrie bleek 
relatief makkelijk in de klinische praktijk. Dit maakt deze techniek toegankelijk voor 
toekomstig wetenschappelijk onderzoek. Indien we de onderzoeksresultaten willen 
vertalen naar de dagelijkse praktijk zou het wenselijk zijn om tot een complete set van 
meetinstrumenten te komen die zowel de conservatieve als invasieve behandeling van 






Aan het tot stand komen van dit proefschrift hebben veel mensen bewust en onbewust 
een bijdrage geleverd. Enkele wil ik in het bijzonder bedanken. 
Allereerst dank aan alle patiënten met perifeer arterieel vaatlijden van de vaatpoli 
van het Catharina Ziekenhuis die hebben bijgedragen aan dit proefschrift. Zonder uw 
bijdrage was dit proefschrift niet tot stand gekomen. 
Prof. dr. J.A.W. Teijink, beste Joep
In juli 2009 begon ik als ANIOS in het Catharina ziekenhuis en na een enerverend 
zeilweekend besloot jij dat ik onderzoek bij jou ging doen. Een keuze die mij geen 
windeieren heeft gelegd! Jouw eindeloze energie, enthousiasme en overtuigingskracht 
zijn voor mij gedurende dit promotietraject van grote waarde geweest. Het is 
inspirerend om te zien hoe jij jouw passie met betrekking tot ClaudicatioNet weet over 
te brengen op mensen om je heen. Mij heb je altijd de juiste kant op gestuurd en jouw 
onvoorwaardelijke steun gegeven. Daarvoor ben ik je veel dank verschuldigd. Ik hoop 
dat ik ook in de toekomst nog veel van je mag leren op OK 7 of in een van de nieuwe 
hybride operatiekamers. 
Prof. dr. R.A. de Bie, beste Rob
Als fysiotherapeut, bewegingswetenschapper en epidemioloog heb jij een scherpe 
kijk op het onderzoek naar gesuperviseerde looptherapie. Ik wil je danken voor jouw 
relativeringsvermogen en frisse blik. Dit heeft mij meer dan eens goede moed gegeven 
om vanuit een andere invalshoek naar mijn onderzoek te kijken.
Dr. B.L.W. Bendermacher, beste Bianca
Als CHIVO vaatchirurgie in het Catharina Ziekenhuis heb jij mij geleerd centraal 
veneuze lijnen te plaatsen: “Iedere stap goed nadenken over de mogelijke gevolgen”. 
Nog steeds als ik een lijn plaats hoor ik jouw stem in mijn hoofd en weet ik dat het goed 
komt. Als copromotor heb jij op eenzelfde manier bijgedragen aan de totstandkoming 
van dit proefschrift. Je hebt er nooit doekjes om gewonden hoe ik onderzoek moest 
combineren met de opleiding tot chirurg. Dankzij jouw motiverende gespreksvoering is 
het uiteindelijk gelukt om ook dit hoofdstuk tot een succesvol einde te brengen.
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Leden van de Stichting ClaudicatioNet, beste Loes, Yvonne, Lindy, Steven, Robert, Stijn, 
Frans, Ben en Eva
Menig weekend reizen jullie het land door om fysiotherapeuten bij te scholen in 
het geven van gesuperviseerde looptherapie en leefstijlinterventies. Zelf heb ik er 
iedere keer weer van genoten om dit te mogen doen en deel uit te maken van het 
ClaudicatioNet team. Ik hoop dat we samen nog vele jaarcongressen bijwonen en 
uiteindelijk kunnen bijdragen aan een betere kwaliteit van zorg voor alle patiënten met 
perifeer arterieel vaatlijden. 
Fysiotherapeuten ClaudicatioNet
Jullie maken de patiënten met perifeer arterieel vaatlijden echt beter. Ik hoop dat 
jullie de komende jaren veel voldoening vinden in het trainen, motiveren en daarmee 
gezonder maken van het grote aantal claudicanten dat naar jullie verwezen gaat 
worden.
Dr. S. Spronk, beste Sandra
Bedankt voor de plezierige en vruchtbare samenwerking. Ik ben altijd met veel plezier 
naar Rotterdam gekomen en heb het fijn gevonden dat jij ons Cochrane onderzoek 
mede wilde begeleiden. Ik wens je veel succes met jouw huidige baan bij de Inspectie 
voor de Gezondheidszorg.
Dr. H.J.M. Hendriks, Prof. dr. M.G.M. Hunnink, Dr. M.J. Koelemay, Harm Gijsbers en 
Farzin Fakhry
Ik wil jullie hartelijk danken voor de constructieve samenwerking. 
Rob van Lummel en alle medewerkers McRoberts
Dankzij jullie hulp is het gelukt om in detail de fysieke activiteit van patiënten met 
claudicatio intermittens te beschrijven. Jullie ondersteuning bij de analyses en het 
uitlezen van data was essentieel en van groot belang voor dit proefschrift. Bedankt 
voor jullie hulp en ik wens jullie veel succes met toekomstige innovaties.
Leden van de beoordelingscommissie, Dr. M.R.M. Scheltinga, Dr. E.M. Willigendael, 
Prof.dr. P.R.G. Brink, Prof.dr. M.H. Prins




Dr. G.A.P. Nieuwenhuijzen en Dr. S. Nienhuijs, beste Grard en Simon
Het combineren van de opleiding Heelkunde met promotieonderzoek is regelmatig 
mensen teleurstellen, inclusief jezelf. Grard, als opleider zag jij al gauw dat het 
proefschrift zo snel mogelijk afgerond moest worden. Ik wil zowel jou als Simon van 
harte danken voor jullie steun en vertrouwen. Es gibts nur ein gas – Vollgas.
Maatschap Chirurgie van het Catharina Ziekenhuis, beste Marc, Philippe, Joep, Harm, 
Alex, Gust, Frans, Yvonne, Jean-Paul, Misha, Grard, Simon en Ignace
Wat ben ik blij om in jullie tent in opleiding te zijn. De complexiteit en volume aan 
ingrepen die in ‘t Cathrien verricht worden, in combinatie met een grote portie 
Brabantse gezelligheid, maakt werken in dit ziekenhuis uniek. 
Fellows Chirurgie van het Catharina Ziekenhuis, beste Bart-Jeroen, Robert en Sabrina
Bedankt voor alle gezellige en leerzame momenten, zowel op als buiten de OK.
Polikliniekmedewerkers Chirurgie en medewerkers vaatlaboratorium Catharina 
Ziekenhuis, beste Marga, Monique, Helga, Hannie, Ine, Jose, Nicole, Cindy, Dyanne, 
Ynette, Joyce, Nicole, Silvie, Milou, Rukiye, Arianne, Jolien, Olga, Yvonne en Anja
Dank voor jullie dagelijkse inbreng in het chirurgisch bedrijf, maar zeker ook de 
ondersteuning bij de totstandkoming van dit proefschrift.
Onderzoekers & semi-artsen Chirurgie Catharina Ziekenhuis
Fel zijn!
Arts-assistenten en oud-assistenten Chirurgie Catharina Ziekenhuis
Het is geweldig om deel uit te mogen maken van deze hechte club Heelkunde Helden. Ik 
kijk alweer met smacht uit naar het assistentenweekend, de jaarlijkse winterbijscholing, 
onze hardloopavonturen of de vele stapavondjes. 
Danielle van Dalen en Nicole Verhofstadt
Daantje en Nicole, jullie waren vanaf het eerste moment betrokken bij het opzetten van 
mijn onderzoek in het Catharina Ziekenhuis. Daan, ik heb genoten van de spannende 
tijden waarin we samen ClaudicatioNet mee in de steigers hebben gezet. Nicole, erg 




Perifere jongens!!! Samen met Stokkie waren wij de drie musketiers van het Chirurgie 
onderzoekshok. Ik zal nooit vergeten hoe je als broekie tussen de haaien werd gegooid. 
We konden je in het begin werkelijk alles wijsmaken. Inmiddels heb je ons dubbel en 
dwars ingehaald, zowel qua snelheid van promoveren als qua portie assertiviteit. Ik 
wens de afdeling Orthopedie in het Maxima en Maastricht veel succes daarmee. Wat 
mij betreft blijf je altijd een ‘perifere jongen’ en ik kan niet wachten tot we dat dit 
najaar weer op onze eigen ludieke wijze mogen uitdragen tijdens de jaarlijkse ESVS 
trip: Porto, here we come!
Rutger Stokmans
Dat ik als ‘perifere jongen’ uiteindelijk besluit om twee ‘aorta-boys’ te vragen als 
paranimfen voor mijn proefschrift. Het moet niet gekker worden…
Rutger, samen waren wij the Founding Fathers van het Chirurgie onderzoekshok. 
Hard werken, maar vooral ook veel lachen. Zo kan ik me nog een ontploffend 
koffiezetapparaat herinneren waar we heel Philips Nederland voor op de kop gezet 
hebben. Ik ben blij dat we deze zomer weer herenigd worden in het Catharina 
Ziekenhuis. Dat wordt ongetwijfeld weer veel lachen, zet de Prosecco maar koud.
Pieter Broos
Mijn hardcore gym buddy en uitlaatklep in barre tijden. Het laatste setje zit er op, 
ik heb alweer zin in een shake. Vanaf nu zal ik als jouw uitlaatklep fungeren bij het 
completeren van jouw proefschrift en start van je carrière als arts-assistent. De tijd is 
weer gekomen om locht te worden. Ben je fel?
Vrienden van W•A•L•E•W•Y•N, beste Franken, Ter Horst, Hermsen, Van Schijndel, 
Van der Zande, Roerink en Van Gennip
Wat hebben we toch een mooie tijd beleefd in Nijmegen! Dankzij jullie is voor mij 
studeren synoniem aan de woensdagavond (gratis) bieren in Café Daen, balletje 
hooghouden op de bushalte van de golfbaan, zingen uit volle borst tijdens de cantus 
en terugfietsen van het Radboudfeest met Jan Smit. Inmiddels zijn we allemaal wat 
rustiger geworden. Toch hoop ik dat we nog vele avonturen mogen beleven op onze 
toekomstige W•A•L•E•W•Y•N weekendjes.
Lieve schoonfamilie, beste Lisette, Jan, Eva en Martijn,
Dank voor jullie interesse en dat jullie altijd voor ons klaar staan, bijvoorbeeld bij onze 
zoveelste verhuizing naar Centerparcs Eindhoven.
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Lieve Robbert en Yola
Bro, ondanks dat we qua karakter in menig opzicht elkaars tegenpolen zijn, hebben 
wij het altijd super gezellig met elkaar. Veel waardering heb ik voor de manier waarop 
jij, samen met Yola, jullie leven ingericht hebben en het eigenlijk perfect voor elkaar 
hebben. Dank voor jullie jarenlange belangstelling en steun in alle aspecten van mijn 
leven.
Lieve pap en mam 
Ik ben blij dat jullie beiden in goede gezondheid mijn promotie kunnen bijwonen. Dit 
proefschrift draag ik op aan jullie. De persoon die ik ben geworden is het resultaat van 
jullie onvoorwaardelijke liefde en steun in alles wat ik doe. Van jullie heb ik altijd de 
vrijheid gekregen om mijn eigen weg te kiezen. Ik zeg het misschien minder vaak als ik 
zou moeten maar jullie zijn werkelijk de beste ouders die een zoon zich kan wensen. 
Liefste Lauren
Samen met jou kan ik de hele wereld aan
Durf ik weer mezelf te zijn
Geniet ik van elk moment
Geloof ik oprecht in elk mens
Ben ik mij bewust van mij eigen kracht
En droom ik weer over de toekomst
Lieve Lau, bedankt dat je er altijd voor me bent en mij zoveel liefde en vertrouwen 
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Gert-Jan Lauret werd geboren op 15 juli 1984 in het AZ 
Sint-Jan te Brugge, België. Na het behalen van het 
eindexamen VWO aan het Reynaert College te Hulst 
(Zeeuws-Vlaanderen) startte hij in 2002 met de studie 
Geneeskunde aan de Radboud Universiteit Nijmegen. 
Hij volgde een keuze coschap Heelkunde aan de Spitalul 
Clinic Judetean de Urgenta te Sibiu, Roemenië. In 2009 
behaalde hij zijn artsexamen na een afsluitend coschap 
Plastische- en Reconstructieve Chirurgie en begon hij 
aansluitend als ANIOS Heelkunde in het Catharina 
Ziekenhuis te Eindhoven. Na anderhalf jaar klinische 
ervaring opgedaan te hebben vervolgde hij zijn carrière 
als arts-onderzoeker en coördinator ClaudicatioNet bij de sectie Vaatchirurgie in het 
Catharina Ziekenhuis. Gedurende deze tijd werd onder leiding van promotoren 
prof.dr. Teijink en prof.dr. de Bie (CAPHRI, Universiteit Maastricht) de basis gelegd van 
zijn promotieonderzoek naar de conservatieve behandeling van claudicatio 
intermittens. Op 1 juli 2012 startte hij met zijn opleiding tot algemeen chirurg en tot op 
heden werkt hij als AIOS Heelkunde in het Catharina Ziekenhuis te Eindhoven (opleiders 
dr. Nieuwenhuijzen en dr. Nienhuijs). Gert-Jan Lauret woont in Eindhoven samen met 
zijn vriendin Lauren Bullens. In 2016 zal hij zijn opleiding voortzetten in het Maastricht 
Universitair Medisch Centrum.
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